

Medicus  
Sapientiae



Thesis  
Obsequium



# **Regulation of p75<sup>NTR</sup> Trafficking by Neurotrophins in the NSC-34 Motor Neuron Cell Line**

**Dusan Matusica**  
BHlth Sc, BSc (Hons)

A thesis submitted for the degree of  
Doctor of Philosophy

(29<sup>th</sup> of February 2008)

Centre for Neuroscience  
Department of Human Physiology  
Flinders University School of Medicine  
Adelaide, South Australia

“The product of mental labor - science - always stands far below its value, because the labor-time necessary to reproduce it has no relation at all to the labor-time required for its original production”

**Karl Marx (1818-1883)**

“The most heated defenders of a science, who cannot endure the slightest sneer at it, are commonly those who have not made very much progress in it and are secretly aware of this defect”

**Georg C. Lichtenberg (1742-1799)**

---

# CHAPTER 1: NEUROTROPHINS, NEUROTROPHIN RECEPTORS AND SIGNALING MECHANISMS VIA ENDOSOMAL TRANSPORT ..... 1

|   |           |
|---|-----------|
| <b>1.A General Introduction .....</b>   | <b>2</b>  |
| 1.A.1 The Neurotrophic Hypothesis.....  | 2         |
| 1.A.2 Diverse Roles Of Neurotrophins .....  | 3         |
| 1.A.3 Current Progress In Neurotrophin Receptor Trafficking.....                            | 3         |
| 1.A.4 Neurotrophin Signaling Is Regulated By Intracellular Transport.....                   | 4         |
| 1.A.5 Significance Of Understanding Neurotrophin Receptor Trafficking In Motor Neurons..... | 4         |
| 1.A.6 Aims .....  | 5         |
| <b>1.B Neurotrophins .....</b>  | <b>6</b>  |
| 1.B.1 Nerve Growth Factor (NGF) .....   | 6         |
| 1.B.2 Brain Derived Neurotrophic Factor (BDNF) And Neurotrophins 3 - 4 (NT-3-4) .....       | 7         |
| 1.B.3 Synthesis And Secretion Of Neurotrophins.....   | 7         |
| <b>1.C Neurotrophin Receptors.....</b>  | <b>10</b> |
| 1.C.1 Tyrosine Kinase Receptor Family (Trk's) .....   | 11        |
| 1.C.2 Alternative Splicing Of Trk Receptors .....   | 11        |
| 1.C.3 Extracellular Splice Variants .....   | 13        |
| 1.C.4 Intracellular Splice Variants .....   | 13        |
| 1.C.5 The p75 Neurotrophin Receptor .....   | 14        |
| 1.C.6 p75 Splice Variant And Homologue Receptors .....                                      | 15        |
| 1.C.7 Neurotrophin Receptors And Ligand Specificity .....                                   | 16        |
| 1.C.8 Neurotrophin Receptor Interactors .....   | 17        |
| 1.C.9 Ligand Promiscuity Of p75 <sup>NTR</sup> .....  | 20        |
| <b>1.D Neurotrophin Receptor Signaling.....</b>   | <b>23</b> |
| 1.D.1 Tyrosine Kinase Mediated Signaling.....   | 23        |
| 1.D.2 p75 <sup>NTR</sup> Signaling .....  | 26        |
| 1.D.3 Summary .....   | 29        |
| <b>1.E Neuronal Membrane Dynamics .....</b>   | <b>30</b> |
| 1.E.1 General Overview Of Endocytosis.....  | 30        |
| 1.E.2 Macropinocytosis.....   | 31        |
| 1.E.3 Clathrin Mediated Endocytosis.....  | 31        |
| 1.E.4 Caveolin Mediated Endocytosis .....   | 33        |
| 1.E.5 Clathrin And Caveolin Independent Coated Pit Formation.....                           | 34        |
| 1.E.6 Identification Of Endosomal Compartments .....  | 34        |
| 1.E.7 Dynamic Regulation Of Endocytosis .....   | 35        |
| 1.E.8 Summary .....   | 35        |
| <b>1.F Endocytosis And Signaling: An Evolving Partnership .....</b>                         | <b>36</b> |
| 1.F.1 Receptor Internalization Mechanisms .....   | 37        |
| 1.F.2 The Signaling Endosome Hypothesis.....  | 39        |
| 1.F.3 Signaling Endosome Components .....   | 41        |
| 1.F.4 Alternative Models Of Retrograde Signal Propagation.....                              | 42        |
| 1.F.5 Unbounded Receptor Model .....  | 44        |
| 1.F.6 Wave Propagation Model.....   | 44        |
| 1.F.7 Signaling Effector Model .....  | 46        |
| 1.F.8 Summary.....  | 47        |
| <b>1.G Motor Neuron Cell Line Clones in Research.....</b>                                   | <b>48</b> |
| 1.G.1 Existing Motor Neuron Cell Lines.....   | 48        |
| 1.G.2 Current Uses For Motor Neuron Cell Lines .....  | 49        |
| 1.G.3 NSC-34 Motor Neuronal Characteristics.....  | 50        |
| 1.G.4 Morphological Comparison Between NSC-34 Cells and Primary Motor Neuron Cultures ..    | 52        |
| <b>1.H Concluding Remarks .....</b>   | <b>56</b> |

|   |            |
|---|------------|
| <b>CHAPTER 2: MATERIALS AND METHODS.....</b>  | <b>57</b>  |
| <b>2.A Materials .....</b>  | <b>58</b>  |
| 2.A.1 Cell culture, media supplements and growth factors .....  | 58         |
| 2.A.2 Tissue culture plastic and glassware .....  | 58         |
| 2.A.3 Fluorescent dyes and compounds.....   | 58         |
| 2.A.4 Primary and secondary antibodies .....  | 59         |
| 2.A.5 Protein chromatography.....   | 63         |
| 2.A.6 Chemical reagents, kits and compounds.....  | 63         |
| 2.A.7 Data analysis.....  | 63         |
| <b>2.B Methods.....</b>   | <b>63</b>  |
| 2.B.1 Mammalian cell culture .....  | 63         |
| 2.B.2 Adhesion matrix for cell culture .....  | 64         |
| 2.B.3 Cell viability assays measuring effects of low serum media conditions.....                                  | 65         |
| 2.B.4 Cell viability assays measuring the effects of neurotrophins .....  | 65         |
| 2.B.5 Retinoic acid and BDNF treatment of cell cultures .....   | 65         |
| 2.B.6 Acid phosphatase hydrolysis assay .....   | 66         |
| 2.B.7 Annexin-V-FITC apoptosis assay .....  | 66         |
| 2.B.8 Purification of antibodies.....   | 67         |
| 2.B.9 Conjugation of antibodies to fluorescent compounds.....   | 67         |
| 2.B.10 Fluorescence Activated Cell Sorting (FACS) flow cytometry .....  | 68         |
| 2.B.11 FACS analysis of neurotrophin binding on antibody binding.....   | 68         |
| 2.B.12 Cell lysate preparation and Western Blot analysis.....   | 69         |
| 2.B.13 p75 <sup>NTR</sup> internalization and pharmacological inhibition of endocytosis .....                     | 69         |
| 2.B.14 Immuno-endocytosis assays .....  | 70         |
| 2.B.15 Phase contrast microscopy .....  | 72         |
| 2.B.16 Confocal microscopy .....  | 72         |
| <br>  |            |
| <b>CHAPTER 3: OPTIMIZATION OF NSC-34 CULTURE AND DIFFERENTIATION .....</b>  | <b>74</b>  |
| <b>3.A Introduction .....</b>   | <b>75</b>  |
| <b>3.B Culture, Maintenance and Differentiation of NSC-34 cells .....</b>   | <b>77</b>  |
| 3.B.1 Optimization of NSC-34 cell culture conditions.....   | 77         |
| 3.B.2 Analysis of cell survival rates in serum-supplemented and defined media.....                                | 80         |
| 3.B.3 Effects of serum-supplemented and defined media on cell subtype .....                                       | 80         |
| 3.B.4 Effect of media on cell size and neurite extension in long term cultures .....                              | 82         |
| 3.B.5 Effects of long term RA treatment in NSC-34 cells.....  | 85         |
| 3.B.6 Optimization of culture growth matrix for glass coverslips .....  | 87         |
| 3.B.7 Long-term culture in serum free media.....  | 88         |
| <b>3.C Discussion .....</b>   | <b>90</b>  |
| <br>  |            |
| <b>CHAPTER 4: CHARACTERIZATION OF NSC-34 CELLS FOR THE USE IN NEUROTROPHIN RECEPTOR TRAFFICKING STUDIES .....</b> | <b>95</b>  |
| <b>4.A Introduction .....</b>   | <b>96</b>  |
| <b>4.B Analysis of Cell Membrane and Cytosolic Markers .....</b>  | <b>97</b>  |
| 4.B.1 FACS and Immunofluorescence screening.....  | 97         |
| 4.B.2 Western Blot analysis of neurotrophin receptors and endogenously expressed neurotrophins .....              | 98         |
| 4.B.3 Effects of Culture Media on Neurotrophin Receptor Expression .....  | 104        |
| <b>4.C Physiological responses of NSC-34 cells to neurotrophins.....</b>  | <b>106</b> |
| 4.C.1 Effect of exogenous neurotrophins on NSC-34 cells .....   | 106        |
| 4.C.2 Analysis of neurotrophin induced cell death .....   | 108        |

|  |            |
|--|------------|
| <b>4.D. Neurotrophin receptor interactions with receptor specific antibodies</b> .....   | <b>112</b> |
| 4.D.1 Effects of neurotrophins on binding of p75 <sup>NTR</sup> , TrkB, TrkC and Sortilin.....   | 112        |
| 4.D.2 Effects of p75 <sup>NTR</sup> antibodies on NGF induced apoptosis.....   | 114        |
| 4.D.3 Time-lapse internalization of p75 <sup>NTR</sup> .....   | 116        |
| 4.D.4 Time-lapse internalization of TrkB.....  | 118        |
| 4.D.5 Effects of k252a on neurotrophin receptor internalization.....   | 118        |
| <b>4.E Discussion</b> .....  | <b>120</b> |
| <br>   |            |
| <b>CHAPTER 5: EXOGENOUS NEUROTROPHINS REGULATE THE SUB-CELLULAR FATE OF P75<sup>NTR</sup></b> .....  | <b>127</b> |
| <br>   |            |
| <b>5.A Introduction</b> .....  | <b>128</b> |
| <br>   |            |
| <b>5.B Internalization of p75<sup>NTR</sup> in the presence of neurotrophins</b> .....   | <b>129</b> |
| 5.B.1 p75 <sup>NTR</sup> internalization rates are altered in the presence of exogenous neurotrophins. ....  | 129        |
| 5.B.2 p75 <sup>NTR</sup> associates with GT1b on the cell membrane but is internalized via clathrin mediated endocytosis.....                              | 132        |
| 5.B.3 p75 <sup>NTR</sup> associates with clathrin HC and transferrin positive endocytic carriers. ....   | 134        |
| 5.B.4 Inhibition of clathrin-mediated endocytosis prevents p75 <sup>NTR</sup> internalization in the presence of BDNF and NT-4, but not NGF and NT-3. .... | 137        |
| <br>   |            |
| <b>5.C p75<sup>NTR</sup> endosomal trafficking dynamics</b> .....  | <b>139</b> |
| 5.C.1 NGF and NT-3, but not BDNF and NT-4 decrease lysosomal targeting of p75 <sup>NTR</sup> .....   | 139        |
| 5.C.2 p75 <sup>NTR</sup> enrichment of EEA-1 positive endosomes is dependent on NGF and NT-3, but not BDNF and NT-4.....                                   | 144        |
| 5.C.3 NGF and NT-3 reduce p75 <sup>NTR</sup> recycling to the plasma membrane.....   | 148        |
| <br>   |            |
| <b>5.D Discussion</b> .....  | <b>153</b> |
| <br>   |            |
| <b>CHAPTER 6: DISCUSSION AND FUTURE PROSPECTS</b> .....  | <b>158</b> |
| <br>   |            |
| <b>6.A Discussion</b> .....  | <b>159</b> |
| 6.A.1 Neurotrophin Biology.....  | 159        |
| 6.A.2 The NSC-34 cell line as a motor neuron model.....  | 160        |
| 6.A.3 Neurotrophin receptor trafficking.....   | 162        |
| 6.A.4 Is there a distinct p75 <sup>NTR</sup> signaling endosome?.....  | 164        |
| <br>   |            |
| <b>6.B Future Prospects</b> .....  | <b>167</b> |
| <br>   |            |
| <b>APPENDIX</b> .....  | <b>169</b> |
| <br>   |            |
| <b>Appendix 1: Mapping of MLR antibodies binding domains to p75NTR</b> .....   | <b>170</b> |
| <br>   |            |
| <b>REFERENCES:</b> .....   | <b>I</b>   |

---

## LIST OF TABLES

|  |    |
|--|----|
| TABLE 1 - NEURONAL PROPERTIES AND MARKERS OF NSC-34 CELL LINE .....  | 54 |
| TABLE 1 - NEURONAL PROPERTIES AND MARKERS OF NSC-34 CELL LINE .....  | 55 |
| TABLE 2.1 - LIST OF PRIMARY ANTIBODIES AND WORKING DILUTIONS. ....   | 60 |
| TABLE 2.2 - LIST OF PRIMARY ANTIBODIES AND WORKING DILUTIONS. ....   | 61 |
| TABLE 3 - LIST OF FLUORESCENT SECONDARY ANTIBODIES AND WORKING<br>DILUTIONS.....                             | 62 |
| TABLE 4 - LIST OF HRP AND ALKALINE PHOSPHATASE CONJUGATED SECONDARY<br>ANTIBODIES AND WORKING DILUTIONS..... | 62 |
| TABLE 5 - PMT GATE SETTINGS FOR CELL MEMBRANE AND NUCLEAR MARKER<br>EMISSION.....                            | 73 |
| TABLE 6 - PMT GATE SETTINGS FOR FLUID-PHASE MARKER EMISSION.....   | 73 |

## TABLE OF FIGURES

|  |     |
|--|-----|
| FIGURE 1.1- THE PROCESSED AND UNPROCESSED MONOMERIC FORM OF<br>NEUROTROPHINS.....                                | 9   |
| FIGURE 1.2 - SCHEMATIC REPRESENTATION OF TRK AND P75 <sup>NTR</sup> STRUCTURAL<br>ISOFORMS.....                  | 12  |
| FIGURE 1.3 - NEUROTROPHIN INTERACTIONS WITH THEIR RECEPTORS.....   | 18  |
| FIGURE 1.4 - SCHEMATIC REPRESENTATION OF RECEPTOR INTERACTORS AND<br>P75NTR ALTERNATE LIGANDS.....               | 22  |
| FIGURE 1.5 - TRK RECEPTOR-MEDIATED SIGNALING PATHWAYS.....   | 24  |
| FIGURE 1.6 - P75NTR-MEDIATED SIGNALING PATHWAYS.....   | 27  |
| FIGURE 1.7 - BIOSYNTHETIC AND RECYCLING ROUTES AND THE ENDOSOMAL<br>NETWORK.....                                 | 32  |
| FIGURE 1.8 - NEUROTROPHIN RECEPTOR INTERNALIZATION.....  | 38  |
| FIGURE 1.9 - THE RETROGRADE “SIGNALING ENDOSOME” MECHANISM.....  | 40  |
| FIGURE 1.10 - THE SIGNALLING ENDOSOME.....   | 43  |
| FIGURE 1.11 - ALTERNATIVE MODELS OF RETROGRADE NEUROTROPHIN SIGNALING.<br>.....                                  | 45  |
| FIGURE 1.12 - MORPHOLOGICAL COMPARISON BETWEEN CULTURED PRIMARY<br>EMBRYONIC MOTOR NEURONS AND NSC-34 CELLS..... | 53  |
| FIGURE 2.1 - SCHEMATIC REPRESENTATION OF APOPTOSIS ASSAY TIMELINE.....   | 67  |
| FIGURE 2.2 - SCHEMATIC REPRESENTATION OF LIVE AND FIXED<br>IMMUNOENDOCYTOSIS ASSAY TIME LINE.....                | 71  |
| FIGURE 3.1 - GROWTH MEDIA ASSOCIATED MORPHOLOGICAL CHARACTERISTICS OF<br>NSC-34 CELLS.....                       | 79  |
| FIGURE 3.2 - EFFECTS OF SERUM SUPPLEMENTED AND DEFINED MEDIA ON CELL<br>SURVIVAL.....                            | 81  |
| FIGURE 3.3 - ANALYSIS OF NSC-34 CELL SUBTYPES IN SERUM SUPPLEMENTED AND<br>DEFINED MEDIA.....                    | 83  |
| FIGURE 3.4 - CELL BODY SIZE AND NEURITE PROCESS QUANTIFICATION.....  | 84  |
| FIGURE 3.5 - RETINOIC ACID INDUCED NSC-34 DIFFERENTIATION.....   | 86  |
| FIGURE 3.6 - OPTIMISATION OF CULTURE SUBSTRATE MATRIX FOR GLASS<br>COVERSLIPS.....                               | 89  |
| FIGURE 3.7 - LONG-TERM CULTURE OF DIFFERENTIATED NSC-34 CELLS.....   | 91  |
| FIGURE 4.1 - FACS SCREENING OF NSC-34 CELLS.....   | 99  |
| FIGURE 4.2 - IMMUNOFLUORESCENCE OF MOTONEURONAL MARKERS EXPRESSED BY<br>NSC-34 CELLS.....                        | 100 |
| FIGURE 4.3 - WESTERN BLOT ANALYSIS OF NEUROTROPHIN RECEPTORS AND<br>INTRACELLULAR TRANSPORT PROTEINS.....        | 101 |

---

|   |     |
|---|-----|
| FIGURE 4.4 - ANALYSIS OF NEUROTROPHIN RECEPTOR EXPRESSION IN DEFINED GROWTH MEDIA.....  | 105 |
| FIGURE 4.5 - EFFECTS OF NEUROTROPHINS ON NSC-34 AND NSC-34D CELL SURVIVAL. ....   | 107 |
| FIGURE 4.6 - ANALYSIS OF NGF INDUCED CELL DEATH WITH ANNEXIN-V APOPTOTIC STAIN.....   | 109 |
| FIGURE 4.7 - ANALYSIS OF NT-3 INDUCED CELL DEATH.....   | 110 |
| FIGURE 4.8 - ANALYSIS OF BDNF AND STAUROSPORINE INDUCED CELL DEATH. ....  | 111 |
| FIGURE 4.9 - BINDING OF P75NTR, TRKB, TRKC AND SORTILIN ANTIBODIES IN THE PRESENCE OF NEUROTROPHINS. ....   | 113 |
| FIGURE 4.10 - EFFECTS OF P75NTR ANTIBODIES ON NGF INDUCED APOPTOSIS.....  | 115 |
| FIGURE 4.11 - TIME-LAPSE LIGAND DEPENDENT AND INDEPENDENT INTERNALIZATION OF P75NTR. ....   | 117 |
| FIGURE 4.12 - TIME-LAPSE LIGAND DEPENDENT AND INDEPENDENT INTERNALIZATION OF TRKB.....  | 119 |
| FIGURE 4.13 - EFFECTS OF K252A ON NEUROTROPHIN RECEPTOR INTERNALIZATION.....  | 121 |
| FIGURE 5.1 - INTERNALISATION KINETICS OF P75NTR FOLLOWING NEUROTROPHIN TREATMENT.....   | 131 |
| FIGURE 5.2 - GT1B ASSOCIATES WITH P75NTR ON THE PLASMA MEMBRANE BUT IS NOT INTERNALIZED WITH THE RECEPTOR.....  | 133 |
| FIGURE 5.3A - P75NTR COLOCALISATION WITH CLATHRIN-HC. ....  | 135 |
| FIGURE 5.3B - P75NTR COLOCALISATION WITH TRANSFERRIN.....   | 136 |
| FIGURE 5.4 - SELECTIVE INHIBITION OF P75NTR VIA CLATHRIN-MEDIATED ENDOCYTOSIS COMPLETELY PREVENTS BDNF AND NT-4, BUT NOT NGF AND NT-3 MEDIATED P75NTR INTERNALIZATION. .... | 138 |
| FIGURE 5.5A - LYSOSOMAL TARGETING OF P75NTR IS INFLUENCED BY NEUROTROPHINS.....   | 140 |
| FIGURE 5.5B - LYSOSOMAL TARGETING OF P75NTR IS INFLUENCED BY NEUROTROPHINS.....   | 141 |
| FIGURE 5.5C - LYSOSOMAL TARGETING OF P75NTR IS INFLUENCED BY NEUROTROPHINS.....   | 142 |
| FIGURE 5.5D - LYSOSOMAL TARGETING OF P75NTR IS INFLUENCED BY NEUROTROPHINS.....   | 143 |
| FIGURE 5.6A - ENRICHMENT OF P75NTR IN EEA1 POSITIVE ENDOSOMES.....  | 145 |
| FIGURE 5.6B - ENRICHMENT OF P75NTR IN EEA1 POSITIVE ENDOSOMES.....  | 146 |
| FIGURE 5.6C - ENRICHMENT OF P75NTR IN EEA1 POSITIVE ENDOSOMES.....  | 147 |
| FIGURE 5.7A - NEUROTROPHINS REDUCE THE RECYCLING OF P75NTR BACK TO THE PLASMA MEMBRANE.....   | 150 |
| FIGURE 5.7B - NEUROTROPHINS REDUCE THE RECYCLING OF P75NTR BACK TO THE PLASMA MEMBRANE.....   | 151 |
| FIGURE 5.7C - NEUROTROPHINS REDUCE THE RECYCLING OF P75NTR BACK TO THE PLASMA MEMBRANE.....   | 152 |
| FIGURE 5.8 - SCHEMATIC REPRESENTATION OF P75NTR INTERNALIZATION AND TRAFFICKING IN NSC-34 CELLS.....  | 155 |
| FIGURE A1 - MAPPING OF MLR ANTIBODY BINDING EPITOPES OF P75NTR.....   | 171 |

---

## Abstract

Neurotrophins are a family of growth factors necessary for the development and maintenance of the nervous system. They produce their effects through receptor mediated signaling mechanisms that are highly regulated by sophisticated intracellular transport networks. The impairment of intracellular trafficking of neurotrophins in motor neurons has been identified as one possible factor in the development of motor neuron diseases, but remains inadequately studied. Aided by advances in imaging technology and the development of more powerful and sensitive detection tools for *in-vitro* studies, the dynamics of intracellular transport of neurotrophins are beginning to be unraveled. However, a primary limiting factor in the study of neurotrophin-transport dynamics in motor neurons has been the lack of alternative and easily available *in-vitro* systems able to substitute the often difficult and costly primary motor neuron cultures.

The aim of this project was to develop a suitable motor neuron model using the NSC-34 cell line for the study of receptor mediated trafficking events through endosomal transport pathways. Successful evaluation and characterization of NSC-34 cells for motor neuron specific markers would result in the investigation of the p75 neurotrophin receptor (p75<sup>NTR</sup>) trafficking pathways in the presence of exogenous neurotrophins, with a variety of confocal imaging techniques.

Chapter 3 describes the optimisation of NSC-34 cell culture conditions through media modification and the development of a suitable growth substrate matrix, which significantly improved cell adhesion, differentiation and the ability to culture the cells for extended time periods in serum free conditions. Quantitative measurements of cell proliferation, culture viability, cell-body size and neurite length are described to highlight the increased value of the cell line for long-term culture and experiments examining a broad range of issues relevant to motor neurons.

---

In Chapter 4, multiple experimental approaches were used to extensively screen the NSC-34 cell line for the presence of motor neuron-specific markers, neurotrophin receptors and proteins involved in regulation of endosomal transport. This characterization established the presence of a developing motor neuron-like neurotrophin receptor profile (p75<sup>NTR</sup>, TrkB and TrkC), a genetic marker of developing motor neurons, cholinergic markers, proteins regulating transport within the endosomal pathway, and additional proteins previously shown to directly interact with neurotrophin receptors, including sortilin, and the lipid raft associated ganglioside GT1b. Furthermore, evidence is provided that NSC-34 cells undergo apoptosis in response to exogenous nerve growth factor (NGF) or neurotrophin-3 (NT-3), but not brain derived neurotrophic factor (BDNF) or neurotrophin-4 (NT-4). In addition characterization of mouse specific p75<sup>NTR</sup> antibodies is presented to establish their suitability for internalization studies without altering the binding of exogenous neurotrophins to the receptor.

Subsequent confocal microscopy examination focusing on p75<sup>NTR</sup> trafficking in Chapter 5 revealed that internalization and intracellular transport of this receptor is regulated by exogenous neurotrophins at the cell surface where ligand binding and internalization occur, and in endosomal compartments where the bulk of receptors and ligands are targeted to their specific destinations. Evidence is provided showing that p75<sup>NTR</sup> internalization is altered in the presence of NGF, NT-3, or NT-4, but not BDNF, and the receptor is diverted into non-clathrin mediated endosomal pathways in response to NGF but not BDNF. Immunofluorescence confocal microscopy suggests that p75<sup>NTR</sup> recycles to the plasma membrane in a Rab4 GTPase dependent manner in the absence of neurotrophins. Addition of neurotrophins diverted p75<sup>NTR</sup> from the recycling Rab4 positive pathway, into EEA-1 positive sorting endosomes in the presence of NGF or NT-3, or lysosomal degradation in the presence of BDNF or NT-4.

---

This study clearly demonstrates the suitability of the NSC-34 cell line as an alternate in-vitro system for the study of motor neuron biology, particularly the study of neurotrophin receptor trafficking. Taken together the results represented in this study suggest for the first time, that the fate of the p75<sup>NTR</sup> receptor depends on which neurotrophin is bound. These findings have important implications for understanding the dynamic mechanisms of action of p75<sup>NTR</sup> in normal neuronal function, and may also offer further insight into the potential role of neurotrophins in the treatment of neurodegenerative diseases.

---

## Declaration

I certify that this thesis does not incorporate without acknowledgment any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge or belief it does not contain any material previously published or written by another person except where due reference is made in the text.



Dusan Matusica

---

## **Acknowledgements**

I am most grateful to my principle supervisor Robert Rush, not just for his passionate approach to science, but also the countless critical, constructive and intellectually stimulating contributions. His wholehearted and enthusiastic belief in my abilities not only provided me with much needed fuel to get through many challenges, but also offered me unique freedom coupled with valuable opportunities to develop as a scientist.

For a variety of reasons too long to list, I am grateful to Ian Gibbins. His patience, enthusiasm, attention to detail, knowledge of confocal microscopy techniques and advice were fundamental to refining many core experimental ideas.

Thank you also to members of the Neurotrophic Laboratory. In particular, the contributions of Mary-Louise Rogers in developing the MLR antibodies and for her constructive and meticulous input into many facets of experimental design and manuscript reviews, and Matthew Fenech for his assistance and troubleshooting of Western Blot techniques.

For help with the myriad of technical issues I would like to thank Jen Clarke (for her super-human patience, stamina, sense of humor and invaluable assistance during the installation, testing stages and day-to-day operation of the confocal microscope), and Peter MacArdle and Sheree Bailey (for always being accommodating with assistance in the flow cytometry facility).

I owe a debt of gratitude to the all of the past and present members of the Centre for Neuroscience for their unwavering support and rigorous and critical analysis of my research findings. I am also deeply thankful to the FMC Volunteers Foundation for continuing financial support in the form of scholarships and travel grants.

---

Above all, I thank my girlfriend Lee Johnson, for providing unwavering emotional and moral support, and for being unconditionally accepting and understanding throughout the duration of my candidature, regardless of the magnitude of sacrifice required to accommodate my needs.

---

## Publications and manuscripts arising from this research

ROGERS, M. L., ATMOSUKARTO, I., BERHANU, D. A., MATUSICA, D., MACARDLE, P. & RUSH, R. A. (2006) Functional monoclonal antibodies to p75 neurotrophin receptor raised in knockout mice. *Journal Of Neuroscience Methods*, 158, 109-20.

MATUSICA, D., FENECH, M. P., ROGERS, M. L. & RUSH, R. A. (2007) Characterization and use of the NSC-34 cell line for study of neurotrophin receptor trafficking. *Journal Of Neuroscience Research*. 86, (3):553-65

MATUSICA, D., ROGERS, M. L. & RUSH, R. A. (Submitted) NSC-34 cells: enhanced differentiation and adhesion increases value as a motor neuron cell line.

MATUSICA, D., ROGERS, M. L. & RUSH, R. A. (Submitted) NGF and NT-3, but not other neurotrophins, prevent trafficking of p75<sup>NTR</sup> to lysosomes in NSC-34 cells.

---

## LIST OF ABBREVIATIONS

|                    |   |
|--------------------|---|
| Ab                 | Antibody  |
| Akt                | Serine/threonine kinase / protein kinase B                            |
| BDNF               | Brain derived neurotrophic factor                                     |
| BSA                | Bovine serum albumin  |
| CNS                | Central nervous system  |
| DMEM               | Dulbecco's modified Eagle's medium                                    |
| DMSO               | Dimethyl sulfoxide  |
| DRG                | Dorsal root ganglia   |
| EE                 | Early endosome  |
| EEA-1              | Early endosomal antigen 1   |
| ER                 | Endoplasmic reticulum   |
| ERK                | Extracellular signal-regulated kinase                                 |
| FADD               | Factor associated death domain  |
| FAP-1              | Fas associated phosphatase 1  |
| HB9                | Homeobox gene 9   |
| IgG                | Immunoglobulin  |
| LE                 | Late endosome   |
| MAP                | Mitogen-activated protein   |
| MAPK               | Mitogen-activated protein kinase                                      |
| MC-192             | Monoclonal antibody against rat p75 receptor                          |
| MEK                | MAPK kinase / ERK kinase  |
| MLR-2              | Monoclonal antibody a   |
| mRNA               | messenger ribonucleic acid  |
| MVB                | Multi-vesicular body  |
| NaCl               | Sodium chloride   |
| NADE               | p75-associated cell death executor                                    |
| NF-1               | Neurofibromatosis-1   |
| NF- $\kappa$ B     | Nuclear factor $\kappa$ B   |
| NGF                | Nerve growth factor   |
| NRAGE              | Neurotrophin receptor interacting melanoma associated antigen homolog |
| NRIF               | Neurotrophin receptor interacting factor                              |
| NT-3               | Neurotrophin-3  |
| NT-4               | Neurotrophin-4  |
| p75 <sup>NTR</sup> | p75 neurotrophin receptor   |
| PC-12              | Pheochromocytoma-12 cells   |
| PI3K               | Phosphatidyl inositol-3 kinase  |
| PNS                | Peripheral nervous system   |
| Rab4               | Rab 4 GTPase protein  |
| Ras                | Ras GTPase protein kinase   |
| REX                | Receptor external domain  |
| RIP                | Ribosome inactivating protein   |
| RIP <sup>1</sup>   | Receptor interacting protein  |
| RNA                | Ribonucleic acid  |
| rRNA               | Ribosomal ribonucleic acid  |
| SC-1               | Schwann cell factor 1   |

---

|              |   |
|--------------|---|
| SDS-PAGE     | Sodium dodecyl sulfate-polyacrylamide gel electrophoresis |
| SE           | Sorting endosome  |
| TGN          | Trans-Golgi network                                       |
| TNF          | Tumour necrosis factor                                    |
| TRAD         | TNF receptor associated death domain                      |
| Trk          | Tropomyosin receptor kinase                               |
| Western Blot | Immunoblot  |

**CHAPTER 1: Neurotrophins, Neurotrophin  
Receptors And Signaling Mechanisms Via  
Endosomal Transport**

## 1.A General Introduction

Among the most morphologically complex cells, neurons reside at the pinnacle of cellular specialization (Kandel *et al.*, 2000). They are highly polarized cells with axonal and somatodendritic membrane surfaces that spatially separate signal-sending from signal-receiving membrane domains (Schmidt & Haucke, 2007). Neurons are characteristically involved in large-scale intracellular movement as a result of molecular synthesis, degradation, uptake and disposal (Almenar-Queralt & Goldstein, 2001). Their long (up to 1m) extended axons and elaborate dendritic trees establish and maintain the circuitry that detects, stores and transmits information that is essential to the function of all complex organisms.

### 1.A.1 The Neurotrophic Hypothesis

In the early 1900's it was demonstrated that neurons must contact their target organs in order to survive (Hamburger, 1958). Today, we know that throughout their life, all neurons depend on numerous target-released growth factors and other molecules to maintain their highly ordered functionality. In development, the survival and differentiation of neurons depends on competition for specific growth factors, which are available in limited amounts from target tissues (Hendry, 1992). Neurons that are able to obtain a sufficient amount of growth factors, survive and form synapses; the neurons that do not are removed by developmentally programmed cell death (Hendry *et al.*, 1974; Oppenheim, 1991). In the mature nervous system these factors play vital roles in the maintenance of activity dependent neuronal plasticity, and possibly regulate higher systemic brain function (Dechant, 2001).

Neurotrophins represent perhaps the most characterized, and intensely studied growth factors associated with neuronal development and functional maintenance (Thoenen & Sendtner, 2002; Lu *et al.*, 2005). Unlike conventional growth factors, neurotrophin signal transduction differs, in that the ligands activate their receptors at the synapse and require to be retrogradely transported to the cell body in order to elicit changes in gene expression (Howe & Mobley,

2005).

### **1.A.2 Diverse Roles Of Neurotrophins**

At the cellular level, the biological effects of neurotrophins are highly diverse, cell type specific and often paradoxical. Although initially identified as growth factors, neurotrophins mediate a multitude of biological functions including survival, differentiation, cell cycle arrest, neurodegeneration, neuroprotection, apoptosis and modulation of synaptic plasticity (Chao, 2003). From a genetic point of view, the neurotrophin ligand-receptor system used to produce these diverse physiological phenomena appears simple. In higher vertebrates, neurotrophins are derived from four genes (Hallbook, 1999), with five genes encoding three unrelated receptors responsible for signaling effects (Bronfman & Fainzilber, 2004).

### **1.A.3 Current Progress In Neurotrophin Receptor Trafficking**

The receptor-ligand relationships between neurotrophins and their receptors were mostly elucidated using various cell-lines overexpressing the receptors in recombinant form (Kaplan, 1998; Dechant, 2001). Although the mechanisms used to convey neurotrophin signals over great distances remain contentious (Howe & Mobley, 2005), the fact that binding of neurotrophins to their receptors initiates internalization of a receptor-ligand complex (Campenot & MacInnis, 2004), followed by a vesicular-based mechanism for transporting a biological signal to the cell body, has been substantiated by an increasing body of evidence (Grimes *et al.*, 1996; Grimes *et al.*, 1997; Bronfman *et al.*, 2003; Howe & Mobley, 2004). The experimental design in these studies focused primarily on the transport of nerve growth factor (NGF) and its cognate receptors (Bronfman *et al.*, 2003). The role of the PC-12 cell-line (Greene *et al.*, 1975), a rat adrenal pheochromocytoma cell line that responds to NGF and resembles sympathetic neurons, but also differs from neurons in many aspects, has been instrumental in the majority of these breakthrough discoveries (Kaplan & Stephens, 1994). This *in vitro* platform has provided valuable insights into these complex sub-cellular mechanisms (Grimes *et al.*, 1996; Grimes *et al.*, 1997), which have been

subsequently validated *in vivo* (Ye *et al.*, 2003; Howe & Mobley, 2004).

#### **1.A.4 Neurotrophin Signaling Is Regulated By Intracellular Transport**

A fundamental concept that has clearly emerged from decades of neurotrophin research is that the spatio-temporal regulation of neurotrophin signaling through receptor internalization and vesicular sorting is highly significant for the physiology of neurotrophins (Barker *et al.*, 2002; Ginty & Segal, 2002; Heerssen & Segal, 2002). These mechanisms are further complicated, as different cell types have the capacity to translate neurotrophin receptor activation into a myriad of cellular responses, clearly enforcing that it is paramount to examine these events on a cell-type specific basis (Bibel & Barde, 2000; Huang & Reichardt, 2001). At present there is no agreed way of specifically identifying the vesicular structures containing neurotrophin receptors and ligands, also referred to as cargo carriers, in relation to predicting the targeted destination of these vesicles, within the neuronal cytoplasm.

#### **1.A.5 Significance Of Understanding Neurotrophin Receptor Trafficking In Motor Neurons**

Historically motor neurons had a fundamental role in establishing the concept that neurotrophins have an important influence on the development of neurons (Thoenen *et al.*, 1993). Yet despite the importance of motor neurons in human health and disease, and in contrast to the importance of motor neurons in establishing the target dependent neurotrophic concept, ligand-receptor complex internalization and transport in these cells are relatively poorly understood when compared to the intensely studied sensory and sympathetic neurons (Sendtner *et al.*, 2000). Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) remain high priority neurodegenerative disorders due to their relentless progressive course and the invariably fatal prognosis (Bartlett *et al.*, 1998). The significance of neurotrophin receptor transport has recently come to attention, as it appears likely, that numerous neurodegenerative diseases could be caused by "indirect" effects on neurotrophin trafficking and signaling (Kruttgen *et al.*, 2003; Bronfman *et al.*, 2007).

### 1.A.6 Aims

Difficulties associated with obtaining, isolating and growing primary motor neuron cultures (Kuhn, 2003), the difficulty of transfecting primary motor neuron populations (Read *et al.*, 2005), and the lack of existing, well characterized motor neuron cell lines (Deinhardt & Schiavo, 2005), have to date been the primary obstacles in elucidating motor neuron specific knowledge regarding neurotrophin transport and signaling.

The aim of this thesis is to characterize and establish a motor neuron cell-line model to be used in the study of neurotrophin receptor transport and cytosolic localization. More specifically, attention will be focused primarily on one of the most enigmatic and controversial neurotrophin receptors, the p75 neurotrophin receptor (p75<sup>NTR</sup>), and its sub-cellular localization, following neurotrophin dependent internalization. The following pages will cover the overview of current concepts detailing three converging areas including neurotrophin function, including detailed description of interactions between neurotrophins, their receptors; description of general and neurotrophin receptor-specific uptake pathways; and a brief but thorough introduction to motor neuron cell lines used in research.

## 1.B Neurotrophins

A large number of molecules have been identified based on the ability to support the survival of immature neurons *in vitro* (DiStefano, 1993). The majority of these represent the gene families of neurotrophins, neurocytokines and other related molecules (Mitsumoto & Tsuzaka, 1999b; a). Neurotrophic factors can be defined as polypeptides that are required for the survival of specific neuronal populations during development and at adult stages (Davies, 1994). A wide variety of factors are now considered to fit this definition, but it remains hard to apply this definition rigorously for two reasons. First, the physiological roles of many neurotrophic factors are still not clearly defined, and often they are inferred from pharmacological experiments *in vitro* or *in vivo*. Second, some molecules initially identified due to their survival-promoting activity may elicit other physiological effects that are at least as important (Henderson *et al.*, 1998), and neurotrophins are prototypical of such growth factors.

### 1.B.1 Nerve Growth Factor (NGF)

Neurotrophins are responsible for the regulation of neuronal survival and physiology in both the peripheral (PNS) and central (CNS) nervous system (Levi-Montalcini *et al.*, 1996; Bibel & Barde, 2000). The first neurotrophin to be discovered was nerve growth factor (NGF) (Levi-Montalcini & Hamburger, 1951). Subsequent systemic search of mammalian tissues revealed that male mouse salivary glands contained substantial amounts of NGF (Cohen, 1960). Ongoing work in the field established that NGF is released by the target tissues of sympathetic and sensory fibers, and is taken up by the fibers and retrogradely transported to the cell body (Hendry *et al.*, 1974).

Human NGF gene is located on the short arm of chromosome 1 and codes for a polypeptide of 307 amino acids which, when the signal peptide and pro region are cleaved gives rise to a mature protein of 118 amino acids that naturally exists as a non-covalently bound homodimer (Francke *et al.*, 1983). Although NGF is the only member of the neurotrophin family that has not been demonstrated to support motor neuron survival (Sendtner *et al.*, 1992; Hughes *et*

*al.*, 1993), its represents by far the most studied and functionally defined molecule of all the growth factors in the nervous system.

### **1.B.2 Brain Derived Neurotrophic Factor (BDNF) And Neurotrophins 3 - 4 (NT-3-4)**

Thirty years after the discovery of NGF, before another factor that demonstrated neuronal growth-promoting properties was purified from pig brain, and later called Brain Derived Neurotrophic Factor (BDNF) (Barde *et al.*, 1982). The eventual cloning of the gene some seven years later revealed a relatively close homology to NGF with 51 identical amino acids. This close similarity also suggested that BDNF occurred naturally as a homodimer. By using the contiguous regions between NGF and BDNF to design oligonucleotides for polymerase chain reaction (PCR) cloning, a third member of the family called neurotrophin 3 (NT-3) was cloned in 1990 (Ernfors *et al.*, 1990).

Just a year later, and after an exhaustive search the last of the neurotrophin family members, neurotrophin 4 (NT-4), was cloned and identified in *Xenopus* (Ibanez *et al.*, 1992). However the equivalent human cDNA proved to be sufficiently different from *Xenopus* NT-4, and was subsequently identified as a separate gene called neurotrophin 5 (NT-5) (Berkemeier *et al.*, 1991). Following further investigation it was later realized that NT-4 and NT-5 were orthologous genes, and therefore this neurotrophin has been often referred to as NT-4/5. A new member of the neurotrophin family was identified in 1994, named neurotrophin 6 (NT-6), but has so far been found only in fish (Hallbook, 1999).


### **1.B.3 Synthesis And Secretion Of Neurotrophins**

All mammalian neurotrophins are synthesized as precursors called proneurotrophins which are approximately 30 ~ 35 kDa in size (Lee *et al.*, 2001b). Proneurotrophins are cleaved by furin and pro-convertases to form mature neurotrophins, all of which form non-covalently-linked homodimer with each monomer being approximately 12 ~ 13 kDa (Lee *et al.*, 2001b)(Figure 1.1). The X-ray crystal structures of mammalian neurotrophins have all been elucidated, and

because of their characteristic formation of a double loop formed by two disulfide bonds, penetrated by a third disulphide bond, they are classed as part of the Cysteine Knot Superfamily (Lu, 2003).

After synthesis in the endoplasmic reticulum (ER), proneurotrophins must be folded correctly, and subsequently sorted into the appropriate secretory pathway, regulated or constitutive, and then transported to the appropriate cellular compartment (Harrington *et al.*, 2004). In the majority of non-neuronal cells, neurotrophins are secreted through the constitutive pathway, where intracellular vesicle compartments fuse spontaneously with the plasma membrane to release them into the extracellular space (Lee *et al.*, 2001b). In most neuronal populations, neurotrophins are loaded into secretory granules and are subsequently transported to dendrites and spines to be released post-synaptically (Fahnestock *et al.*, 2004). However, neurotrophins are also loaded into vesicles and are targeted for anterograde transport to the axonal terminals where they undergo extracellular stimuli-dependent secretion (Harrington *et al.*, 2004). Ultimately there are three known fates of intracellular neurotrophins. Intracellular cleavage followed by secretion; secretion followed by extracellular cleavage; or excretion without extracellular cleavage (Lu *et al.*, 2005).

Traditionally, pro-neurotrophins have been considered as inactive precursors, with no significant biological function (Hempstead *et al.*, 1992). However the findings that in some tissues a substantial amount of proNGF and proBDNF escapes cleavage raised the possibility that these uncleaved forms of neurotrophins may have biological functions (Lee *et al.*, 2001b).



**Figure 1.1 The processed versus the unprocessed monomeric form of neurotrophins.** With the exception of NT4/5, neurotrophin sequences are highly conserved in mammals. They are synthesized as glycosylated pre-pro-proteins that undergo proteolytic cleavage. The pro-domain may be cleaved either intracellularly by furin or extracellularly by matrix metalloproteases (MMPs) and plasmin. The extracellular cleavage sites have not been specified yet, but do not coincide with the furin site. Both the processed and the unprocessed protomers form stable dimers in solution. The structural hallmark of neurotrophins is the cystine-knot motif, which comprises several conserved cysteine residues within the mature moiety. (adapted from Schweigreiter, R. 2006)

ProNGF and proBDNF are currently emerging as potent inducers of apoptosis (Harrington *et al.*, 2004; Teng *et al.*, 2005), but further investigations are needed as contradicting reports of proNGF mediated survival effects have also been observed (Fahnestock *et al.*, 2004; Buttigieg *et al.*, 2007).

## 1.C Neurotrophin Receptors

Neurotrophins bind two main types of cell surface receptors, the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (Barbacid, 1994; Patapoutian & Reichardt, 2001), and the p75 neurotrophin receptor (p75<sup>NTR</sup>), a member of the tumour necrosis factor (TNF) receptor family (Barker, 1998). P75<sup>NTR</sup> was the first identified receptor for NGF (Chao *et al.*, 1986; Radeke *et al.*, 1987), and the first Trk receptor was originally discovered as a rearrangement of non-muscle tropomyosin, and a then unknown tyrosine kinase (Martin-Zanca *et al.*, 1986).

This tyrosine kinase was referred to as TrkA and subsequently identified as a receptor for NGF (Martin-Zanca *et al.*, 1989; Kaplan *et al.*, 1991a). The identification of TrkB and TrkC, based on their similarity to TrkA, followed thereafter (Klein *et al.*, 1989; Hempstead *et al.*, 1991; Lamballe *et al.*, 1991).

These receptors are often co-expressed on the same cell, and their function varies markedly as the signals generated by the two receptors are able to either augment or oppose each other (Segal, 2003). Hence, Trk's and p75<sup>NTR</sup> exist in a complex paradoxical relationship, in some instances each taking a role in either supporting or suppressing each other actions, as well as sharing and enhancing binding affinities for multiple neurotrophins. To add to the complexity of this two-receptor system, p75<sup>NTR</sup> also associates with a number of other receptors in a variety of functions not always associated with neurotrophin action.


### 1.C.1 Tyrosine Kinase Receptor Family (Trk's)

The *trk* proto-oncogene encodes three closely related tyrosine kinases, TrkA, TrkB and TrkC (Eide *et al.*, 1993; Barbacid, 1994), and numerous splice variants of each Trk (Barbacid, 1994). Trk receptors are prototypical receptor tyrosine kinases that possess a tripartite structure containing an extracellular domain composed of three leucine-rich motifs flanked by two cysteine clusters, two immunoglobulin-like C2 type domains (Ig-C2), a single transmembrane domain, and a cytoplasmic tail containing ten conserved tyrosines for the purpose of initiating signaling cascades (Barbacid, 1994; Kaplan & Miller, 1997)(Figure 1.2).

Binding of neurotrophins to Trk receptors occurs mainly through the Ig-C2 domains, with the domain closer to the transmembrane region playing a more prominent role (Perez *et al.*, 1995; Urfer *et al.*, 1998). The leucine-rich motifs and the cysteine clusters may also be involved (MacDonald & Meakin, 1996). In addition to ligand binding, the Ig-C2 domains can also stabilize the monomeric form of the Trk receptor to prevent spontaneous dimerization and activation in the absence of neurotrophins (Arevalo *et al.*, 2000). Neurotrophin binding to Trk receptors results in allosteric receptor dimerisation followed by kinase activation (Kaplan & Miller, 2000). Phosphorylation of several evolutionarily conserved tyrosine residues present in the cytoplasmic activation loop, including Y670, Y674, and Y675 lead to the recruitment of signaling proteins (Huang & Reichardt, 2003). Phosphorylation of the other residues promotes signaling by creating docking sites for a number of adaptor proteins that couple these receptors to intracellular signaling cascades (Lee *et al.*, 2001a; Huang & Reichardt, 2003), and to components of cytoplasmic motors for axonal transport (Yano *et al.*, 2001).

### 1.C.2 Alternative Splicing Of Trk Receptors

Splice variants of *trk* receptors represent another puzzling feature of neurotrophin signal transduction complexity. All Trk neurotrophin receptor genes are expressed in multiple naturally occurring protein isoforms that are



**Fig 1.2 Schematic representation of Trk and p75NTR structural isoforms.** Trk and p75NTR receptors occur in their full-length (FL) forms, but alternative splicing has also been reported for all neurotrophin receptors. **(A)** Two different isoforms of TrkA have been described and named TrkA-I and TrkA-II. Three TrkA-I isoforms (two are shown) have been isolated which carry a total or partial deletion of amino cysteine-rich region in the extracellular matrix. TrkA-II differs from TrkA-I in that it carries an extracellular six amino acid insertion next to the transmembrane domain. **(B)** Both TrkA and TrkB transcripts are alternatively spliced at a small exon in their extracellular domain creating a corresponding protein isoform termed TrkA/B-S. Alternative splicing on the intracellular domain of the TrkB transcript results in isoforms with truncated tyrosine kinase domains (TrkB-T1 and TrkB-T2). **(C)** Truncated tyrosine kinase domain isoforms Trk-T1 and Trk-T2 also exist for the TrkC receptor. In addition tyrosine kinase peptide insertion isoforms for TrkC have been described (TrkC.KI-14, 25 or 39 equivalent to the number of amino acids forming the insertion). **(D)** A protein isoform has been described for p75NTR which lacks the cysteine-rich domains 2, 3 and 4 (s-p75NTR) due to alternative splicing of exon III of p75NTR-FL. p75NTR homologue NRH2 is also present in mammals. p75NTR also undergoes cleavage by metalloproteinases  $\alpha$ -secretase and  $\gamma$ -secretase to produce an ectodomain piece and a transmembrane and cytoplasmic domain fragment with signaling capability.

*Legend: NH2 CRD's, amino cysteine-rich regions; COOH CRD's, carboxy cysteine-rich regions; TK, tyrosine kinase; DD, death domain; LRR, leucine-rich repeat; IgC1, Immunoglobulin C1 domain; IgC2, Immunoglobulin C2 domain.*

generated through alternative splicing of their primary gene transcripts. Splice variants of Trk receptors are expressed with insertions in the extracellular domain (TrkA and TrkB), insertions in the tyrosine kinase domain (TrkA and TrkC), or truncated forms lacking the kinase domains (TrkB and TrkC) (Barbacid, 1994; Dechant, 2001; Vega *et al.*, 2003)(Figure 1.2 A-C).

### 1.C.3 Extracellular Splice Variants

The splicing of a small exon in the extracellular domain of TrkA (Barker, 1993) (Clary & Reichardt, 1994) and TrkB (Strohmaier *et al.*, 1996) produces isoforms with altered ligand interactions compared with the full-length receptors (Dechant, 2001). These TrkB isoforms have reduced affinities for NT-3 and NT-4 (Dechant, 2001), and increased specificity for BDNF (Strohmaier *et al.*, 1996). The corresponding TrkA isoforms differ in their interaction with the non-preferred ligand NT-3 (Dechant, 2001). Alternate variants of TrkB with deletions of the leucine-rich domains completely lack ligand binding and signaling capabilities (Ninkina *et al.*, 1997).

### 1.C.4 Intracellular Splice Variants

Isoforms for TrkB (Klein *et al.*, 1990; Middlemas *et al.*, 1991) and TrkC (Tsoulfas *et al.*, 1993; Valenzuela *et al.*, 1993) with truncations or insertions in the catalytic tyrosine kinase domains have been described. Truncated TrkB receptors (T1 and T2) can function as dominant negative inhibitors of the TrkB kinase if both forms are expressed in *cis* on the same cell (Ninkina *et al.*, 1996; Eide *et al.*, 1996). If the same isoforms are expressed in *trans*, they function as scavenger receptors by sequestering BDNF and removing it from the extracellular space via internalization (Alderson *et al.*, 2000). This mechanism restricts the activation of the catalytic full-length TrkB temporally and spatially (Dechant, 2001). The full-length and truncated TrkB isoforms also differentially regulate dendritic growth of cortical neurons (Yacoubian & Lo, 2000). Evidence has also emerged suggesting that non-catalytic TrkB receptor isoforms may have intrinsic signaling capabilities (Baxter *et al.*, 1997; Esteban *et al.*, 2006), and a truncated form of TrkC promotes neuronal differentiation in neural crest cells, but only in the

presence of p75<sup>NTR</sup> (Hapner *et al.*, 1998). Further, the intricate differential expression of multiple Trk isoforms during development may play a crucial role in sculpting axonal morphology (Ichinose & Snider, 2000).

### 1.C.5 The p75 Neurotrophin Receptor

Initial efforts to identify the NGF receptors resulted in discovery of p75<sup>NTR</sup> by expression cloning of a trans-membrane protein capable of binding NGF (Johnson *et al.*, 1986). For many years p75<sup>NTR</sup> was believed to be a low affinity receptor for NGF, but studies have demonstrated that it binds to all of the mammalian neurotrophins (NGF, BDNF, NT-3 and NT-4/5) with a similar affinity (Chao & Hempstead, 1995). When initially discovered and cloned, p75<sup>NTR</sup> represented a novel type of receptor, but a large number of structurally related cytokine receptors have since been discovered, the best characterized of which is the tumour necrosis factor (TNF) receptor family (Chao, 2003). A prototypic member of the TNF receptor family, p75<sup>NTR</sup> contains four cysteine-rich extracellular domains, a single short serine- and threonine-rich trans-membrane domain, and a small and poorly conserved ~80 amino acid cytoplasmic domain (also termed the “death” domain) (Figure 1.2D)(Liepinsh *et al.*, 1997; Barker, 1998). Due to the presence of the “death domain”, cell death and apoptosis attributed to p75<sup>NTR</sup> mediated signaling received considerable attention (Rabizadeh *et al.*, 1994). Cell death and apoptosis induced by p75<sup>NTR</sup> have been demonstrated in sensory neurons (Barrett & Bartlett, 1994), oligodendrocytes (Casaccia-Bonofil *et al.*, 1996), cultured neonatal sympathetic neurons (Bamji *et al.*, 1998), motor neurons (Sedel *et al.*, 1999), and neuronal populations with reduced or non-existent Trk receptor activity (Davey & Davies, 1998).

After the discovery of Trk receptors as the signaling components of the neurotrophin receptor complex (Kaplan *et al.*, 1991a), reviewed in (Bothwell, 1995), p75<sup>NTR</sup> was relegated to the role of a binding protein modifying the binding and signaling capabilities of the Trk receptors. For many years, the p75<sup>NTR</sup> intracellular “death” domain was still believed to lack intrinsic ligand inducible enzymatic function. The continuous discovery of increasingly varied signaling capabilities of p75<sup>NTR</sup> were attributed to the recruitment of numerous cytosolic

interactors and adaptors that result in diverse and frequently opposing outcomes like survival (DeFreitas *et al.*, 2001), apoptosis (Rabizadeh *et al.*, 1994; Bamji *et al.*, 1998), axonal growth (Bentley & Lee, 2000), axonal collapse, and cell cycle arrest (Salehi *et al.*, 2000), reviewed in: (Dechant & Barde, 1997; Barker, 1998; Hempstead, 2002) (Figure 1.6). Most of these molecules also lack catalytic activity, suggesting that p75<sup>NTR</sup> signaling requires recruitment of multiple transducers through protein–protein interactions (Bai *et al.*, 2003; Roux & Barker, 2002; Tcherpakov *et al.*, 2002; Blochl & Blochl, 2007).

Recent investigations however, have revealed that the p75<sup>NTR</sup> intracellular domain contains two tyrosine kinase residues, Y337 and Y336, which undergo phosphorylation upon NGF binding (Blochl, 2004). Further, the tyrosine-phosphorylated p75<sup>NTR</sup> activates Ras through the same adaptor proteins as Trk receptors (Blochl *et al.*, 2004).

### 1.C.6 p75 Splice Variant And Homologue Receptors

The p75 gene is also expressed in multiple receptor isoforms. The alternative splice variant named short p75 (s-p75) (Figure 1.2D) contains an open reading frame that translates into a naturally occurring isoform of the receptor with a spliced exon III encoding the cysteine-rich domains 2, 3, and 4 which are essential for neurotrophin binding (Lee *et al.*, 1992; von Schack *et al.*, 2001). Even though the s-p75 variant does not bind any of the neurotrophins, it shares an identical intracellular domain, and it appears likely that it may bind some of the intracellular signaling proteins and interactors of the full-length p75<sup>NTR</sup> (Dechant, 2001). Because the relationship between ligand binding and activation of signaling is not clearly defined for p75<sup>NTR</sup>, a ligand-independent function for s-p75 could be plausible.

A gene structurally related to p75<sup>NTR</sup> encodes for the neurotrophin receptor homologue (NRH) (Hutson & Bothwell, 2001). NRH is homologous to p75<sup>NTR</sup> with a strong sequence similarity in the transmembrane, juxtamembrane and death-domain regions (Figure 1.2D)(Kanning *et al.*, 2003). NRH1 and NRH2 have been identified (Hutson & Bothwell, 2001), however only NRH2 has been found

in the mammalian genome (Kanning *et al.*, 2003). NRH2 has been identified recently in rat and been alternatively termed PLAIDD (p75-like apoptosis inducing death domain protein) (Frankowski *et al.*, 2002) and also NRADD (neurotrophin receptor alike death domain protein) (Wang *et al.*, 2003).


### 1.C.7 Neurotrophin Receptors And Ligand Specificity

Neurotrophin ligand affinity and specificity is inherently complex due to the use of multi-receptor systems (Figure 1.3). In addition to Trks and p75<sup>NTR</sup> having their own signaling properties, p75<sup>NTR</sup> also has the ability to modulate and alter ligand specificity of Trk receptors (Hempstead, 2002). Although TrkA is able to bind NGF and NT-3, p75<sup>NTR</sup> co-expression with Trk A restricts NGF signaling via TrkA only (Mischel *et al.*, 2001). TrkB has the ability to bind BDNF, NT-3 and NT-4/5 (Bothwell, 1995). However in the presence of p75<sup>NTR</sup>, only BDNF is able to elicit a functional response (Bibel *et al.*, 1999). In contrast, TrkC exhibits binding affinity for NT-3 only, but shows a decrease in its absolute specificity for NT-3 in the presence of p75<sup>NTR</sup> (Yuen & Mobley, 1999). In addition, recently investigated structure-function relationship studies of Trk receptors indicate, that when they are co-expressed with p75<sup>NTR</sup>, extracellular Trk receptor domains are altered to offer additional docking sites for neurotrophin ligands (Zaccaro *et al.*, 2001). In 2001, utilizing a furin resistant form of proNGF, Hempstead and colleagues shattered this traditional view, by demonstrating that proNGF binds to p75<sup>NTR</sup> with an affinity 5 times higher than mature NGF, and is a potent inducer of p75<sup>NTR</sup> dependent apoptosis in sympathetic neurons, oligodendrocytes and in a vascular smooth muscle cell line (Barker, 2004; Nykjaer *et al.*, 2004). Furthermore, these studies also demonstrated that proNGF binds p75<sup>NTR</sup> and sortilin only, but not TrkA, and have therefore suggested that proNGF is an apoptotic ligand that is specific for p75<sup>NTR</sup> alone or in a partnership with sortilin.

### 1.C.8 Neurotrophin Receptor Interactors

In addition to its interactions with Trk receptors, p75<sup>NTR</sup> forms functional partnerships with other non-related membrane proteins (Figure 1.4). The sortilin receptor represents the most recent member and a conceptual twist in the neurotrophin receptor family. Sortilin is a ~95-kDa type-I receptor first isolated from human brain by receptor associated protein (RAP) affinity chromatography (Petersen *et al.*, 1997), and recently shown to be identical with the neurotensin receptor-3 (Mazella *et al.*, 1998). It has strong homology to yeast vacuolar protein-sorting 10 protein (Vps-10p), with a single transmembrane domain, and a short cytoplasmic tail with a C terminus strongly homologous to that of the mannose 6-phosphate (M6P-R)/insulin-like growth factor-II (IGF-II) receptor (Petersen *et al.*, 1997). In mature sortilin, an N-terminal 44-residue propeptide has been cleaved off, and recent results show that furin-mediated propeptide cleavage conditions sortilin for ligand binding (Munck Petersen *et al.*, 1999). The Vps-10p family of receptors are involved in trafficking cargo from the trans-golgi network (TGN) to the endocytic and lysosomal compartments, and more than 90% of sortilin is found in intracellular compartments (Nielsen *et al.*, 2001). Sortilin is expressed in a wide variety of tissues but is most abundant in the central nervous system from development through to adulthood (Barker, 2004).

The intriguing twist in this tale has been added by the implication that neurotrophins use not two, but three distinct receptor classes to dictate and regulate opposing biological responses of survival and death. Sortilin binds pro-NGF molecules (Nykjaer *et al.*, 2004), and pro-BDNF (Teng *et al.*, 2005), in the presence of p75<sup>NTR</sup> (Figure 1.3C-D) with high affinity, subsequently leading to neuronal apoptosis.



**Figure 1.3 Neurotrophin interactions with their receptors.** Trk A binds NGF and NT-3 (with a lower affinity), Trk B binds BDNF, NT-3 and NT-4. Trk C binds NT-3 only, with an affinity  $K_d$  of about 1-10 nM (A). p75NTR is able to bind all mammalian neurotrophins with similar affinity (B). Recent findings confirm that p75NTR is able to bind proNGF and proBDNF with a five times higher affinity than the mature neurotrophins, and add a third receptor to the family; sortilin. Sortilin serves as the neurotensin receptor, but the lack of processing of proNGF and proBDNF results in these ligands having a higher binding affinity for sortilin (C). Further, biochemical evidence supports the existence of complexes consisting of sortilin and p75NTR as a result of pro-neurotrophin binding, and Trk and p75NTR receptors in the presence of mature neurotrophins (D). The formation of Trk and p75NTR complexes has been correlated with higher ligand affinity and specificity.

*Legend: NH2 CRD's, amino cysteine-rich regions; COOH CRD's, carboxy cysteine-rich regions; TK, tyrosine kinase; DD, death domain; LRR, leucine-rich repeat; IgC1, Immunoglobulin C1 domain; IgC2, Immunoglobulin C2 domain.*

Although both p75<sup>NTR</sup> and sortilin are required for the transduction of proNGF and proBDNF induced apoptotic signaling, sortilin also binds proNGF (Nykjaer *et al.*, 2004) and proBDNF (Chen *et al.*, 2005b) in the absence of p75<sup>NTR</sup>. The ability of sortilin to block the sorting of BDNF with a single substitution in its pro domain (BDNF-V66M) from TGN to secretory granules, suggests that a specific pro-domain region may be required for the efficient, regulated secretion of proBDNF from neurons (Chen *et al.*, 2005b). Therefore, sortilin functions not only as a co-receptor to p75<sup>NTR</sup> in apoptotic signaling, but it appears that it may be crucial in correctly sorting the intracellular movement of newly synthesized proNT's.

In addition to the multiple roles already attributed to p75<sup>NTR</sup>, this versatile receptor has recently emerged as a key player in the regulation of neuronal growth (Yamashita *et al.*, 2002) Wang, K.C. *et al.* 2002). CNS-derived myelin-based growth inhibitors (MBGIs) including myelin-associated glycoprotein (MAG), Nogo and oligodendrocyte myelin glycoprotein (OMgP) are potent inhibitors of neurite outgrowth in many neuronal populations (Mukhopadhyay *et al.*, 1994; McGee & Strittmatter, 2003). P75<sup>NTR</sup> is also expressed during the time of neurite growth, and inhibition by MAG is blocked if neurons are exposed to neurotrophins before encountering the inhibitor (Cai *et al.*, 1999).

The Nogo receptor (NogoR), the ganglioside GT1b and Lingo-1 have been identified as components of the receptor complex responsible for attenuating responses to MBGIs (Figure 1.4A) (Yamashita *et al.*, 2002), Mi *et al.*, 2004), and in vitro studies suggest that the co-expression of at least NogoR, p75<sup>NTR</sup> and Lingo-1 is required for MBGI signaling (Barker, 2004). Both Trk and p75<sup>NTR</sup> have been reported to interact with the ankyrin repeat-rich membrane-spanning protein substrate (ARMS) (Kong *et al.*, 2001).

### 1.C.9 Ligand Promiscuity Of p75<sup>NTR</sup>

Apart from having important roles in the binding, internalization and trafficking of neurotrophins, recent reports show that p75<sup>NTR</sup> has an amazing ability to bind directly or indirectly to an astonishing array of proteins including lectins, pathogens and toxins (Figure 1.4B) (Butowt & Von Bartheld, 2003). Even more amazing is the fact that some of these molecules, such as tetanus neurotoxin (TeNT), have the ability to enter specific neurons and travel transneuronally among connected cell populations within the nervous system (Lalli *et al.*, 2003; Von Bartheld, 2004). Hence specific binding to p75<sup>NTR</sup> does not only play a role in the trafficking of neurotrophins, but seem to present an explicit transport entry system for foreign proteins.

The diversity of non-neurotrophin ligands reported to bind to p75<sup>NTR</sup> include the neuronal membrane-binding lectin wheat germ agglutinin (WGA) which competes partially with saturating doses of NGF, possibly because both molecules bind to p75<sup>NTR</sup> (Butowt & Von Bartheld, 2003). Studies have also revealed, that the glycoprotein responsible for neuronal penetration from certain rabies virus strains specifically binds the p75<sup>NTR</sup> neurotrophin receptor (Tuffereau *et al.*, 1998), as part of a multi-receptor complex (Von Bartheld, 2004). Rabies virus binds with high affinity to the first cystein- rich domain of mammalian p75<sup>NTR</sup> (Langevin *et al.*, 2002). This domain is retained in the partial p75-knock-out mouse (von Schack *et al.*, 2001), probably explaining unimpaired rabies virus infection in this model system (Jackson & Park, 1999).

Tetanus toxin and cholera toxin also appear to have a special relationship with p75<sup>NTR</sup>. Tetanus toxin is transported in vesicles containing p75<sup>NTR</sup> bound NGF (Lalli & Schiavo, 2002). Tetanus toxin binds specifically to polysialogangliosides, GD1b, and GT1b, as well as other yet unknown cell surface proteins (Schiavo *et al.*, 2000). GT1b has already been established as a p75<sup>NTR</sup> interactor in Nogo signaling (Wang *et al.*, 2002). Cholera toxin subunit B binds to


the cell surface ganglioside GM1, as GM1 also associates with Trk receptors and may bind (and be trafficked) in a GM1-Trk-p75 complex (Butowt & Von Bartheld, 2003).

In Alzheimer's disease, p75<sup>NTR</sup> also appears to be involved in neuronal damage owing to  $\beta$ -amyloid's binding to p75<sup>NTR</sup> and activation of its death domain (Yaar *et al.*, 1997; Yaar *et al.*, 2002; Perini *et al.*, 2002). A series of recent studies provided an unexpected new twist to the role of p75<sup>NTR</sup> in Alzheimer's disease by showing that p75<sup>NTR</sup> directly interacts with  $\beta$ -amyloid and serves as a receptor for  $\beta$ -amyloid to promote cell death via NF- $\kappa$ B (nuclear factor kappa B) (Kuner *et al.*, 1998) and JNK (c-Jun N-terminal kinase (Perini *et al.*, 2002; Yaar *et al.*, 2002).

Prion peptides are responsible for the fatal neurological diseases named transmissible spongiform encephalopathies (TSEs) (Prusiner, 1987). The pathogenic form of the prion protein (PrP<sup>C</sup>) has been demonstrated to bind, and be transported by p75<sup>NTR</sup> (Della-Bianca *et al.*, 2001). In addition, evidence supporting the role of p75<sup>NTR</sup> activation as a primary cellular damage mechanism through prion peptides has also emerged (Della-Bianca *et al.*, 2001).

The significance of alternate and often lethal ligands gaining entry into neurons remains a matter of speculation, but it may indicate the evolutionary importance of neuronal trafficking pathways established by neurotrophins.

However, the simplest evolutionary explanation is that these molecules hijack a less discriminatory receptor transport system to gain entry into cells. Direct proof for the precise role of the p75<sup>NTR</sup> mechanisms and activation by pathogens and toxins is still largely lacking. However, a sufficient body of data now supports further investigation, to unravel how p75<sup>NTR</sup> facilitates these harmful agents in accessing endosomal transport to gain access to, and ultimately destroy, neurons (Butowt & Von Bartheld, 2003).



**Fig 1.4 Schematic representation of receptor interactors and p75NTR alternate ligands.** (A) Nogo receptor (NogoR), Gt1b and Lingo-1 are involved in inhibition of neurite outgrowth via CNS-derived myelin-based growth inhibitors (MBGIs), including myelin-associated glycoprotein (MAG), Nogo and oligodendrocyte myelin glycoprotein (OMgP). Ankyrin-rich membrane spanning protein (ARMS) interacts with p75NTR and Trk to distinguishing neurotrophin action from other growth factors. p75NTR may also interact with truncated forms of Trks. (B) p75NTR also binds or associates with lectins, pathogens and toxins such as prion protein (PrP), wheat germ agglutinin (WGA) tetanus toxin (TeNT), amyloid peptide beta (A $\beta$ ), certain variants of rabies virus (RV-G), and cysteine-rich neurotrophic factor (CRNF).

## **1.D Neurotrophin Receptor Signaling**


### **1.D.1 Tyrosine Kinase Mediated Signaling**

The signaling pathways activated by neurotrophins through Trk receptors result in critical neuronal fates such as cell survival, differentiation, dendritic arborization, synapse formation, plasticity, axonal growth, and axonal guidance, and have been a topic of extensive reviews (Kaplan & Stephens, 1994; Huang & Reichardt, 2003; Arevalo & Wu, 2006; Schweigreiter, 2006), and only a brief overview is necessary for the purpose of this thesis.

Binding of neurotrophins to Trk receptors leads to dimerization and phosphorylation of the receptors, recruitment of various adaptors and enzymes, and activation of several signaling pathways (Summarized in Figure 1.5) (Bhattacharyya *et al.*, 1997; Senger & Campenot, 1997). Specific responses for neurotrophins are achieved through the unique combination of Trk receptor docking sites, recruitment of different cytoplasmic adaptors and enzymes, and regulated receptor trafficking (Whitmarsh & Davis, 2001). There are as many as ten tyrosine residues present in the Trk cytoplasmic domain (Stephens *et al.*, 1994). Several of these, including tyrosines Y490, Y670, Y674, Y675 and Y785 are phosphorylated in response to neurotrophins and serve as the major docking sites for binding of adaptor proteins and enzymes (Inagaki *et al.*, 1995; Zirrgiebel *et al.*, 1995).

The most well-defined signaling pathways activated by Trk receptors in response to neurotrophins are the Shc-Ras-MAPK, Rap-MAPK, PI3K-Akt, and PLC $\gamma$ -PKC survival and differentiation pathways (Heumann, 1994; Huang & Reichardt, 2003), however new downstream effectors are continually being identified (Arevalo & Wu, 2006).

Transcriptional regulation of neuronal survival and differentiation occurs by four main cascades including transient or prolonged forms of extracellular signal-regulated kinases/mitogen activated protein kinases (ERK/MAPK) through



**Fig. 1.5 Trk receptor-mediated signaling pathways.** Neurotrophin binding to Trk receptors leads to their activation and to the recruitment of different proteins that associate with specific phosphotyrosine residues in the cytoplasmic domain of Trk receptors. Numerous tyrosine kinase interactions trigger the activation of signaling pathways, such as the Shc-Ras-MAPK, Rap-MAPK, PI3K-Akt, and PLCγ-PKC pathways, which result in survival, neurite outgrowth, gene expression, and synaptic plasticity. Some of these effectors are also associated with endosomal compartments for long range signaling.

the small GTPase Ras (Marshall, 1995). Transient activation engages via Shc-Grb2-GEF/SOS-Ras-B-Raf/Raf-1-MAPK protein activation (Kao *et al.*, 2001). Prolonged tyrosine kinase ERK/MAPK activation requires additional adaptors CrkII/CrkL, GEF-C3G and the GTPases Rap1/B-Raf (York *et al.*, 1998; Wu *et al.*, 2001a), but may also include interactions with fibroblast receptor substrate-2 adaptor (FRS2) (Kao *et al.*, 2001) and ankyrin repeat-rich membrane-spanning protein substrate (ARMS) (Kong *et al.*, 2001). In addition, sustained but not transient activation of ERK/MAPK pathways requires endosomal internalization of the Trk receptor (York *et al.*, 2000; Wu *et al.*, 2001a).

The third signaling cascade critical for the survival of both cell lines and neurons is the Phosphoinositide-3 kinase / serine/threonine protein kinase Akt (PI3K-Akt) pathway, which engages Shc in association with Grb2/Gab1 (Holgado-Madruga *et al.*, 1997; Atwal *et al.*, 2000; Encinas *et al.*, 1999). Moreover, Akt phosphorylation can also activate the NF- $\kappa$ B pro-survival response (Foehr *et al.*, 2000), or regulate axonal growth and branching through GSK-3 $\beta$  inactivation (Zhou *et al.*, 2004).

The fourth survival and differentiation response involves the activation of phospholipase C-gamma (PLC $\gamma$ ), which results in the generation of inositol triphosphate (IP3) and diacylglycerol (DAG), and triggers various protein kinase C (PKC) pathways (Vetter *et al.*, 1991; Corbit *et al.*, 1999).

PKC's in turn engage the already mentioned Raf-MEK-ERK1 survival and differentiation cascade (Corbit *et al.*, 1999). In addition, PLC $\gamma$  signaling has been shown to also play an important role in BDNF mediated synaptic plasticity (Kang & Schuman, 1995). Investigations addressing the regulation of synaptic plasticity by neurotrophins have become a growing discipline, and have been recently reviewed in detail (Lu *et al.*, 2005).


Although the knowledge regarding Trk receptor signaling cascades is rapidly increasing, it needs to be highlighted that the majority of these pathways have been studied largely in the context of cell-line-derived NGF/TrkA signaling,

and subsequently extrapolated to the other Trk receptors. Further, many studies use transfection methods to insert Trk receptors of interest into cell lines. As a result of this technique, the receptor behavior may not represent the tangible outcomes associated with true physiological states. This means that many of the cell type specific details regarding Trk receptors and their isoforms remain to be addressed both *in vivo* and *in vitro*.

### 1.D.2 p75<sup>NTR</sup> Signaling

Unlike the well-defined trophic roles of the Trk receptors, p75<sup>NTR</sup> multifunctionality makes it extremely hard to formulate unified p75<sup>NTR</sup> signaling models. This high level of complexity is unavoidable considering variable effects ranging from trophism to programmed cell death, but further confusion stems from attempts to incorporate the fact that p75<sup>NTR</sup> functions are often integrated with other receptors and multiple ligands (Figure 1.4A-B), which mediate both synergistic and antagonistic interactions. As with Trk receptors, a summary of p75<sup>NTR</sup> signaling (Figure 1.6) is necessary to illustrate the complexity of signaling pathways.

As p75<sup>NTR</sup> was believed to be primarily involved in death signaling through protein interactors, its apoptotic pathways are the best-understood and described (Miller & Kaplan, 1998; 2001a; Roux & Barker, 2002; Blochl & Blochl, 2007). They can be triggered by neurotrophins, proneurotrophins and alternate p75<sup>NTR</sup> ligands (Schor, 2005). A core function of the p75 intracellular domain (p75<sup>ICD</sup>) appears to be ceramide production (Brann *et al.*, 1999; Lievremont *et al.*, 1999), and ceramide is involved in almost all apoptotic mechanisms (Blochl & Blochl, 2007). Increased or high ceramide production upon p75<sup>NTR</sup> activation results in the upregulation of multiple apoptotic proteins (Roux & Barker, 2002).



**Fig 1.6 p75NTR-mediated signaling pathways.** Binding of mature neurotrophins or pro-neurotrophins to p75NTR triggers the activation of multiple signaling pathways through different adaptors that result in diverse and at times opposite outcomes like survival, apoptosis, axonal growth, axonal collapse, and cell cycle arrest. Adapter proteins involved in p75NTR-mediated signaling include ceramide induced NRIF, NRAGE, TRAF6, NADE pathways converge on JNK and various caspases driving apoptosis. These effects can be blocked by Trk signals. SC-1 induces cell cycle arrest through nuclear regulation of cyclins E and B. Important survival signaling is transduced through TRAF4/6, p62, IRAK and RIP2 leading to NF-κB. p75NTR activation causes RhoA disassociation from the receptor leading to axonal growth. NF-κB translocation to the nucleus modulates dendritic growth via Hes1/5 expression.

The p75<sup>NTR</sup>-associated cell death executor (NADE) (Mukai *et al.*, 2000), neurotrophin receptor interacting factor (NRIF) (Casademunt *et al.*, 1999), TNF receptor-associated factor (TRAF6) (Khursigara *et al.*, 1999), nuclear factor- $\kappa$ B (NF- $\kappa$ B), and neurotrophin receptor-interacting MAGE homologue (NRAGE) (Salehi *et al.*, 2000) have been identified as primary interactors associated with death signaling cascades. However, all apoptotic signaling pathways appear to converge on the activation of Jun kinase (JNK) (Blochl & Blochl, 2007), tumour suppressor protein p53 (Aloyz *et al.*, 1998), and several caspases (Kaplan & Miller, 2000; Roux & Barker, 2002). NRIF and NRAGE, in collaboration with the Schwann cell factor 1 (SC-1) are also involved in cell-cycle arrest, regulating levels of cyclins E and B upon NGF activation (Chittka *et al.*, 2004).

In contrast to high ceramide production resulting from continuous receptor activation, short pulse ceramide production activates PI3-K, which subsequently produces trophic effects (neurite extension and survival) through Akt or RhoA-Ras-Raf-Erk1/2 activation (Blochl & Blochl, 2007). However continued ceramide production in this pathway will negatively influence the Akt/Erk1/2 pathways, blocking trophic effects (Brann *et al.*, 2002). A pro-survival pathway associated with NGF binding to p75<sup>NTR</sup> utilizes NF- $\kappa$ B (Carter *et al.*, 1996), which influences gene transcription mediated through TRAF6, p62, interleukin-1 receptor-associated kinase (IRAK) and receptor-interacting protein-2 (RIP2) (Khursigara *et al.*, 1999).

In an alternate scenario NF- $\kappa$ B has the ability to translocate to the nucleus and trigger the expression of Hes1/5 to influence dendritic growth (Salama-Cohen *et al.*, 2005). Ligand binding can also initiate cleavage of p75<sup>NTR</sup>, and the resulting p75<sup>ICD</sup> has also been reported in nuclear translocation (Frade, 2005), however the physiological relevance of this remains unclear. Like Trk receptors, p75<sup>NTR</sup> can also modulate synaptic transmission and plasticity in mature neurons (Rosch *et al.*, 2005; Zagrebelsky *et al.*, 2005).

### 1.D.3 Summary

Neurotrophins are a small family of growth factors including NGF, BDNF, NT-3 and NT-4, and exist in biologically active pro- and mature forms. They regulate critical and diverse aspects of developing and adult nervous system such as differentiation, survival, cell death, axonal elongation, myelination and synaptic plasticity. Neurotrophins cause these effects by binding to three distinct families of receptors, the tyrosine kinases TrkA, TrkB and TrkC, the TNF receptor family member p75<sup>NTR</sup>, and the sortilin receptor. The signaling outcome of neurotrophins depends on several factors including cell type specific expression of their receptors (including numerous functional splice variants), and individual or compound interactions between the various receptors in multiple receptor ligand complexes. P75<sup>NTR</sup> plays a central role in attenuating survival signaling by increasing ligand specificity for Trk's, or partnering sortilin in apoptosis. Further, interactions with numerous other ligands and interactors determine p75<sup>NTR</sup> mediated cellular responses. An array of various cascades involved in neurotrophin signaling have been identified, providing opportunities to uncover the details of neurotrophin receptor functional biology, but the physiological relevance, and identity of compartments involved in Trk and p75<sup>NTR</sup> activity are emerging as key components in neurotrophin signal regulation and will be described in the next section. In addition, p75<sup>NTR</sup> internalization and processing is turning out to be increasingly fascinating, as it also appears to be exploited as an effective entry portal to many harmful molecules.

## 1.E Neuronal Membrane Dynamics

All neuronal processes depend on the fidelity of intracellular membrane transport. Lipids, proteins, receptor ligands and solute molecules are trafficked to distinct compartments within the cell through both the biosynthetic and endocytic pathways (Watson *et al.*, 2005). These pathways play a critical role in translating the external stimuli into biological responses through a high level of ordered compartmentalization into multiple intracellular structures possessing their own distinct identity and function (Ceresa & Schmid, 2000). Neurotrophins are some of the most crucial external stimuli producing signal transduction via ligand activated receptor internalization (Campenot & MacInnis, 2004). Over the last decade the role of neurotrophin receptor endocytosis has evolved from a mechanism merely responsible for the downregulation of signal transduction, to a critical component of neurotrophin signal distribution, delivery and spatio-temporal regulation (Heerssen & Segal, 2002). The following section will focus on the relationship between endocytosis and neurotrophin receptor trafficking.

### 1.E.1 General Overview Of Endocytosis.

Endocytosis occurs by multiple mechanisms that fall into two broad categories, ‘phagocytosis’ or “cell eating” (the uptake of large particles) and ‘pinocytosis’ or “cell drinking” (the uptake of fluid and solutes) (Rodman *et al.*, 1990). Phagocytosis is typically restricted to specialized mammalian cells, including macrophages, monocytes and neutrophils, that function to clear large pathogens such as bacteria or yeast (Conner & Schmid, 2003), but macroautophagy is also constitutively active in healthy neurons and is vital to cell survival responsible for the turnover of organelles and long-lived proteins (Boland & Nixon, 2006). Pinocytosis is the primary mode of internalization for plasma membrane receptors and occurs in all cells by at least four basic mechanisms: macropinocytosis, clathrin-mediated endocytosis (CME), caveolae mediated endocytosis, and clathrin- and caveolae independent endocytosis (Perret *et al.*, 2005)



### 1.E.2 Macropinocytosis

Macropinocytosis, or fluid-phase uptake, can be measured by the intracellular accumulation of tracer molecules present in the medium (Cohen *et al.*, 2004). Macropinosomes (MPs) are large endocytic vesicles formed by signal based, actin-driven formation of membrane protrusions that fuse with the plasma membrane (Rodman *et al.*, 1990). They encapsulate large volumes of fluid and can be recycled back to the cell surface, or enter the degradative pathway and fuse with lysosomes (Lys) (D'Hondt *et al.*, 2000).

### 1.E.3 Clathrin Mediated Endocytosis

Clathrin mediated endocytosis (CME) is by far the most widely studied and best-understood mechanism of cellular uptake (Ceresa & Schmid, 2000). CME is often referred to as 'receptor mediated' endocytosis, but it is now becoming clear that this is a misnomer, as most pinocytic pathways have been demonstrated to involve specific receptor–ligand interactions (Cavalli *et al.*, 2001; Conner & Schmid, 2003). CME involves mechanisms where different receptors are internalized and trafficked through highly individualized endocytic mechanisms (Haucke, 2006).

CME involves the concentration of high-affinity transmembrane receptors and their bound ligands into 'coated pits' on the plasma membrane, which are formed by the sequential recruitment of accessory and recruitment proteins including AP-2, epsin, dynamin, actin and ARP2/3 (Conner & Schmid, 2003; Rappoport *et al.*, 2004), with the main assembly unit being the clathrin triskelions (Hirst & Robinson, 1998). Coated pits pinch off to form clathrin-coated vesicles (CCVs) that carry concentrated receptor–ligand complexes into the cell (Puthenveedu & von Zastrow, 2006). Following internalization the vesicles rapidly lose the clathrin coats and are sorted for fusion with early endosomes (EEs)/sorting endosomes (SEs), and/or multivesicular bodies (MVBs) (Mellman, 1996).



**Figure 1.7 Biosynthetic and recycling routes and the endosomal network.**

Various exo/endocytic routes and the endosomal network highlighting the intracellular itinerary of a typical ligand for each internalization route is depicted; some ligands such as cholera toxin (CTx) can use multiple routes (see text for details). Dashed two-headed arrows represent fusion between organelles. Biosynthetic traffic from the Golgi complex to the late endosome (LE), recycling endosome (RE) and the plasma membrane is shown by red arrows. Organellar pH, rab GTPases and other effectors necessary for organelle identity and sorting are also shown. **(A)** Macropinocytosis. Stimulation by growth factors or other signals causes the actin-driven formation of membrane protrusions that fuse with the plasma membrane to form large endocytic vesicles known as macropinosomes (MP) that encapsulate large volumes of the extracellular fluid. MPs can either fuse with lysosomes (Lys) or recycle back to the cell surface. **(B)** Phagocytosis. Signaling cascades trigger the rearrangement of the actin cytoskeleton and form membrane extensions that envelop the particle and engulf it. Membrane required for the formation of the phagocytic cup can be supplied by RE, LE and/or the ER. After internalization, the phagosome (Ph) fuses with lysosomes to form the phagolysosome (Ph-Ly) which requires hydrolytic enzymes to degrade its cargo. **(C)** Clathrin-mediated endocytosis. Receptors internalized into early endosomes/sorting endosomes (EE/SE) are segregated from their ligands due to the low pH (5.9) generated by vacuolar proton ATPases. Ligands and fluid are sorted into LE for subsequent degradation in lysosomes, while receptors (LDLR, TFR) are transferred to REs which lie deeper in the cell near the microtubule organizing center. REs are composed of tubules (60 nm diameter) and are characterized by a more neutral pH and a longer half-life than SEs. REs are also considered 'early' endosomes, as opposed to LEs, which are characterized by their commitment to a degradative route. Recycling from RE to the plasma membrane in non-polarized cells is under the control of rab4 and rab11. **(D)** Caveolae-mediated endocytosis. Glycosylphosphatidylinositol-anchored proteins (GPI-APs) and opportunistic ligands such as Simian virus 40 (SV40) and CTx can trigger the formation of caveolae, thus enhancing their uptake. These ligands are internalized into specialized vesicles known as caveosomes. From here, SV40 is transported to the endoplasmic reticulum (ER) while GPI-APs can traffic to the Golgi complex. SV40 can also be sorted into the EE/SE. **(E)** Clathrin- and caveolin-independent endocytosis. CTx and GPI-APs can be internalized via 40–50-nm raft-like structures into the GPI-anchored protein-enriched early endosomal compartment (GEEC), from where they are sorted to the Golgi complex (CTx) or to REs (GPI-APs). Mechanisms regulating these secondary endosomal sorting pathways are unclear. (adapted from: Perret et al., 2005)

EEs/SEs represent a dynamic array of tubules and vesicles distributed throughout the peripheral and perinuclear cytoplasm (Clague & Urbe, 2001).

Due to the slightly acidic pH (pH ~ 6.0 - 6.8) inside the EEs, many receptor-ligand complexes disassociate, and are subsequently sorted to establish the destination of the receptors and ligands (Von Bartheld, 2004). Receptors can be rapidly recycled back to the plasma membrane (Sheff *et al.*, 1999). The ligand may remain bound to the receptor and may be carried back to the surface membrane during recycling, or the ligand may dissociate from the receptor (Maxfield & McGraw, 2004). Thus, ligands and receptors can be targeted to different destinations. Different receptors may follow different fates, allowing for fine-tuned regulation of the internalization step and account for the sensitivity and specificity of the neuron's response to ligand exposure (Di Fiore & De Camilli, 2001). Free receptors selectively accumulate in early endosomal tubular extensions, which bud off to yield recycling endosomes (REs), which transport receptors, directly or indirectly to the plasma membrane (Maxfield & McGraw, 2004). Disassociated ligands collect in the vesicular compartments of EEs simply because of their high internal volume relative to the endosome tubular extensions. These vesicular structures subsequently pinch off, or are left behind following the budding of REs, and traverse to the perinuclear cytoplasm on microtubule tracks, and fuse with late endosomes (LEs), characterized by their commitment to lysosomal delivery (Piper & Luzio, 2001).

#### **1.E.4 Caveolin Mediated Endocytosis**

Caveolae are extremely abundant flask-shaped, sphingolipid-rich microdomain invaginations of the plasma membrane in which many diverse signaling molecules and membrane transporters are concentrated (Nichols, 2003). A dimeric cholesterol binding protein caveolin (van Meer & Sprong, 2004) confers the shape and structural organization of caveolae. In most cells, even after activation, caveolae are only slowly internalized (half-time,  $t_{1/2}$ , 20min) and the small vesicles (50–60 nm in diameter) carry little fluid-phase volume. However,

caveolae-mediated endocytosis seems to be highly regulated and driven by the cargo molecules themselves (Ikonen, 2001; Paratcha & Ibanez, 2002). The molecular basis for this link between cargo molecules, caveolae-localized receptors and triggered endocytosis remains to be elucidated.

### **1.E.5 Clathrin And Caveolin Independent Coated Pit Formation**

Caveolae represent just one type of cholesterol-rich microdomain on the plasma membrane. Others, more generally referred to as 'rafts', are small structures, 40–50nm in diameter, which diffuse freely on the cell surface (Nichols & Lippincott-Schwartz, 2001). Their unique lipid composition provides a physical basis for specific sorting of membrane proteins and/or glycolipids based on their transmembrane regions. These small rafts can presumably be captured by, and internalized within, any endocytic vesicle (van Meer & Sprong, 2004).

### **1.E.6 Identification Of Endosomal Compartments**

One of the distinguishing features of the endocytic pathway is the pH variation in different sub-compartments (Demaurex, 2002). Acidification increases progressively from plasma membrane to endocytic vesicles and early endosomes, through to multivesicular bodies, late endosomes, and ultimately lysosomes (Grabe & Oster, 2001). Conversely, the pH of the secretory pathway also becomes more acidic as the cargo travels from the ER and the Golgi network to towards the cell surface (Wu *et al.*, 2001b). Molecules entering cells through the endocytic pathway rapidly undergo a drop in pH from neutral (6.8), to pH 5.9 – 6.0 in the lumen of early endosomes / recycling vesicles (Watson *et al.*, 2005). Further reduction from pH 6.0 to 5.0 occurs through the transition from late endosomes to lysosomes (Watson *et al.*, 2005).

Regulation of the endocytic pathway pH is controlled by several factors, including vacuolar ATPase, chloride and sodium channels, NaK-ATPase, passive proton leaks and the buffering capacity of the organelle lumen (Grabe & Oster, 2001).

### 1.E.7 Dynamic Regulation Of Endocytosis

The dynamics of the endocytic network are regulated by small GTPases of the Rab family (Miaczynska & Zerial, 2002). Rab proteins are well recognized for their roles in vesicle fusion (Schimmoller *et al.*, 1998). However, recent evidence also supports their role in vesicle transport and motor protein recruitment (Jordens *et al.*, 2005). Although over 60 mammalian Rab proteins have been identified (Jordens *et al.*, 2005), only a small fraction of these have been implicated in neurotrophin receptor trafficking (Saxena *et al.*, 2005a; Deinhardt *et al.*, 2006). Rab5 regulates early endosomal sorting (Sonnichsen *et al.*, 2000); Rab4 and Rab11 regulate early and recycling transport (Cavalli *et al.*, 2001); and Rab7 is essential in transitions from EEs to LEs and through to lysosomes (Bucci *et al.*, 2000)(Figure 1.7). Perhaps not surprisingly Rab4, Rab5, Rab7 and Rab11 all represent GTPases that interact with cytoplasmic motor proteins (Jordens *et al.*, 2005).

### 1.E.8 Summary

Receptors activated at the plasma membrane can be internalized via several routes, each one with unique distinguishing membrane, adaptor and scaffolding protein composition. However all these internalization pathways converge on recycling, intracellular transport or degradation of cargo fates. The identity of the distinct endosomal compartments is dynamically regulated through vesicle acidification and specific regulatory protein association.

## 1.F Endocytosis And Signaling: An Evolving Partnership

The concept that the establishment and maintenance of target innervation in neurons depends on the coordinated effects of neurotrophins is supported by an array of data from morphological, biochemical and genetic studies, and the neurotrophic factor hypothesis represents one of the key tenets of neurobiology (Sofroniew *et al.*, 2001). It fails, however, to explain how neurotrophin signal transduction through multiple receptors is communicated across the distance separating the synapse and the cell body.

The retrograde transport of NGF was demonstrated decades ago, creating plausible theories and models for neurotrophin signaling, but receptor signaling was generally believed to occur on the plasma membrane only (Hendry, 1992). Observations that shortly after ligand activation, the majority of activated epidermal growth factor receptors (EGFR's), and their downstream signaling effectors were detected not on the plasma membrane, but on early endosomes (Di Guglielmo *et al.*, 1994), led to the deduction that signaling continues from these compartments after the internalization cascade (Baass *et al.*, 1995). Subsequent work with NGF in PC12 cells (Grimes *et al.*, 1996) was instrumental in the development of the "signaling endosome hypothesis".

It has become apparent in recent years that signaling processes depend not only on activation of a particular set of receptors and downstream secondary effectors, but also on the location and duration of the signal being transduced (Miaczynska *et al.*, 2004b). Furthermore, exciting new findings suggest that signaling machinery is able to achieve a high order of regulation by exploiting the compartmentalization and functional specialization of the endocytic pathway (Gonzalez-Gaitan & Stenmark, 2003). Although endosomal compartmentalization appears ideally suited for regulation of signaling events, alternative facets of long distance growth factor signaling events are also emerging (Howe & Mobley, 2005). The following section will describe the current views on endosomal neurotrophin signaling.


### 1.F.1 Receptor Internalization Mechanisms

The majority of the structural information regarding the internalization of neurotrophin receptors is derived from observations in PC12 cells and DRG neurons, and centers primarily on the interaction of NGF with the TrkA receptor (Grimes *et al.*, 1996; Grimes *et al.*, 1997; Beattie *et al.*, 2000; Howe *et al.*, 2001). So far, three distinct mechanisms of NGF induced TrkA internalization, have been reported (Figure 1.8A).

In PC12 cells NGF treatment results in the formation of dynamin-1, endophilin,  $\beta$ -adaptin and AP-2 dependent clathrin-coated pits situated close to the cell membrane (Grimes *et al.*, 1997; Beattie *et al.*, 2000; Howe *et al.*, 2001). In addition, NGF treatment increases the internalization of multiple membrane-bound and fluid phase markers of clathrin-mediated endocytosis (CME) (Beattie *et al.*, 2000). Ligand dependent p75<sup>NTR</sup> internalization also seems to depend heavily on CME (Bronfman *et al.*, 2003), but with slower internalization kinetics and different vesicular distribution to TrkA (Saxena *et al.*, 2004; Saxena *et al.*, 2005a; Saxena *et al.*, 2005b).

An alternate non-CME route for both Trks (Bilderback *et al.*, 1999; Suzuki *et al.*, 2004; Nagappan & Lu, 2005) and p75<sup>NTR</sup> (Higuchi *et al.*, 2003; Hibbert *et al.*, 2006; Gil *et al.*, 2007) involves internalization mediated by the structural protein caveolin-1 and lipid raft components, which is also dynamin-1 dependent (Nichols, 2003). Although Trks and p75<sup>NTR</sup> appear to have individual fates via caveolae, formation of a high-affinity binding complex between the two receptors relies on lipid raft localization (Ross *et al.*, 1998).

The third emerging route of internalization for both TrkA and TrkB but not p75<sup>NTR</sup> is a form of macropinocytosis mediated by a chaperone protein named pincher (Shao *et al.*, 2002; Valdez *et al.*, 2005). This process is independent of clathrin or caveolin assisted vesicle formation, and is initiated by plasma membrane ruffling (Shao *et al.*, 2002; Valdez *et al.*, 2005), possibly due to



**Figure 1.8 Neurotrophin receptor internalisation.** (A) Neurotrophins and their receptors enter cells via clathrin dependent endocytosis and clathrin independent endocytic mechanisms, such as caveolin-mediated or Pincher-mediated endocytosis into small vesicles of poorly defined origin. These vesicles contain numerous markers of early endosomes, but differ in molecular composition depending on the receptor, ligand and cell population type. (B) Internalised receptors are sorted for different fates either from early endosomes (EEs) or multi-vesicular bodies (MVBs). They can be recycled back to the plasma membrane or undergo rapid degradation, possibly in proteasomes. Some are shuttled for retrograde axonal transport to the cell body where they are able to elicit their effect and be subsequently degraded in lysosomal compartments.


increased receptor aggregation (Nakamura *et al.*, 2002). Interestingly, pincher mediates internalization of activated and autophosphorylated TrkA and TrkB receptors independent of ligand activation (Valdez *et al.*, 2005). These observations are consistent with previously reported density-dependent Trk receptor activation (Hempstead *et al.*, 1992; Saragovi *et al.*, 1998), and Trk signaling in the absence of a ligand (MacInnis & Campenot, 2002; Heerssen *et al.*, 2004).

### 1.F.2 The Signaling Endosome Hypothesis

No consensus has been reached so far regarding the dominant mode of neurotrophin receptor internalization. What makes this issue so puzzling is that independent evidence for neurotrophin-signaling platforms has been provided for each of the three modes of internalization (Zweifel *et al.*, 2005). Internalized receptors can be sorted into various pathways (Figure 1.8B), which include recycling, retrograde transport or degradation (Dechant, 2001; Yano & Chao, 2004). Agreement has been reached, accepting that internalized neurotrophin-receptor pathways appear to converge on a population of poorly defined endocytic vesicles associated with various and specific signaling components (Howe & Mobley, 2004; Zweifel *et al.*, 2005; Bronfman *et al.*, 2007).

The “signaling endosome hypothesis” provides a mechanism for long distance communication between the synapse and the cell body (Howe & Mobley, 2004). It states that target derived NGF, bound to tyrosine phosphorylated TrkA at the pre-synaptic terminal, is internalized into membrane bound signaling organelles that are retrogradely transported along microtubules to the cell body. Moreover, it argues that delivery of tyrosine-phosphorylated TrkA to the soma activates effector-signaling molecules to evoke the changes in gene expression and metabolic activity required for survival and differentiation (Howe & Mobley, 2004) (Figure 1.9).

## Retrograde "Signaling Endosome" Model



**Figure 1.9 The retrograde "signaling endosome" mechanism.** The main mode of retrograde neurotrophin signaling is through the retrograde transport of a membrane-enveloped ligand-receptor complex (clathrin coated pits, CCPs) with characteristics of early endosomes. Some of these endosomes become platforms for unique signaling effectors which are essential for activation of downstream signaling pathways and transport of retrograde neurotrophin signals. These "signaling endosomes" are retrogradely transported to the cell body with the assistance of dynein and microtubule dependent transport mechanisms. The vesicle-associated Trk receptors remains autophosphorylated (also possibly in the absence of the initially bound ligand) and capable of promoting unique sets of signaling cascades depending on whether their location is at the nerve terminal or cell body. Diverse signalling cascades (arrows in boxed diagrams) that are crucial for neurotrophin-dependent survival and axon growth are associated with nerve growth factor (NGF)-TrkA containing endosomes. These include MEK-(MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase) kinase and phosphatidylinositol 3-kinase (PI3K) signalling pathways. The mechanisms responsible for the nucleation of these complexes remain unresolved. Concepts adapted from (Barker et al. 2002)

Evidence supporting the signaling endosome hypothesis includes: accumulation of activated TrkA distal to a lesion site in sciatic nerves (Ehlers *et al.*, 1995; Bhattacharyya *et al.*, 1997), dynein motor based transport of NGF in sensory axons dependent on TrkA and PI3-K (Reynolds *et al.*, 1998), and the requirement of Trk internalization and kinase activity for retrogradely transmitted nuclear responses in compartmentalized sympathetic cultures (Riccio *et al.*, 1997; Watson *et al.*, 2001; Heerssen *et al.*, 2004). Moreover, NGF remains tightly associated with TrkA at an acidic pH generally responsible for receptor-ligand disassociation (Zapf-Colby & Olefsky, 1998), indicating these vesicles may have special properties different from regular endocytic carriers. Recent studies have begun to identify specific of the components of the signaling endosome (Howe *et al.*, 2001; Bronfman *et al.*, 2003; Valdez *et al.*, 2005). However, the identity of these vesicles remains elusive.

### 1.F.3 Signaling Endosome Components

The best characterized model for the study of signaling endosomes comes primarily from PC12 cell investigations of isolated NGF/TrkA (Grimes *et al.*, 1997; Howe *et al.*, 2001) or NGF/p75 complexes (Bronfman *et al.*, 2003). Trk activation induced signaling endosomes have been isolated from clathrin coated vesicles (CCV's), containing associated signaling effectors of the MAPK mediated neuronal survival pathway, and members of the Raf-MEK-Erk1/2 signaling pathway (Howe *et al.*, 2001). Remarkably, several of these components, including inactive Erk1/2, were present in CCV's in the absence of NGF (Howe *et al.*, 2001; Delcroix *et al.*, 2003; Valdez *et al.*, 2005).


Other constituents include members of the phospholipase C- $\gamma$  (PLC $\gamma$ ) and phosphatidylinositol 3-kinase (PI3K) survival signaling pathways (Bartlett *et al.*, 1997; Reynolds *et al.*, 1998; Howe *et al.*, 2001; Watson *et al.*, 2001).

Direct evidence for the association of TrkA with the dynein light chain (Yano *et al.*, 2001), and microtubules (Delcroix *et al.*, 2003), suggests that retrograde transport of signaling endosomes requires dynein-dependent motor function and is necessary component of neurotrophin survival signaling (Figure 1.10).

The PC12 cell model has recently also provided some evidence to the existence of the p75<sup>NTR</sup> receptor in signaling endosomes, internalized via clathrin-coated pits (Bronfman *et al.*, 2003). These cellular interactors include the members of the MAGE family (Salehi *et al.*, 2000). Subcellular fractionation of PC12 cell early/recycling endosomes established that NGF stimulation increased the associated levels of the MAGE associated proteins Rab5, Necdin and NRAGE (Bronfman *et al.*, 2003). In addition it was demonstrated that p75<sup>NTR</sup> internalizes through the clathrin-mediated pathway to the recycling endosome but with kinetics distinct from NGF-TrkA containing vesicles (Bronfman *et al.*, 2003). Although further examination is required, experimental evidence so far supports the existence of spatially and temporally distinct vesicles that have the ability to propagate significantly different biological signals from neuronal terminals to cell bodies (Figure 1.10).

#### 1.F.4 Alternative Models Of Retrograde Signal Propagation

Despite evidence for the signaling endosome model, alternative models for growth factor propagation have been put forward in recent years. Once again the best evidence for these proposals comes from the study of NGF signal propagation (MacInnis & Campenot, 2002). However, none of these models should be considered mutually exclusive, and it makes good evolutionary and biological sense for a neuron to have multiple pathways for important events such as transmission of survival signals (Miller & Kaplan, 2001b).



**Figure 1.10 The signalling endosome.** The main mode of retrograde neurotrophin signalling is through the retrograde transport of a membrane-enveloped ligand–receptor complex with characteristics of early endosomes. These signalling endosomes are platforms for unique signalling effectors such as the small G-proteins Rap1 and Rab5, which are essential for activation of downstream signalling pathways and transport of retrograde neurotrophin signals. Various signalling cascades (arrows) that are crucial for neurotrophin-dependent survival and axon growth are associated with nerve growth factor (NGF)–TrkA containing endosomes. These include constituents of the phospholipase C- $\gamma$  (PLC $\gamma$ ), Raf (a serine/ threonine protein kinase)–MEK (MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase) kinase)–ERK and phosphatidylinositol 3-kinase (PI3K) signalling pathways. The mechanisms responsible for the nucleation of these complexes remain unresolved. Akt, v-akt murine thymoma viral oncogene homologue, also known as protein kinase B; ARMS, ankyrin-rich membrane-spanning protein; B-Raf, v-raf murine sarcoma viral oncogene homologue B1; CRKL, v-crkl sarcoma virus CT10 oncogene homologue; C3G, Rap guanine nucleotide exchange factor (GEF) 1; EEA1, early endosome antigen 1; GAB1, GRB2 (growth factor receptor-bound protein 2)-associated binding protein 1; p85, regulatory subunit of phosphatidylinositol 3-kinase; p110, catalytic subunit of phosphatidylinositol 3-kinase; Shc, Src homology 2 domain-containing transforming protein C. Adapted from (Zweifel *et al*, 2005)


### 1.F.5 Unbounded Receptor Model

The unbounded receptor model is based on the modification of the signaling endosome model, but the receptors within the vesicles are not bound to a ligand (Ye *et al.*, 2003) (Figure 1.11A). The evidence for this concept comes from one of the more unusual properties of TrkA: its propensity to dimerize and auto-activate in the absence of NGF when its concentration in the plasma membrane reaches high enough levels (Hempstead *et al.*, 1992). Another unique property of TrkA, its sustained activity following NGF binding, might also support this model (Miller & Kaplan, 2001b).

In contrast to TrkA, other tyrosine kinases such as the EGF receptor are rapidly internalized and neutralized following EGF binding (Dikic, 2003). These properties suggest that TrkA is a receptor suited to be a retrograde signal carrier, even if NGF dissociates from the receptor during the process of, or after internalization (Miller & Kaplan, 2001b). However, the fact that these unique properties of TrkA have only been reported in PC12 cells, with over expressed TrkA receptors (Hempstead *et al.*, 1992), means that further experimental support of this model is needed, especially under conditions of native TrkA or other tyrosine kinase receptor expression.

### 1.F.6 Wave Propagation Model

The “wave propagation model” or “domino model” stipulates that a wave of activated TrkA on distal axons is propagated retrogradely along the plasma membrane of the cell, delivering the signal to its somatic destination independent of its ligand (Howe & Mobley, 2005). Support for this model of long distance retrograde signaling comes from the observed rapid kinetics of retrograde TrkA phosphorylation (Senger & Campenot, 1997). Other supporting evidence emerged from experiments using focal application of EGF to demonstrate a ligand-



**Figure 1.11 Alternative models of retrograde neurotrophin signaling.** In the “retrograde effector model” local signals downstream from the Trk receptor ligand-dependent phosphorylation in the distal axons are propagated to the cell body where they support activation of other Trk receptors (X), or alternatively relay their signal directly to the nucleus to promote survival (Y). In the “domino wave model”, neurotrophin binding to Trk receptors induces phosphorylation of the tyrosine kinase motifs which subsequently initiate a domino-like wave of ligand-independent Trk phosphorylation down the length of the axon. Upon reaching the cell body, this signaling cascade initiates phosphorylation of somatic Trk receptors that mediate cell survival. Alternatively, this wave of phosphorylation activates secondary messenger survival cascades directly. Concepts adapted from (Ginty et al, 2002).

independent wave of EGF receptor activation for several micrometers along the plasma membrane in transformed A431 cells (Verveer *et al.*, 2000).

As with the previous model, these findings suggest that the signaling endosome is not the only avenue available for the propagation of long distance signals, but further experimental evidence is required to determine whether lateral propagation of activated tyrosine kinases along the plasma membrane can truly account for long range (millimeters, centimeters or longer) signaling in neurons.

### 1.F.7 Signaling Effector Model

The possible existence of alternative retrograde signaling mechanisms not involving the transport of receptor ligand complexes came from experiments showing rapid NGF-induced retrograde tyrosine phosphorylation of TrkA at 1 minute, and other proteins at 15-30 minutes using [<sup>125</sup>I] NGF beads, which are able to bind to TrkA but cannot internalize through its normal activation mechanism (Senger & Campenot, 1997). Further experiments demonstrating that this retrograde signal was not inhibited by tyrosine kinase inhibitor k252a at cell bodies, gave rise to the possibility that survival signaling was achieved without the TrkA-NGF complex, the retrograde transport of phosphorylated TrkA without NGF, or the serial propagation of plasma membrane phosphorylated TrkA (Campenot & MacInnis, 2004). This led to the signaling effector theory, which predicts that NGF binding to TrkA on the axonal membrane activates downstream survival proteins such as PI3-kinase, and that it's these downstream effectors that generate the retrograde signal (Miller & Kaplan, 2002). Interestingly, the essential PI 3-kinase-Akt survival-signaling pathway is activated both locally in axons and retrogradely in the soma by NGF (Miller & Kaplan, 2001b).

In contrast, the issue of spatial segregation has been highlighted, by NGF induced axonal-growth effector mitogen-activated protein (MAP) signaling (Watson *et al.*, 2001). A neurotrophin cocktail-induced activation at the distal

axon was able to activate MAP kinases ERK1 and ERK2 at the local axonal site (Watson *et al.*, 2001). However, an identical stimulus failed to activate ERK1 and ERK2 in the cell bodies, and instead caused the activation of another MAP kinase, ERK5 (Watson *et al.*, 2001). Not surprisingly, things get even more complicated from here. In the experiments using [<sup>125</sup>I] NGF beads, MacInnis and Campenot demonstrated that NGF binding but not internalization, leads to PI 3-kinase-Atk pathway activation but not ERK1 and ERK2 (Miller & Kaplan, 2001b). This finding is similar to that reported when internalization of NGF is disrupted pharmacologically, or by blocking dynamin dependent endocytosis (Miller & Kaplan, 2001b).

These findings imply that secondary effector proteins are able to propagate a survival signal independent of receptor-ligand internalization, and that tyrosine kinase signaling substrates activated in this manner can differ, depending on the local or retrograde nature of this signal.

### 1.F.8 Summary

The study of retrograde signaling has leapt beyond the categorical principle that retrograde signals are carried to the cell body only in the form of receptor-ligand complex endosomes internalized at axon terminals. The described body of evidence divides NGF (and probably other growth factor) signaling into two very distinct mechanisms. One that requires the internalization of the ligand receptor complex which forms that basis of the signaling endosome hypothesis, and a number of possible mechanisms that are independent of ligand internalization.

Even with by far the most studied and experimentally supported model of signaling endosomes (Grimes *et al.*, 1996; Beattie *et al.*, 1996; Grimes *et al.*, 1997; Beattie *et al.*, 2000; Sandow *et al.*, 2000; Howe *et al.*, 2001; Delcroix *et al.*, 2003; Ye *et al.*, 2003), there is now enough evidence to support the existence of alternative models of retrograde growth factor signaling (Miller & Kaplan, 2002; Campenot & MacInnis, 2004). The functional significance of having multiple

retrograde signaling mechanisms is still being contested (Campenot & MacInnis, 2004; Von Bartheld, 2004; Howe & Mobley, 2005).

The concept of signaling endosomes is relevant and biologically important for a number of reasons. One obvious role for endocytosis in signaling is to provide temporal regulation (Miaczynska *et al.*, 2004b), as the duration of signaling is a crucial parameter in determining the biological output of a specific signaling cascade (Ginty & Segal, 2002). The duration of the signaling process also depends on the proportion of internalized receptors undergoing degradation, compared to those targeted for recycling back to the plasma membrane (Weible *et al.*, 2001).

All this evidence suggests the existence of numerous highly specific and regulated pathways in neurons designed to deliver signals crucial to the development and survival of the nervous system. The number of degenerative diseases that affect motor neurons suggests that the extremely long axons of these neurons may be particularly susceptible to defects in axonal transport (Hirokawa & Takemura, 2003). Given the evidence that neuronal retrograde transport is important for the survival and maintenance of neurons, it is not surprising that evidence is also emerging in support of failures in retrograde transport playing a crucial part in the degeneration of motor neurons (Hirokawa & Takemura, 2003).

## **1.G Motor Neuron Cell Line Clones in Research**

### **1.G.1 Existing Motor Neuron Cell Lines**

Clonal cell lines derived from specific neuronal populations with somatic cell fusion techniques have been widely used to identify and characterize properties specific to those neurons (Greene *et al.*, 1975; Heumann *et al.*, 1979; Hammond *et al.*, 1986; Crawford *et al.*, 1992; Lee *et al.*, 1990). A thorough database search of the literature, describing development and subsequent studies using immortalized cell lines with motor neuron-like characteristics reveals only four such clones in existence. Altogether, these amount to just over 60 peer reviewed publications, compared to well over 9600 published studies utilizing and

manipulating the PC12 cell, which has become the most commonly used neuronal cell line model system. Three of these hybrid cell lines have been produced through somatic fusion between the N18TG2 neuroblastoma and isolated embryonic spinal cord-enriched cells. These include, NSC-34 and NSC-19 (Cashman *et al.*, 1992), MN-1 (Salazar-Grueso *et al.*, 1991), and rat ventral spinal cord (VSC 4.1) motor neuron cells (Smith *et al.*, 1994). Other motor neuron-like cell lines, the human spinal cord cell lines (HSP1, HSP2 and HSP4) have also been reported in the literature (Li *et al.*, 2000). However, they were immortalized using a retroviral vector method.

### 1.G.2 Current Uses For Motor Neuron Cell Lines

Major motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy remain high priority disorders due to their incessant progressive course and unfailingly fatal prognosis. Hence, it's no surprise that majority of studies using these motor neuron cell lines focus on areas of apoptotic cell death mechanisms and motor neuron disease patho-physiology (Durham *et al.*, 1993; Mosier *et al.*, 1995; Colom *et al.*, 1997; Turner *et al.*, 2003; Park *et al.*, 2004; Koh *et al.*, 2005; Wen *et al.*, 2006; Rizzardini *et al.*, 2006), as well as neuroprotection (Chapman & Chan, 1999; Mercer *et al.*, 2000; Keir *et al.*, 2001; Liu *et al.*, 2002; Rembach *et al.*, 2004; Das *et al.*, 2005; Zhai *et al.*, 2005; Weishaupt *et al.*, 2006).

Although the MN-1 and VSC 4.1 clones have been described as motoneuron-like, not a great deal of information has been forthcoming regarding more detailed physiological properties shared with motor neurons. Both of these clones express the cholinergic marker choline acetyltransferase (ChAT) (Salazar-Grueso *et al.*, 1991; Smith *et al.*, 1994), a property lacking in the parent neuroblastoma cell line (Amano *et al.*, 1974), and common with motor neurons. However the expression of ChAT in the spinal cord is not restricted solely to motor neurons (Phelps *et al.*, 1984), and should not be used as a definitive motor neuronal marker. Robust cell morphology including the extension of neurite-like processes has been partly used as a characteristic shared with the neuronal

phenotype, but offers little more in terms of further motor neuron-comparative biochemical analysis, such as acetyl choline (ACh) accumulation and release (Cashman *et al.*, 1992). Hence, in comparison with the NSC-34 cell line, relatively little is known about the biological similarities between MN-1 and VSC 4.1 cell lines and motor neurons.

Since its introduction, the NSC-34 cell line has become the best-characterized and most routinely used to investigate motor neuron biology and pathology, with relatively detailed biochemical characterization undertaken by the creators of the NSC clones (Hunter *et al.*, 1991; Cashman *et al.*, 1992; Durham *et al.*, 1993). To our knowledge, only the NSC-34 and NSC-19 clones originating from (Cashman *et al.*, 1992) and MN-1 cells (Salazar-Gruesso *et al.*, 1991) have been briefly examined in relation to basic motor neuronal biology and behavior (Hunter *et al.*, 1991; Matsumoto *et al.*, 1995; Moscoso & Sanes, 1995; Usuki *et al.*, 2001), including studies describing the effects of growth factors (Trupp *et al.*, 1999; Usuki *et al.*, 2001; He *et al.*, 2002; Turner *et al.*, 2004).

### 1.G.3 NSC-34 Motor Neuronal Characteristics

Murine neuroblastoma × spinal cord (NSC) hybrid cell lines were developed as an inexhaustible resource available for the study of motor neuron biology (Cashman *et al.*, 1992). The availability of a motor neuron cell line could surmount many of the difficulties inherent in the use of motor neurons derived from primary tissues including low yield, limited purity of motor neuron preparations and poor survival rates (Fischbach & Dichter, 1974; Kato *et al.*, 1985; O'Brien & Fischbach, 1986). Of the 30 NSC hybrids produced only two, NSC-19 and NSC-34, expressed properties expected of motor neurons (Kato *et al.*, 1985). Only NSC-34 cells however, possessed further characteristics similar to those occurring in neuronal development (Cashman *et al.*, 1992).

All NSC hybrid cell lines were produced through somatic fusion between the N18TG2 aminopterin-sensitive neuroblastoma and motor neuron enriched embryonic day 12-14 spinal cord cells (Cashman *et al.*, 1992). NSC-34 express

many of the morphological and physiological properties of motor neurons including: extension of processes, synthesis and storage of ACh, support of action potentials, induction of myotube twitching, formation of contacts with cultured myotubes, and expression of neurofilament proteins (Cashman *et al.*, 1992). In addition NSC-34 cells are also able to induce ACh receptor (AChR) clustering upon co-culture with myotubes, suggesting that these cells might be able to model aspects of early neuromuscular synapse formation (Martinou *et al.*, 1991). It has also been shown that NSC-34 cells adhere specifically to the leucine-arginine-glutamate (LRE) motif of S-laminin, a neuromuscular synapse specific basal lamina glycoprotein (Hunter *et al.*, 1991).


Since the availability of the NSC-34 cell line a multitude of other neuronal characteristics have been reported (summarized in Table 1). Among these are findings reporting the expression of numerous receptors to motor neuron growth factors including: CNTF (Usuki *et al.*, 2001), responsiveness to NGF, BDNF, and NT-4 (Turner *et al.*, 2004), as well as tumour necrosis factor-alpha receptor (TNF- $\alpha$ R) (He *et al.*, 2002). Further studies have used NSC-34 cells in development of a glutamate-sensitive motor neuron cell line (Eggett *et al.*, 2000; Rembach *et al.*, 2004) and a novel NSC-34tTA<sup>40</sup> cell line that permits tetracycline-regulated gene expression (Babetto *et al.*, 2005), as well as in detailed characterization of their membrane ganglioside profile (Matsumoto *et al.*, 1995).

#### 1.G.4 Morphological Comparison Between NSC-34 Cells and Primary Motor Neuron Cultures

Spinal cord motor neurons have been studied in various forms of dissociated spinal cord preparations (Sobkowicz *et al.*, 1968; Peacock *et al.*, 1973; Berg & Fischbach, 1978; Phelps *et al.*, 1984; Lombard-Golly *et al.*, 1990) and purified motor neuron populations (O'Brien & Fischbach, 1986; Krieger & Kim, 1991; Citron *et al.*, 1997; Anderson *et al.*, 2004). Morphologically, motor neurons are typically identified as having a large soma harboring multiple dendritic arborizations and a long axon, usually identifiable by its relatively constant diameter (Figure 1.12A) (Deinhardt & Schiavo, 2005). However dissociated spinal cord cultures or pure isolated motor neuron cultures generally contain a range of large bipolar and multi-polar cell types with robust neurites (Figure 1.12 B and C) (Fischbach & Dichter, 1974; O'Brien & Fischbach, 1986). In the case of dissociated spinal cord cultures, these also contain other neuronal types and non-neuronal cells (Peacock *et al.*, 1973; Berg & Fischbach, 1978; Digby *et al.*, 1985).

An overwhelming majority of differentiated NSC-34 cells resemble cultures of spinal cord neurons and purified motor neurons (Figure 1.12C). These are typically large cells with multi-polar neurite projections, although a small percentage of the cell population exhibits a flat fibroblast-like morphology. However, these flat fibroblast-like cells also sometimes possess neurite like projections.

In summary, NSC-34 cell represent to date the best-characterized and most extensively studied immortal motor neuron-like cells. Their expanding characterization of many motor neuron properties, and close morphological resemblance to primary motor-neuronal cultures makes them a superior candidate for investigating various aspects of motor neuron biology. Nevertheless, due to the very different neural crest lineage of the NSC-34 cells, it would be of future interest to examine a number of other neuronal and non-neuronal characteristics compared to (1) neural crest-like cell lines that do not



**Figure 1.12 Morphological comparison between cultured primary embryonic motor neurons and NSC-34 cells.** (A) Scanning electron micrograph of a cultured spinal cord motor neuron. Motor neurons typically have a large cell body, multiple dendritic arborizations and a single long axon with a relatively constant diameter, scale bar = 10  $\mu\text{m}$  (figure adapted from : *Deinhardt and Schiavo, 2005*). Interference contrast micrographs of (B) dissociated embryonic spinal cord cell in culture; scale bar = 25  $\mu\text{m}$  (adapted from fig.12a in: *Fischbach & Dichter, 1974*), and (C) 7-day old sorted embryonic motor neurons (taken from Fig.6 in: *O'Brian & Fischbach, 1986*). (D) Relief contrast micrograph of a differentiated NSC-34 cell cultured for 5 days. In a differentiated population there are neuronal type cells as well as cells resembling fibroblasts (arrows). When differentiated, the motor neuron-like cells possess a large soma and multiple neuronal-like arborizations and projections, resembling motor neurons, scale bar = 25  $\mu\text{m}$ .

**Table 1 - Neuronal Properties and Markers of NSC-34 cell line**

|                                    | N18TG2 | NSC-34 | NSC-34 <sub>p</sub> | Method                     | Reference                        |
|------------------------------------|--------|--------|---------------------|----------------------------|----------------------------------|
| <b>Cholinergic Markers</b>         |        |        |                     |                            |                                  |
| ACh release                        | -      | +      | +                   | [ <sup>14</sup> C] Choline | (Cashman <i>et al.</i> , 1992)   |
| ChAT                               | -      | +      | +                   | Fonnum Assay               | (Cashman <i>et al.</i> , 1992)   |
| nAChR                              | -      | +      | +                   | IHC                        | (Rembach <i>et al.</i> , 2004)   |
| <b>Growth Factor Receptors</b>     |        |        |                     |                            |                                  |
| Trk A                              | ND     | -      | -                   | Western Blot               | (Turner <i>et al.</i> , 2004)    |
| Trk B                              | -      | +      | +                   | Western Blot               | (Turner <i>et al.</i> , 2004)    |
| p-75                               | -      | +      | +                   | Western Blot               | (Turner <i>et al.</i> , 2004)    |
| NRH2                               | -      | +      | +                   | Western Blot               | (Turner <i>et al.</i> , 2004)    |
| CNTF-r                             | -      | +      | +                   | IHF                        | (Usuki <i>et al.</i> , 2001)     |
| Lif-R                              | -      | ND     | ND                  | N/A                        | (Usuki <i>et al.</i> , 2001)     |
| Gp-130                             | -      | +      | ND                  | IHF                        | (Usuki <i>et al.</i> , 2001)     |
| TNF- $\alpha$ R                    | ND     | +      | +                   | Viability Assay            | (He <i>et al.</i> , 2002)        |
| <b>Cytoskeletal Proteins</b>       |        |        |                     |                            |                                  |
| NF-68                              | -      | +      | +                   | IHC                        | (Cashman <i>et al.</i> , 1992)   |
| NF-150                             | -      | +      | +                   | IHC                        | (Cashman <i>et al.</i> , 1992)   |
| NF-200                             | -      | +      | +                   | IHC                        | (Cashman <i>et al.</i> , 1992)   |
| MAP-1a                             | -      | +      | +                   | IHC                        | (Cashman <i>et al.</i> , 1992)   |
| MAP-2                              | -      | -      | -                   | IHC                        | (Cashman <i>et al.</i> , 1992)   |
| GFAP                               | -      | -      | -                   | IHC                        | (Cashman <i>et al.</i> , 1992)   |
| Vimentin                           | -      | +      | -                   | IHC                        | (Cashman <i>et al.</i> , 1992)   |
| $\beta$ -tubulin III               | ND     | +      | +                   | Western Blot               | (Rembach <i>et al.</i> , 2004)   |
| <b>Gangliosides</b>                |        |        |                     |                            |                                  |
| GM-1                               | +      | +      | +                   | CT IHC                     | (Matsumoto <i>et al.</i> , 1995) |
| GM-2                               | +      | +      | +                   | IHC                        | (Matsumoto <i>et al.</i> , 1995) |
| GM-3                               | +      | ND     | ND                  | IHC                        | (Matsumoto <i>et al.</i> , 1995) |
| GD1a                               | +      | +      | +                   | IHC                        | (Matsumoto <i>et al.</i> , 1995) |
| GD1b                               | ND     | ND     | ND                  | Western Blot               | (Matsumoto <i>et al.</i> , 1995) |
| <b>Glutamate Receptor Proteins</b> |        |        |                     |                            |                                  |
| NMDAR1                             | -      | -      | +                   | IHC                        | (Eggett <i>et al.</i> , 2000)    |
| NMDAR2a/b                          | -      | -      | +                   | IHC                        | (Eggett <i>et al.</i> , 2000)    |
| GluR1                              | -      | -      | +                   | IHC                        | (Eggett <i>et al.</i> , 2000)    |
| GluR2/3                            | -      | -      | +                   | IHC                        | (Eggett <i>et al.</i> , 2000)    |
| GluR2                              | -      | -      | +                   | IHC                        | (Eggett <i>et al.</i> , 2000)    |
| GluR4                              | -      | -      | +                   | IHC                        | (Eggett <i>et al.</i> , 2000)    |
| KA2                                | -      | -      | +                   | IHC                        | (Eggett <i>et al.</i> , 2000)    |

**Table 1 cont.- Neuronal Properties and Markers of NSC-34 cell line**

|                                       | N18TG2 | NSC-34 | NSC-34 <sub>p</sub> | Method           | Reference                      |
|---------------------------------------|--------|--------|---------------------|------------------|--------------------------------|
| <b>Cell Adhesion Molecules (CAMs)</b> |        |        |                     |                  |                                |
| L1                                    | +      | +      | ND                  | mRNA/PCR         | (Moscoso & Sanes, 1995)        |
| Nr-CAM/Bravo                          | -      | +      | ND                  | mRNA/PCR         | (Moscoso & Sanes, 1995)        |
| Neurofascin/ABGP                      | +      | +      | ND                  | mRNA/PCR         | (Moscoso & Sanes, 1995)        |
| N-CAM                                 | -      | +      | ND                  | mRNA/PCR         | (Moscoso & Sanes, 1995)        |
| <b>Neuronal Nuclear Markers</b>       |        |        |                     |                  |                                |
| NeuN                                  | ND     | +      | +                   | Western Blot     | (Rembach <i>et al.</i> , 2004) |
| <b>Other Neuronal Properties</b>      |        |        |                     |                  |                                |
| Process extension                     | -      | +      | +                   | Phase Contrast   | (Cashman <i>et al.</i> , 1992) |
| Myotube twitch induction              | -      | +      | +                   | dbcAMP add.      | (Cashman <i>et al.</i> , 1992) |
| Action potential generation           | -      | +      | +                   | Electrical stim. | (Cashman <i>et al.</i> , 1992) |
| AchR clusters on myotubes             | -      | +      | ND                  | Co-culture       | (Cashman <i>et al.</i> , 1992) |

Table legend: ND – Not Determined; N18TG2 – parent neuroblastoma, NSC-34<sub>p</sub> – Differentiated NSC-34 cells; IF – Immunofluorescence; IHC – Immunohistochemistry; CT – Cholera toxin; ES – Electrical Stimulation; PCM – Phase Contrast Microscopy.

differentiate in serum; (2) progenitor cell lines, some of which can partially differentiate in culture; and (3) mature neuronal cell lines or bipotential cell lines of murine origin.

## **1.H Concluding Remarks**

Neurotrophins are essential regulators of neuronal development, which mediate their effects through multiple ligand-receptor complexes, and an array of downstream signaling effectors. Advances in understanding the nature and regulation of endocytic mechanisms have established this process as a suitable candidate for spatio-temporal regulation of complex signaling events. Subsequently, the emergence of structural details regarding multiple modes of ligand-dependent receptor internalization, and downstream signaling, have been instrumental in beginning to unravel the diverse and highly regulated mechanisms of neurotrophin signal transduction.

The use of PC12 cells and compartmentalized sympathetic neuron cultures have proven extremely valuable in these studies. However, neurotrophin actions can be highly cell type specific due to differential receptor expression and ligand availability. Neurotrophins are as vital to motor neurons as any other neuronal population, and motor neuron diseases have been recently linked with defects in neurotrophin signaling and transport. Unfortunately a reliable motor neuron model for the study of neurotrophin biology has not yet been established.

The NSC-34 cell line appears as the most suitable candidate for such a model. The increasing use of NSC-34 cells also means that they represent best-characterized motor neuron cell line available. Although they have been used extensively in studies of ALS associated apoptosis mechanisms, very little is known about their suitability for the study of neurotrophin biology, and receptor trafficking in particular. The following chapters describe the characterization and use of the NSC-34 cell line for the study of neurotrophin receptor trafficking.

## **Chapter 2: Materials And Methods**

## **2.A Materials**

### **2.A.1 Cell culture, media supplements and growth factors**

Dulbecco's modified Eagle's medium (DMEM), Ham's F-12 medium, F-12 Kaighn's modification medium, RPMI 1640 medium, fetal bovine serum (FBS), horse serum (heat inactivated), nonessential amino acids (NEAA), L-glutamine, penicillin-streptomycin-glutamine (PSG), HEPES buffer, N-2 Supplement and Trypsin-EDTA solution were obtained from Invitrogen Life Technologies (Mulgrave, Australia). Rat-tail collagen, poly-L-lysine (70,000MW), all-trans-retinoic acid (RA), bovine serum albumin (BSA) and N-1 supplement were purchased from Sigma (Castle Hill, Australia). Purified mouse nerve growth factor (NGF) was a kind gift from Prof. Ian Hendry (ANU, Australia). Recombinant human BDNF, NT-3 and NT-4 were purchased from Chemicon (Boronia, Australia). Purified S-laminin was a gift from Prof. Salvatore Carbonetto (CRN, McGill University, Canada). Hybridoma fusion and cloning supplement (HFCS) was from Roche Diagnostics GmbH (Mannheim, Germany).

### **2.A.2 Tissue culture plastic and glassware**

Tissue culture plastic-ware was purchased from Interpath Services (West Heidelberg, Australia) and Sardstedt (Adelaide, Australia). Glass coverslips, 12mm and 42mm in diameter and 0.17mm thickness were sourced from Stennick Scientific (Adelaide, Australia).

### **2.A.3 Fluorescent dyes and compounds**

All Alexa-Fluor Succinimidyl ester dyes (488, 568, 594, 647), DAPI, Hoechst 33258, LysoSensor Yellow/Blue-Dextran (MW ~10,000), LysoSensor Green DND-189, LysoTracker Red DN-99, and transferrin 555 conjugates, were purchased from Invitrogen Life Technologies (Mulgrave, Australia). Fluorescein Isothiocyanate (FITC) isomer I, annexin-V-FITC apoptosis kit and propidium iodide (PI) were sourced from Sigma (Castle Hill, Australia). The C-fragment of tetanus toxin-FITC conjugate was provided by List Biological Labs (California,

USA).

#### 2.A.4 Primary and secondary antibodies

Primary antibodies listed in (Table 2.1 -2.2) were obtained from various sources. MLR-1, MLR-2 and MLR-3 antibodies against mouse p75<sup>NTR</sup> (Rogers *et al*, 2006) were kindly supplied by Mary-Louise Rogers (Flinders University, Australia). Polyclonal antibodies 9560 and 9992 against the extracellular and cytoplasmic domains of p75<sup>NTR</sup> respectively, and phospo-TrkB (pTrkB-18664) rabbit polyclonal were kindly supplied by Prof. Moses Chao (NYU, New York, USA). Vesicular acetylcholine transporter (VACht) antibody (V-007) was purchased from Phoenix Pharmaceuticals (Belmont, CA, USA). GT1b hybridoma clones were a kind gift from Prof. Ronald Schnaar (John Hopkins University, Baltimore, USA). The sortilin and neurofilament 200 (NF-200) polyclonal antibodies were purchased from Sapphire Biosciences (Redfern, Australia). Antibodies against clathrin-HC, AP-1 and AP-2 were provided by Antibody Technology Australia Pty. Ltd. (Adelaide, Australia). Monoclonal antibodies against EEA-1, Limp-II and Lamp-1 were produced by Dr. D.A. Brooks, Department of Chemical Pathology, Women's and Children's Hospital (Adelaide, Australia).

All secondary detection antibodies are listed in Table 3 and 4. Secondary detection antibodies conjugated with Cy-fluorophores, horseradish peroxidase (HRP) or alkaline phosphatase, were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Secondary antibody Alexa-Fluor conjugates were obtained from Invitrogen Life Technologies (Mulgrave, Australia). Quantum dot 525 and 655 conjugated secondary [F(ab)<sub>2</sub> –fragments] antibodies were supplied by Chemicon (Boronia, Australia). All secondary detection antibodies purchased, were cross-absorbed against all other species to minimize non-specific binding in multiple-labeling experiments. All other antibodies were produced in our laboratory.

**Table 2.1 - List of primary antibodies and working dilutions.**

| Name                        | Antigen                       | Host Species | Form | Dilution    | Source     |
|-----------------------------|-------------------------------|--------------|------|-------------|------------|
| <b>MC192</b>                | <i>rat p75<sup>NTR</sup></i>  | Mouse        | AP   | FACS 1: 200 | Flinders   |
|                             |                               |              |      | WB N/A      | University |
|                             |                               |              |      | IF 1: 1000  |            |
| <b>MLR-1</b>                | <i>(rh) p75<sup>NTR</sup></i> | Mouse        | AP   | FACS 1: 200 | Flinders   |
|                             |                               |              |      | WB N/A      | University |
|                             |                               |              |      | IF 1: 1000  |            |
| <b>MLR-2</b>                | <i>(rh) p75<sup>NTR</sup></i> | Mouse        | AP   | FACS 1: 200 | Flinders   |
|                             |                               |              |      | WB N/A      | University |
|                             |                               |              |      | IF 1: 1000  |            |
| <b>MLR-3</b>                | <i>(rh) p75<sup>NTR</sup></i> | Mouse        | AP   | FACS 1: 200 | Flinders   |
|                             |                               |              |      | WB N/A      | University |
|                             |                               |              |      | IF 1: 1000  |            |
| <b>027RB-SW0<br/>(TrkB)</b> | <i>(nr)TrkB</i>               | Rabbit       | WS   | FACS 1:200  | Flinders   |
|                             |                               |              |      | WB 1:500    | University |
|                             |                               |              |      | IF 1:1000   |            |
| <b>TrkA</b>                 | <i>(nr)TrkA</i>               | Rabbit       | WS   | FACS 1:200  | Chemicon   |
|                             |                               |              |      | WB 1:500    |            |
|                             |                               |              |      | IF 1:1000   |            |
| <b>Ab07-266<br/>(TrkC)</b>  | <i>(r)TrkC</i>                | Goat         | AP   | FACS 1:200  | Chemicon   |
|                             |                               |              |      | WB 1:500    |            |
|                             |                               |              |      | IF 1:1000   |            |
| <b>MabGT1b-1</b>            | <i>(rh)GT1b</i>               | Mouse        | AP   | FACS 1:200  | JHU        |
|                             |                               |              |      | WB 1:500    |            |
|                             |                               |              |      | IF 1:1000   |            |
| <b>MabGT1b-2a</b>           | <i>(rh)GT1b</i>               | Mouse        | AP   | FACS 1:200  | JHU        |
|                             |                               |              |      | WB 1:500    |            |
|                             |                               |              |      | IF 1:1000   |            |
| <b>AB312<br/>(GQ1b)</b>     | <i>(nr)GQ1b</i>               | Mouse        | AP   | FACS 1:200  | Chemicon   |
|                             |                               |              |      | WB 1:500    |            |
|                             |                               |              |      | IF 1:1000   |            |
| <b>H-V007<br/>(VACHT)</b>   | <i>(r)VACHT</i>               | Goat         | AP   | FACS 1:200  | Phoenix    |
|                             |                               |              |      | WB 1:500    | Pharm.     |
|                             |                               |              |      | IF 1:1000   |            |
| <b>Ab-31544<br/>(VACHT)</b> | <i>(r)VACHT</i>               | Sheep        | AP   | FACS 1:200  | Abcam      |
|                             |                               |              |      | WB 1:500    |            |
|                             |                               |              |      | IF 1:1000   |            |

**Table 2.2 - List of primary antibodies and working dilutions.**

| Name              | Antigen                  | Host Species | Form | Dilution   | Source      |
|-------------------|--------------------------|--------------|------|------------|-------------|
| <b>CB11R</b>      | <i>(nr) Clathrin</i>     | Rabbit       | WS   | FACS N/A   | Antibody    |
|                   |                          |              |      | WB 1:500   | Technology  |
|                   |                          |              |      | IF 1:1000  | Australia   |
| <b>CB21R</b>      | <i>(nr)API-Subunit</i>   | Rabbit       | WS   | FACS N/A   | Antibody    |
|                   |                          |              |      | WB 1:500   | Technology  |
|                   |                          |              |      | IF 1:1000  | Australia   |
| <b>CBR31R</b>     | <i>(nr)API/2-Subunit</i> | Rabbit       | WS   | FACS N/A   | Antibody    |
|                   |                          |              |      | WB 1:500   | Technology  |
|                   |                          |              |      | IF 1:1000  | Australia   |
| <b>AB4680</b>     | <i>(nm) 200kDa</i>       | Chicken      | IgG  | FACS N/A   | Abcam       |
|                   |                          |              |      | WB 1:500   |             |
|                   |                          |              |      | IF 1:1000  |             |
| <b>(NF-200)</b>   | <i>Neurofilament</i>     |              |      | WB 1:500   |             |
|                   |                          |              |      | IF 1:1000  |             |
|                   |                          |              |      |            |             |
| <b>LAMP-1</b>     | N/A                      | Sheep        | AP   | FACS N/A   | WCH         |
|                   |                          |              |      | WB 1:200   |             |
|                   |                          |              |      | IF 1:1000  |             |
| <b>LIMP-2</b>     | N/A                      | Mouse        | AP   | FACS N/A   | WCH         |
|                   |                          |              |      | WB 1:200   |             |
|                   |                          |              |      | IF 1:1000  |             |
| <b>EEA-1</b>      | N/A                      | Goat         | AP   | FACS N/A   | WCH         |
|                   |                          |              |      | WB 1:200   |             |
|                   |                          |              |      | IF 1:1000  |             |
| <b>EEA-1</b>      | N/A                      | Mouse        | AP   | FACS N/A   | BD          |
|                   |                          |              |      | WB 1:500   | Biosciences |
|                   |                          |              |      | IF 1:1000  | Pty. Ltd.   |
| <b>Ab-16640</b>   | <i>(sh)Sortilin</i>      | Rabbit       | AP   | FACS 1:200 | Abcam       |
|                   |                          |              |      | WB 1:500   |             |
|                   |                          |              |      | IF 1:1000  |             |
| <b>(Sortilin)</b> |                          |              |      | WB 1:500   |             |
|                   |                          |              |      | IF 1:1000  |             |
|                   |                          |              |      |            |             |
| <b>anti-Rab-4</b> | <i>(sh) Rab-4</i>        | Rabbit       | WS   | FACS N/A   | Chemicon    |
|                   |                          |              |      | WB 1:100   |             |
|                   |                          |              |      | IF 1:100   |             |
| <b>anti-ChAT</b>  | <i>(nm) ChAT</i>         | Rabbit       | WS   | FACS       | Chemicon    |
|                   |                          |              |      | WB         |             |
|                   |                          |              |      | IF         |             |
| <b>HB-9</b>       | N/A                      | Rabbit       | WS   | FACS N/A   | Flinders    |
|                   |                          |              |      | WB 1:200   | Tech.       |
|                   |                          |              |      | IF N/A     |             |

Legend: AP, affinity purified; IgG, purified immunoglobulin fractions; WS, whole serum; FACS, fluorescence activated scanning; IF, Immunofluorescence assays; WB, Western blot assay; (r), recombinant; (rh), recombinant human; (sh), synthetic human; (nr), native rat.

**Table 3 - List of fluorescent secondary antibodies and working dilutions.**

| Fluorescent Secondary antibody conjugates | Host Species | Form               | Dilution   |
|---|--------------|--------------------|------------|
| Cy-2 / Cy-3 AffiniPure Anti-Goat          | Donkey       | IgG (H+L)          | FACS 1:250 |
|   |              |                    | IF 1:400   |
| Cy-2 / Cy-3 AffiniPure Anti-Mouse         | Donkey       | IgG (H+L)          | FACS 1:250 |
|   |              |                    | IF 1:400   |
| Cy-2 / Cy-3 / Cy-5 AffiniPure Anti-Rabbit | Donkey       | IgG (H+L)          | FACS 1:250 |
|   |              |                    | IF 1:400   |
| Cy-2 / Cy-3 / Cy-5 AffiniPure Anti-Sheep  | Donkey       | IgG (H+L)          | FACS 1:250 |
|   |              |                    | IF 1:400   |
| Alexa Fluor 488, 594, 647 Anti-Mouse      | Goat         | IgG (H+L)          | FACS 1:200 |
|   |              |                    | IF 1:1000  |
| Alexa Fluor 488, 594, 647 Anti-Rabbit     | Goat         | IgG (H+L)          | FACS 1:200 |
|   |              |                    | IF 1:1000  |
| Alexa Fluor 647 Anti-Chicken              | Rabbit       | IgG (H+L)          | FACS 1:200 |
|   |              |                    | IF 1:1000  |
| Alexa Fluor 568 Anti-Goat                 | Donkey       | IgG (H+L)          | FACS 1:200 |
|   |              |                    | IF 1:1000  |
| Quantum Dot 525 Anti-Mouse                | Goat         | F(ab) <sub>2</sub> | IF 1:1000  |
| Quantum Dot 655 Anti-Rabbit               | Goat         | F(ab) <sub>2</sub> | IF 1:1000  |

Legend: IgG (H+L), Immunoglobulin heavy and light chain; F(ab)<sub>2</sub>, Fab immunoglobulin fragment; FACS, fluorescence activated cell scanning; IF, Immunofluorescence assays.

**Table 4 - List of HRP and Alkaline Phosphatase conjugated secondary antibodies and working dilutions.**

| Secondary antibody conjugates           | Host Species | Form               | Dilution      |
|---|--------------|--------------------|---------------|
| Alkaline Phosphatase Anti-Goat,         | Donkey       | IgG (H+L)          | ELISA 1:10000 |
| Mouse, Rabbit and Sheep                 |              |                    | WB 1:5000     |
| Alkaline Phosphatase Anti-Goat,         | Donkey       | F(ab) <sub>2</sub> | ELISA 1:10000 |
| Mouse, Rabbit and Sheep                 |              |                    | WB 1:5000     |
| Horseradish Peroxidase conjugated Anti- | Donkey       | IgG (H+L)          | ELISA 1:10000 |
| Goat, Mouse, Rabbit and Sheep           |              |                    | WB 1:5000     |
| Horseradish Peroxidase conjugated Anti- | Donkey       | F(ab) <sub>2</sub> | ELISA 1:10000 |
| Goat, Mouse, Rabbit and Sheep           |              |                    | WB 1:5000     |

Legend: IgG (H+L), Immunoglobulin heavy and light chain; F(ab)<sub>2</sub>, Fab immunoglobulin fragment; ELISA, Enzyme-Linked ImmunoSorbent Assay; WB, Western blot assays.

### **2.A.5 Protein chromatography**

Sephadex-G25-Fastflow gel and sepharose-6B gel, columns and chromatography reagents were acquired from GE Healthcare Bio-Sciences (Uppsala, Sweden). Protein-G Agarose Fastflow gel was purchased from Chemicon (Boronia, Australia).

### **2.A.6 Chemical reagents, kits and compounds**

Caltag Fix & Perm Cell Permeabilization kit and NuPAGE 4-12% Bis-Tris gels were purchased from Invitrogen Life Technologies (Mulgrave, Australia). TMB Peroxidase EIA Substrate kit and SDS-PAGE pre-stained standards were supplied by Bio-Rad (Regents Park, Australia). ECL and ECF western Blot Kits were from GE Healthcare Bio-Sciences (Uppsala, Sweden). WST-1 ECS cell proliferation assay kits were provided by Chemicon (Boronia, Australia). All custom synthesis peptides and peptide conjugates for antibody production were manufactured by Auspep Pty. Ltd. (Parkville, Australia). (4)-nitrophenyl phosphate disodium salt hexahydrate, dimethyl sulfoxide (DMSO), Staurosporine, Picric Acid, Triton X-100 and other general chemicals were purchased from Sigma (Castle Hill, Australia).

### **2.A.7 Data analysis**

Quantitative data analysis and graphs were compiled with GraphPad PRISM software (San Diego, USA). Unless otherwise stated, image processing and figure compilation was performed with NIH ImageJ and Adobe Photoshop CS software.

## **2.B Methods**

### **2.B.1 Mammalian cell culture**

*Neuroblastoma x spinal cord cells (NSC-34)* (kindly provided by Dr. Neil Cashman, University of Toronto), were maintained in Dulbecco's modified

Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/ streptomycin/glutamine solution (PSG) as previously described (Cashman *et al.*, 1992) Cells were subcultured every 3-4 days at a ratio of 1:5. To slow the proliferation and enhance the maturation of these cells, they were grown to 80% confluence and the maintenance medium (DMEM, 10% FBS, 1% PSG) was exchanged for differentiating medium comprising of 1:1 DMEM plus Ham's F12, 1% FBS, 1% PSG, and 1% modified Eagle's medium non-essential amino acids (NEAA). After 24-48 hours culture in the differentiating medium, there was a large amount of cell death. At this stage the medium was replaced with fresh differentiating medium, and the remaining populations of cells were allowed to proliferate for up to ~7 days, with fresh media change every 2 days. The differentiated cells (NSC-34<sub>D</sub>) survived in the reduced serum medium and were subsequently serially passaged for up to 2 times without loss of viability (Eggett *et al.*, 2000).

*MLR-1*, *MLR-2*, *MLR-3* (created by M-L. Rogers, Flinders University), X-63 and *MC-192* hybridoma cells were grown and maintained in RPMI 1640 with Glutamax, 10% FBS or TCS, 2 mM L-glutamine, 1% liquid mixture of sodium hypoxanthine and thymidine (HT) 1% (PSG).

*GT1b-1* and *GT1b-2a* (kindly provided by R.L. Schnaar, Johns Hopkins School of Medicine) hybridoma clones were grown and maintained in DMEM containing high glucose, 10% FBS or TCS, 2 mM L-glutamine, 1% (100X) liquid mixture of sodium hypoxanthine and thymidine (HT), 1% (PSG), 200 U/I insulin, and 50 mg/l sodium pyruvate. All antibody producing hybridomas were cultured for 3 – 5 days, the conditioned media were then harvested, and cells were subcultured at a ratio of 1: 5 in fresh growth medium.

### **2.B.2 Adhesion matrix for cell culture**

All cell cultures were grown successfully without added adhesion factors in plastic flasks or plates. Glass coverslips were coated with adhesion matrices dependent on the type of experiments performed. For short-term cultures,

0.1mg/ml poly-L-lysine solution in 0.15 M borate buffer (pH 8.3) was used to coat coverlips for 24 hours, which were then washed three times with PBS, and cells were seeded immediately. For cultures longer than 48 hours, rat-tail collaged type-1 at 100 µg/ml in 0.02M acetic acid and 2 µg/ml laminin matrix stock solution were diluted twenty fold in 30% ethanol. Coverlips were coated and air-dried in the laminar flow hood.

### **2.B.3 Cell viability assays measuring effects of low serum media conditions**

NSC-34 and NSC-34<sub>D</sub> cells were seeded in 96 well microtiter plates at  $1 \times 10^4$  per well in 100µl of DMEM containing one of the following: 1% FBS, 2%FBS or 3% FBS supplemented with 2 mM L-glutamine, 20mM HEPES, 1% NEAA, 1% PSG and incubated in time intervals of 24, 48, 72 and 96 hours, at 37°C and 5.1% CO<sub>2</sub>. Cell viability was assessed as described in 2.B.6.

### **2.B.4 Cell viability assays measuring the effects of neurotrophins**

NSC-34 and NSC-34<sub>D</sub> cells were seeded in 96 well microtiter plates at  $1 \times 10^4$  per well in 100µl of DMEM containing one of the following: 1% FBS, 2%FBS or 3% FBS supplemented with 2 mM L-glutamine, 20mM HEPES, 1% NEAA, 1% PSG and incubated for 18 hours at 37°C and 5.1% CO<sub>2</sub>. Cells were then incubated in serum deficient DMEM for 4 hours prior to application of growth factors. Cells were treated with NGF, BDNF, NT-3, and NT-4 at 200, 100, 50, 20 and 10 ng/ml concentrations in 100µl fresh differentiating media for up to 48 hours.

### **2.B.5 Retinoic acid and BDNF treatment of cell cultures**

NSC-34 and SH-SY5Y cells were cultured as described in 2.B.1, in T-75 flasks to about 40% confluence over the period of 2-3 days. 10 µM *all trans*-RA was then added in 10% FBS supplemented DMEM, with fresh media + *all trans*-RA change every two days. After 5 days in the presence of RA, cells were washed three times with DMEM and incubated with 50 ng/ml BDNF in DMEM (without serum) for different intervals. Cell lysates were prepared and analyzed on


Western blots as described in 2.B.11.

### **2.B.6 Acid phosphatase hydrolysis assay**

Cell viability for all in-vitro assays was assessed by (4)-nitrophenyl phosphate hydrolysis. The assay is based on the hydrolysis of the p-nitrophenyl phosphate by intracellular acid phosphatases in viable cells to produce p-nitrophenol. Absorbance of p-nitrophenol at 405 nm is directly proportional to the cell number in the range of  $10^3$ - $10^5$  cells. The assay can quantify as few as 1000 cells per well in 96-well microtiter plates, previously described by [Yang, 1996 #423]. Treated plates were gently washed with 100 $\mu$ l of PBS three times and then incubated with 100 $\mu$ l of 5 mM p- (4)-nitrophenyl phosphate, 0.1M sodium acetate, 0.1% (vol/vol) Triton X-100, pH 5.0 for 30 min ~ 1hr at 37°C and 5.1% atmospheric CO<sub>2</sub>. Cell viability was expressed as a percentage of untreated cell cultures (100%).

### **2.B.7 Annexin-V-FITC apoptosis assay**

Cells were grown in 24-well plates as described in 2.B.1 until 80% confluent. Apoptosis in control experiments was induced by the addition of 1 $\mu$ g/ml of staurosporine in 1.5% BSA supplemented culture media for 4 hours. Neurotrophin treated cells were incubated for up to 96 hours with NGF, BDNF, NT-3 or NT-4. Cells were washed with pre-warmed media and incubated with 3 $\mu$ g/ml annexin-V-FITC in media containing 10mM HEPES, 140mM NaCl and 2.5mM CaCl<sub>2</sub>, for 4 hours at 37°C. Media solution containing PI (propidium iodide) at 2 $\mu$ g/ml and Hoechst 33258 at 1 $\mu$ g/ml were then added to cell cultures for 10 minutes. Cells were washed twice with pre-warmed media and observed under a fluorescence microscope. Cell counts were performed on individual images (6 images per treatment) as described in 2.B.14.

**Figure 2.1 - Schematic representation of apoptosis assay timeline**

### 2.B.8 Purification of antibodies

Conditioned media from all hybridoma clones was harvested and stored at  $-20^{\circ}\text{C}$  until time of purification. This media was sterile filtered through a  $0.2\ \mu\text{m}$  filter and loaded onto a  $0.15\text{M}$  PBS, pH 7.2 equilibrated protein-G column at a flow rate of  $0.5\ \text{ml/min}$  overnight at  $4^{\circ}\text{C}$ , using a Pharmacia P-1 peristaltic pump. The next day the column was washed with  $200\text{ml}$  of  $0.15\text{M}$  PBS, pH 7.2 at a flow rate of  $2\text{-}3\ \text{ml/min}$ , and antibodies were eluted with  $0.1\text{M}$  glycine, pH 2.7, using a Pharmacia P-1 peristaltic pump connected to a single path UV-1 monitor. Collected fractions were neutralized with  $2\text{M}$  Tris to a pH of 7.2. Purified antibodies were extensively dialyzed against  $0.15\text{M}$  PBS at pH 7.2. All antibodies were stored in aliquots at  $-80^{\circ}\text{C}$  until used.

### 2.B.9 Conjugation of antibodies to fluorescent compounds

Antibodies were concentrated using a Nanosep 100K centrifugal device (Pall) to a final concentration  $> 2.0\ \text{mg/ml}$  and conjugations with FITC, Alexa Fluor Succinimidyl esters were performed according to manufacturer's instructions. Conjugates that labeled the brightest positive cells, and which had the lowest background on negative cells, were used for the experiments. The conjugates were stored in PBS 7.2pH containing  $2\text{mM}$  sodium azide at  $4^{\circ}\text{C}$  protected from light. For long term storage the conjugate can be aliquoted and freezed at  $-20^{\circ}\text{C}$ .

### **2.B.10 Fluorescence Activated Cell Sorting (FACS) flow cytometry**

All procedures were carried out at 4°C (or on ice) and in the dark. Single cell suspension in were prepared in 0.15M PBS, 2% FBS, 10 mM HEPES, at a concentration of  $1 \times 10^7$  cells /ml. 100  $\mu$ l of cell suspension were aliquoted into 5ml polystyrene (FACS) tubes. Primary antibodies including fluorescent conjugates were added at 10 -20  $\mu$ g / ml to the cells and mixed gently, followed by incubation for 30 - 60 minutes. Cells were washed two times by adding 2ml 0.15M PBS, 0.2% BSA, 10 mM HEPES, 0.02%  $\text{NaN}_3$  and centrifuged for 5 minutes at 1600rpm (300 x g).

Cells were re-suspended and appropriate secondary antibodies (when required) were added at 1:400 ~ 1:1000 followed by a further incubation for 30 – 60 minutes. Stained cell pellets were re-suspended in 0.15M PBS, 0.2% BSA, 10 mM HEPES 0.02%  $\text{NaN}_3$  for flow cytometry. 20 $\mu$ l of PI solution was added 5 minutes prior to analysis to detect dead cells. Single-cell suspensions for each treatment were prepared and passed through a Becton-Dickinson FACScan flow cytometry. The pattern of viable cells was used to outline a gated region using CellQuest software (Version 3.2.1). Cells showing increased forward scatter fluorescence compared with control antigen stained cells, were judged to be positive.

### **2.B.11 FACS analysis of neurotrophin binding on antibody binding**

The experimental procedure was carried out as described above with the addition of a 1hour pre-incubation step with NGF, BDNF, NT-3 or NT-4 at 100ng/ml to antibody treatment groups. Counting events of viable cells were gated at 20,000 and mean fluorescence measurements were plotted against antibody treated samples not treated with neurotrophins.

### 2.B.12 Cell lysate preparation and Western Blot analysis

Cells were lysed using chilled lysis buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 1% (vol/vol) Triton-X100 with 1% (vol/vol) protease inhibitor cocktail for 10 min on ice. Lysates were solubilized in an equal volume of 2 × SDS sample buffer containing 4% (wt/vol) SDS, 2% (wt/vol) glycine, 0.015% (wt/vol) bromophenol blue, 20% (vol/vol) glycerol, and 10% (vol/vol) β-mercaptoethanol in 100 mM Tris-HCl buffer pH 6.8. Cell lysates were electrophoresed through 12.5% Tris-glycine buffered SDS gels. Proteins from the gels were electroblotted onto nitrocellulose membrane at 100 V for 1 hr. The membranes were blocked in 4% (wt/vol) skim milk powder, 0.1% (vol/vol) Tween-20, and 0.02% (wt/vol) NaN<sub>3</sub> in Tris-buffered saline (TBS), pH 8.0, for 1 hr at room temperature and then incubated overnight with primary antibodies at 4°C. Neuron-specific antibodies in this study included tyrosine kinase B (TrkB), p75<sup>NTR</sup> rat specific antibody (Mc-192), p75<sup>NTR</sup> specific antibodies MLR-1, MLR-2 and MLR-3, choline acetyl transferase (ChAT), vesicular acetylcholine transporter (VAChT), gangliosides GT1b and GQ1b, brain derived neurotrophic factor (BDNF). Blots were then washed three times in Tris-buffered saline-Tween 20 (TBST), pH 8.0, for 10 min and incubated for 1 hr with respective horse-radish peroxidase (HRP)-conjugated secondary antibodies (1:2,500) in TBS at room temperature and then washed three times in TBS for 10 min. Blots were developed with enhanced chemiluminescence (ECL) or enhanced chemifluorescence (ECF).

### 2.B.13 p75<sup>NTR</sup> internalization and pharmacological inhibition of endocytosis

Cells were plated at 10,000 cells/cover slip on 30mm poly-D-lysine/Collagen/Laminin coated coverslips and cultured for 4-5 days (until differentiated) in 6-well plates with DMEM/F-12 differentiating medium containing no phenol red. After pre-incubation for 1 hr at 37°C with incubation buffer (DMEM/F-12, 25mM HEPES, 3 mg/ml BSA) to deplete endogenous transferrin and growth factors, cells were then incubated with transferrin-Alexa-555 (10µg/ml) and MLR-2-Alexa-488 antibody (3µg/ml) alone (vehicle) or in the

presence of NGF, BDNF, NT-3 or NT-4 (100ng/ml) for 45min at 6°C. Following Incubation cells were washed with ice-cold media, followed by pre-warmed incubation media for 0-60 minutes at 37°C in a temperature controlled sealed POC chamber.


Inhibition of receptor internalization in low temperature was assayed by incubation of cells at 4-6 °C for 45 min. Endocytosis inhibitors MDC and PAO were used after vehicle or neurotrophin incubation, by treating cells with 100 µM MDC for 1 h, or 10 µM PAO for 15 minutes in serum-free medium supplemented with 2% bovine serum albumin. Uptake of p75NTR via non clathrin-mediated endocytosis was measured by subtracting internalized staining in the presence of MDC not co-localized with transferrin, and 8 different cells were analyzed per time sequence in each experiment.

#### **2.B.14 Immuno-endocytosis assays**

Cells were cultured on poly-D-lysine/collagen/laminin coated coverslips in 24 well plates as above, but in DMEM/F-12 medium containing no phenol red. After pre-incubation for 1 hr at 37°C with incubation buffer (DMEM/F-12 HEPES, 1 mg/ml BSA) to deplete endogenous transferrin and growth factors, cells were treated with primary antibodies for 1 hr at 4°C in the presence of (100ng/ml NGF or BDNF). Cells were then washed with ice-cold incubation media three times and incubated with secondary antibodies and Lysosensor Blue/Green or LysoTracker Red DN-99 for a further 1 hour at 4°C. Cells were subsequently washed with ice-cold incubation media, followed with pre-warmed incubation buffer for 15–180 min at 37°C in the presence of (100ng/ml NGF or BDNF) followed by three washes in ice-cold PBS and fixation in 3% paraformaldehyde for 20 min. The fixation reaction was quenched in 0.1 mM glycine for 10 min. The schematic representation for individual experiment time lines (A: live and B: fixed), are shown in Figure 2.2. The presence of vesicles positive for individual and/or colocalised markers, were quantified by measuring the fluorescence intensity levels for each dye in individual channels. Results were presented as a percentage of fluorescently labeled intracellular structures within a single image plane. Intracellular structures were defined with the aid of direct

interference contrast (DIC) imaging. Intracellular regions were isolated by marking out the intracellular regions of interest (ROIs) from the extracellular ROIs, according to cellular morphology seen in DIC images. Background subtraction of 25% and threshold compensation of 30% (60 pixels) was applied to all merged images. A double-positive compartment was defined on the basis of the following criteria: the carrier was labeled in two different channels and the morphology of the carrier was very similar in the two channels. 8-12 individual cells were analyzed per time point in each experiment. Quantification of fluorescent data was subsequently performed using ImageJ software.

**Figure 2.2 - Schematic representation of live and fixed immunoendocytosis assay time line.**



**Figure 2.2 legend:** *Ab*, antibody; *NT*, neurotrophins; *Perm*, Permeabilization step; *O/N*, overnight incubation; *RT*, room temperature incubation.

### **2.B.15 Phase contrast microscopy**

Phase contrast microscopy was performed using an Olympus IX71 inverted fluorescence microscope equipped with TH4-200 halogen lamp apparatus, U-RFL-T mercury lamp apparatus, F-View CCD camera and phase contrast / relief contrast (Hoffmans Contrast) objective lenses, including (culture dish, coverslip/slide correction rings. AnalySIS getIT image capture software was used for image collection, analysis and processing.

### **2.B.16 Confocal microscopy**

Confocal imaging of initial characterization experiments using emission spectra detection at 488 nm and 568 nm, were performed using a Bio-Rad MRC 1024 scanning confocal microscope Olympus AX70 microscope, equipped with a Krypton/Argon laser. Analysis used BioRad LaserSharp software.

All other confocal imaging, including live cell imaging was accomplished using a Leica Microsystems TCS SP5 Tandem Scanner confocal microscope rigged with a Leica Tempcontrol 37-2 digital temperature regulator, Leica CTI-Controller 3700 digital CO<sub>2</sub> atmosphere regulator and a LaCon POC-Chamber System for “open” and “closed” applications. Leica LAS AF platform software was used for analysis and processing of images.

Live cell immunofluorescence experiments using NSC-34 cells were performed in a temperature controlled closed system chamber. Chamber temperature was regulated at 35°C. Experiments were done in media with N-2 neuronal cell supplement and 20mM HEPES. Laser power settings were adjusted according to the signal strength during individual experiments. Laser scanning speed varied between 200-400Hz and images were acquired at 1024x1024 pixel resolution. Images were acquired every 20s over a total of up to 60 frames for the first 20 min, and then every 60s for 50 frames for the remainder of the experiment. Multi-fluorescent live cell acquisition was performed with sequential scanning mode between scan lines, and averaging 2-4 lines. Pinhole size was set at

1 Airy unit for all confocal acquisition. Images were acquired in a single optical plane with a distance of 5-10 $\mu$ m between optical planes for all live and fixed experiments. Z-stacks were also taken and analyzed for fixed samples. PMT bandwidth detection settings for all fluorescent markers are summarized in Table 5 and 6. Dye separation was performed in experiments using transferrin-Alexa-555 in combination with Alexa-488 and Alexa-594 fluorescence.

**Table 5 - PMT gate settings for cell membrane and nuclear marker emission.**

| <b>Fluorophore Dye Selection</b><br>(Primary and secondary antibody conjugates) | <b>Laser Source</b><br>Abs (nm)* | <b>PMT Collection</b><br>Em (nm) |
|---|----------------------------------|----------------------------------|
| DAPI / Hoechst 33258  | 405                              | <b>408-480</b>                   |
| Alexa 488 / Cy-2 / FITC   | 488                              | <b>500-540</b>                   |
| Alexa 555   | 514                              | <b>555-590</b>                   |
| Alexa 565 / Cy-3  | 561                              | <b>595-645</b>                   |
| Alexa 594   | 561                              | <b>605-650</b>                   |
| Alexa 647 / Cy-5  | 633                              | <b>660-710</b>                   |

**Table 6 - PMT gate settings for fluid-phase marker emission.**

| <b>pH Sensitive Cellular Compartment Markers</b> | <b>Laser Source</b><br>Abs (nm)* | <b>PMT Collection</b><br>Em (nm) |
|--|----------------------------------|----------------------------------|
| LysoSensor Green DND-189                         | 443                              | <b>460-520</b>                   |
| Lysotracker Red DND-99                           | 561                              | <b>575-610</b>                   |

\* Values represent laser excitation wavelength and not absorption maximum values obtained from datasheet of individual products.

# **Chapter 3: Optimization Of NSC-34 Culture And Differentiation**

### 3.A Introduction

Studies utilizing embryonic spinal cord cultures, including motor neurons have been crucial in gaining knowledge of the development, but also adult physiology, injury, and disease of the nervous system (Kuhn, 2003). Numerous growth factor molecules, including among others the neurotrophins, have been identified and shown to promote the survival, differentiation as well as aid in the recovery of injured motor neurons in vivo (Thoenen *et al.*, 1993; Oppenheim, 1996; Henderson *et al.*, 1998; Sendtner *et al.*, 2000). It is from these discoveries that ideas emerged postulating the possible therapeutic role of neurotrophic factors in the treatment of various motor neuron diseases (Yan & Miller, 1993; Oppenheim, 1996). However, despite the importance of neurotrophins in motor neuron physiology and disease, a very limited number of studies have focused on the trafficking and intracellular sorting of these molecules in motor neurons.

Major reasons for this trend are the difficulties associated with obtaining, isolating and growing primary motor neuron cultures (Berg & Fischbach, 1978; Calof & Reichardt, 1984; Kuhn, 2003; Anderson *et al.*, 2004), the difficulty of transfecting primary motor neuron populations encoding foreign gene products (Yang *et al.*, 1997; Figlewicz *et al.*, 2000; Berry *et al.*, 2001; Read *et al.*, 2005), and the lack of existing, well characterized motor neuron cell lines (Cashman *et al.*, 1992; Smith *et al.*, 1994; Salazar-Grueso *et al.*, 1991). Available methods for purifying motor neurons to relative homogeneity from rodent spinal cords involve retrograde labeling and fluorescence-activated cell sorting (Eagleson & Bennett, 1983; Calof & Reichardt, 1984; O'Brien & Fischbach, 1986) and isolation and purification by panning against p75<sup>NTR</sup> antibodies (Camu & Henderson, 1992; Anderson *et al.*, 2004). Both methods are costly, time consuming, and provide only limited numbers of neurons, which rarely survive longer than seven days in culture (O'Brien & Fischbach, 1986; Camu & Henderson, 1992) with no viable cells at day-14 (O'Brien & Fischbach, 1986), although a more recent study has reported survival of some motor neuron populations up to 14 days (Anderson *et al.*, 2004).

Our interest is in the study of neurotrophin receptor trafficking within motor neurons with a view to better understand the mechanisms by which the neurotrophins elicit their various roles. For this purpose, any primary neuron population must also be further characterized for receptor expression, which is often difficult due to the lack of availability of sufficient cell numbers to perform biochemical analysis (Kaplan, 1998). Further complexity arises from the observations that neurons modulate their expression of neurotrophins, and their receptors during various stages of development (Yan *et al.*, 1993; Hughes *et al.*, 1993; Buck *et al.*, 2000). This means that results could vary depending on the age of the animal that the neurons were obtained from, or the duration of subculture of the isolated populations (Kaplan, 1998).

Many aspects of neurotrophin transport have been studied in primary or immortalized cell lines. Although each have their advantages and disadvantages, a relatively miniscule amount of knowledge has been extracted from motor neurons (Lalli & Schiavo, 2002), compared to sensory and sympathetic neuronal systems (Hendry *et al.*, 1974; Stoeckel *et al.*, 1975; Claude *et al.*, 1982; Johnson *et al.*, 1987; Ehlers *et al.*, 1995; Grimes *et al.*, 1996; Sandow *et al.*, 2000). The five primary neuronal populations used to study neurotrophin effects and behavior are made up of sympathetic, sensory, cortical, cerebellar, and hippocampal neurons (Kaplan, 1998). In contrast mainly two types of immortalized cell lines have been used for in-vitro investigations: the PC-12 pheochromocytoma cells and neuroblastoma cells (Kaplan, 1998).

The PC-12 cells have been to a great extent the major model system to study neurotrophin internalization and subsequent signaling events (Chandler *et al.*, 1984; Kaplan *et al.*, 1991b; Benedetti *et al.*, 1993; Kaplan & Stephens, 1994; Beattie *et al.*, 1996; Grimes *et al.*, 1996; Saxena *et al.*, 2004). The success of the PC-12 cell line as a model system lies in its extensive initial characterization (Greene & Tischler, 1976), followed by 30 years of extensive use. To date only four motoneuron-like cell lines have been generated (Salazar-Grueso *et al.*, 1991; Cashman *et al.*, 1992; Smith *et al.*, 1994 and Li, 2000 #512), and among these, the

NSC-34 clone has become the best characterized and also most frequently used to study motor neuron biology.

This chapter describes the characterization and optimization of the NSC-34 cell line growth conditions. This cell line has been previously characterized for motor neuron properties not expressed by the neuroblastoma parent cell line (summarized in Table 1.7.1), which indicate that NSC-34 cells share many properties with spinal motor neurons in primary culture (Fischbach & Dichter, 1974; Kato *et al.*, 1985; Peacock *et al.*, 1973). However one of the biggest drawbacks of the NSC-34 cells are extremely poor substrate adhesion compared to primary neuronal or non-neuronal cells, and the inability to grow the cells in defined media for longer than one week and one passage (Durham *et al.*, 1993). It is crucial that optimal culture conditions are well defined, in order to ensure that experimental observations result from specific inductive interactions rather than from a more general effect on the health of the cells (O'Brien & Fischbach, 1986), and to ensure the reproducibility of experimental procedures over time. The improvement of the substrate adhesion and defined media culture conditions for the NSC-34 cells is a necessary step required to use this cell line for experimental design and purpose requiring multiple treatments and manipulation.


### **3.B Culture, Maintenance and Differentiation of NSC-34 cells**

#### **3.B.1 Optimization of NSC-34 cell culture conditions**

Some of the documented characteristics of NSC-34 cells, such as poor substrate adhesion (Durham *et al.*, 1993), present a considerable obstacle in being able to culture these cell for long periods of time required for their differentiation, and subsequently use them for intracellular trafficking experiments requiring multiple treatment steps. Conditions for the growth and differentiation of these cells have been previously described in the literature (Cashman *et al.*, 1992; Durham *et al.*, 1993), however these media environments were not suitable for growing NSC-34 cells on coverslips due to extremely poor adhesion.

Stock NSC-34 cell cultures were grown and maintained in standard 10% FBS supplemented medium (Figure 3.1A), for up to 20 passages. After 20 passages there was significant reduction in spontaneous cell differentiation. Cultures contained two morphologically distinct populations. Parent-like neuroblastic cells (N-type, arrowheads) with a rounded morphology and no neurite processes, and substrate adherent (S-type, arrows) with small neurite processes that undergo further differentiation until sub-cultured. Cell grown in differentiating media containing 1% FBS, were only grown for 1 passage. Although, NSC-34 cells differentiate more readily in low (1%) FBS supplemented media (Figure 3.1B), the sudden serum withdrawal results in massive loss of cells followed by surviving cells sprouting extensive neurite projections in a time span of 5-8 days. Cells differentiated in this manner also adhered poorly, and detached with a gentle shake of the culture vessel.

As FBS contains numerous adhesion factors NSC-34 cell were cultured in 2% and 3% FBS medium (Figure 3.1C-D) to investigate whether cell growth and adhesion would be improved under these conditions, while still producing high differentiation rates. The lack of ability to grow the NSC-34 cells in a defined or serum substituted medium in previous studies (Durham *et al.*, 1993), led these authors to omit quantitative measurements and analysis of cell proliferation and neurite extension. NSC-34 cells were successfully grown in serum-free defined media (DMEM/F-12) supplemented with commercially available N-1 (Contains 0.5 mg/ml insulin from bovine pancreas, 0.5 mg/ml human transferrin (partially iron-saturated), 0.5 µg/ml sodium selenite, 1.6 mg/ml putrescine, and 0.73 µg/ml progesterone) or N-2 (Contains 0.5 mg/ml insulin from bovine pancreas, 0.5 mg/ml human transferrin (partially iron-saturated), 0.52 µg/ml sodium selenite, 1.611 mg/ml putrescine, and 0.63 µg/ml progesterone) defined neuronal cell culture additives (Figure 3.1 E-F). Although both N-1 and N-2 media supplements supported NSC-34 cells over numerous passages, the N-2 supplement was significantly more efficient in inducing differentiation (Figure 3.1 E-F).



**Figure 3.1 Growth media associated morphological characteristics of NSC-34 cells.** (A) Cells cultured in 10% FBS growth medium, in (B) 1% FBS medium, (C) 2% FBS medium, and (D) in 3% FBS supplemented medium. NSC-34 cells do not survive in serum free media unless growth factors are added. (E) Cells cultured under serum free conditions with the addition of N-1 neuronal media supplement, and (F) N-2 neuronal media supplement. Relief contrast micrographs were taken 4 days after plating. A heterogeneous neuroblastic (arrows) and substrate adherent (arrowheads) population of cells can be observed under all growth conditions (Scale bar = 100 $\mu$ m).


### **3.B.2 Analysis of cell survival rates in serum-supplemented and defined media.**

Quantification of cell survival in serum-supplemented media (10%, 1-3% FBS; Figure 3.2A), and defined media (no serum, 1%N-1 or 1%N-2; Figure 3.2B), shows that culture in low serum medium formulation results in large-scale cell death due to serum withdrawal and that defined media supplements N-1 and N-2 abolished cells death. Media containing 1% or 2% FBS resulted in a significant loss surviving cells in the first 48 hrs (\* $p < 0.005$ , two-way ANOVA analysis), however cell numbers exhibited signs of increased proliferation by 96 hrs. Increasing serum concentration to 3% FBS almost completely reduced serum withdrawal associated cell death within the first 48 hrs observed in the 1-2% FBS colonies, however cell proliferation was reduced when compared to 10% FBS media cultures. Cells cultured in defined media containing N-1 or N-2 showed reduced rates of proliferation with the exception of N-2 media cultures, which proliferated more readily within the first 48 hours. Total withdrawal of FBS resulted in rapid cell death within 24 hours.

### **3.B.3 Effects of serum-supplemented and defined media on cell subtype**

As described above, NSC-34 cells grown in standard 10% FBS exhibit two distinct morphological phenotypes. Culture in serum reduced and defined media compared to the standard growth media produced major shifts in morphological ratios of cell populations (Figure 3.3A-B). Significant increases in S-type cells in 1%, 2%, 3% FBS, N-1 and N-2 defined media were observed within 24 hours after subculture, and were subsequently quantitated at 48 hours (Figure 3.3B).

All serum reduced media and defined media initiated differentiation and the increased presence of S-type cells, in each case at a higher ratio than the N-type cells. In each treatment the S-type cell remained the dominant phenotype until cells were sub-cultured. However unlike cell grown in 10% FBS where upon sub-culture all the cells loose their projections and revert back to predominantly neuroblastic morphology, all the cells maintained in serum reduced, N-1 or N-2 defined media returned to a differentiating and substrate adherent phenotype



**Figure 3.2 Effects of serum supplemented and defined media on cell viability.** NSC-34 cell viability in FBS supplemented media (**A**). Populations treated with normal (10% FBS) growth media versus low serum media conditions were compared in 24 hr intervals for up to 96 hrs. Culturing cells in 1% and 2% fetal calf serum supplemented media resulted in a significant loss of viable cells in the first 48 hrs of treatment, with signs of cell population recovery by 96 hrs post treatment. Culturing cells in 3% FBS abolished serum withdrawal dependent cell death. Cell cultures in serum-free defined media (**B**). Withdrawal of serum (NS) resulted in rapid loss of cell viability within 24 hr. Addition of 1% N-1 or N-2 supplement restored cell viability to levels comparable with cells grown in 10% FBS ( $n = 6$ , mean  $\pm$  SEM; \* $p < 0.05$ , \*\* $p < 0.001$ , two-way ANOVA analysis of difference to 10% FBS at each time interval).



within 24 hour after sub-culture at a 1:10 ratio into new vessels.

Although both N-1 and N-2 defined media maintained S-type morphology and neurite sprouting in the NSC-34 cells, the effects of the N-2 media superior in aspects of cell differentiation. The cell morphology of the N-1 media was very similar to the cells maintained in 2-3% FBS. This led us to discard the use of the N-1 media supplement in favor of the N-2 nutrient mixture for all subsequent experiments requiring defined media. A major problem with these cells being used in long-term studies testing morphological end-points was their characteristic to detach after 7-10 days, which limits their usefulness. Culture of NSC-34 cells in N-2 defined media can be maintained for up to 21 days with regular media change, eliminating difficulties of regular culture methods. Although cell proliferation is initially increased over the first 2 days of sub-culture in N-2 media (Figure 3.5A), this effect is not maintained with fresh media change and cell population decreases as neuroblastic cells are eliminated and terminally differentiated cells remain.


#### **3.B.4 Effect of media on cell size and neurite extension in long term cultures**

During the experiments described above, we noticed that the NSC-34 hybrids had different morphological characteristics relative to their soma size and neurite length and type of media used for culture. Measurements of population samples from each media treatment 96 hours after plating revealed that cells maintained in 1% FBS media had the overall smallest median cell soma size, although their median measurements neurite extensions were significantly longer than cells grown in 3% FBS or control (10% FBS) media (Figure 3.4A; n=12; \*p>0.01, two-way ANOVA analysis).

Cells maintained in 3% FBS possessed a slightly larger cell body compared to the 1% FBS treatments, however their cell soma were significantly larger than control (10% FBS) cultures (Figure 3.4A; n=12; \*p>0.01, two-way ANOVA analysis).



**Figure 3.3 Analysis of NSC-34 cell subtypes in serum supplemented and defined media.** Relief contrast micrographs of NSC-34 cells cultured in (A) 10%, 1% and 3% FBS control growth medium and serum free N-1 (micrograph not shown) or N-2 medium, for 48 hours. (B) Distribution of neuroblastic (N-type) versus substrate adherent (S-type) cells in total populations. Cells grown in normal growth medium (10% FBS) possess a predominantly neuroblastic appearance. Cells grown in serum reduced (1 or 3% FBS) or serum free defined N-1 or N-2 media have a characteristically higher population of S-type than N-type cells. Quantitative analysis of cell subtypes expressed as a total of cell population (n=8; \*p>0.001; \*\*p>0.0001, two-way ANOVA analysis) scale bar = 200µm.



**Figure 3.4. Cell body size and neurite process measurements.** (A) Cell surface area measurements and (B) cell neurite projection length in cells after 96 hours in control (10% FBS), reduced serum (1% or 3% FBS) or serum free defined (N-2) media (n=12 sample micrographs for each treatment group). Reduced serum media mediate sprouting of longer projections, however 1%FBS media groups have reduced cell body size. N-2 defined nutrient mixture produces healthy cultures with the longest neurite projections and largest soma (\* $p > 0.01$ ; \*\*\* $p > 0.001$ ; paired t-test).


The median neurite length of the 3% FBS maintained cells was marginally shorter than the 1% FBS populations, but still significantly longer than the control cultures (Figure 3.4B; n=12; \*p>0.01, two-way ANOVA analysis).

However the most profound differences were observed when cells were grown in the N-2 defined nutrient media. Cell some median size was twice as large when compared to the control cultures and low serum media treatments (Figure 3.4A; n=12; \*\*\*p>0.001, two-way ANOVA analysis). High degree of differentiation with neurite processes more than double the length of either the control cells or low serum treatments, were also observed in the N-2 cultures (Figure 3.4B; n=12; \*\*\*p>0.001, two-way ANOVA analysis). Although the neurite length in these cell increased over the first 4-6 days in culture with the N-2 media, and individual cells with neurites of up to 120 -150  $\mu\text{m}$  in length were commonly observed, the number of total neurite projection sprouting from individual cells did not change compared to the control or low serum treatments.

### **3.B.5 Effects of long term RA treatment in NSC-34 cells**

NSC-34 cell differentiate spontaneously upon serum reduction or sub-culture with serum free N-2 media. While some growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (FGF) have been reported to maintain attachment and differentiate NSC-34 cells, this effect only lasted one passage (Durham *et al.*, 1993).

Retinoic acid (RA), an analog of vitamin A is well documented to induce the arrest of cell growth in the G1 portion of the cell cycle (Kaplan *et al.*, 1993), and induce dramatic differentiation in neuroblastoma (NB) cells (Thiele *et al.*, 1985). Further, RA produces this effect in 10-15% FBS supplemented media formulations (Thiele *et al.*, 1985; Kaplan *et al.*, 1993; Edsjo *et al.*, 2003). More importantly, RA differentiated NBs possess many biochemical, ultrastructural and electrophysiological similarities to neurons (Abemayor & Sidell, 1989).



**Figure 3.5 Retinoic acid induced NSC-34 differentiation.** Phase contrast micrographs of NSC-34 cells grown in 10% FBS (A), with addition of 1  $\mu$ M retinoic acid (RA) (B), 10  $\mu$ M RA (C), or 10  $\mu$ M RA with 100ng/ml BDNF (D) after 7 days in culture. Addition of 1  $\mu$ M RA to 10% FBS media increases proliferation whereas supplementation with 10 $\mu$ M RA significantly reduces cell growth (F). Quantification of cell neurite length as a marker of cell differentiation shows that 10 $\mu$ M RA treatment induces cell differentiation when compared to cells grown in 10% FBS alone, however the addition of BDNF does not induce increased differentiation (F) as reported in other neuroblastoma cell lines. (n = 6, mean  $\pm$  SEM). (\* $p$ <0.05, two-way ANOVA difference to 10% FBS culture; Scale bar = 50 $\mu$ m).

RA also induces TrkB expression, which in turn mediates BDNF driven survival and differentiation of SH-SY5Y NB cells in serum free media (Kaplan *et al.*, 1993). Concentrations of 1-10 $\mu$ M RA are sufficient enough to induce this effect (Abemayor & Sidell, 1989).

NSC-34 cells were cultured in 10% FBS medium with the addition of 1 $\mu$ M RA, 1 $\mu$ M plus 100ng/ml BDNF, 10 $\mu$ M RA or 10 $\mu$ M RA with added 100ng/ml BDNF for up to 10 days (Figure 3.5A-D). Subculture in 1 $\mu$ M RA did not inhibit cell growth, nor did it result in an increased population of differentiated cells. Instead, we observed an increase in cell proliferation (Figure 3.5E), and a predominant N-type morphological population. Cells grown in 1 $\mu$ M RA supplemented media needed frequent media change would reach confluence and detach within 2-3 days after plating. Subculture in 1 $\mu$ M RA for 5-7 days followed by addition of 100ng/ml BDNF did not reduce cell proliferation, increase differentiation, or enhanced the survival of NSC-34 cells in a BDNF-dependent manner.

In contrast, a ten-fold increase of RA to 10  $\mu$ M partially produced effects resembling observations previously described in other NB cells. NSC-34 cell growth was significantly reduced (Figure 3.5E), and cells differentiated more readily compared to control and 1 $\mu$ M RA treatments (Figure 3.5F). However, the addition of BDNF did not produce cell differentiation that was significantly different to cells grown in 10 $\mu$ M RA only (Figure 3.5F). NSC-34 cells grown in 10 $\mu$ M RA supplemented media remained adherent, and were suitable for further subculture.

### **3.B.6 Optimization of culture growth matrix for glass coverslips**


Sub-culturing NSC-34 cells on poly-D-lysine and / or rat-tail collagen coated glass coverslips, although necessary for adhesion of the cells, had negative effects on cell survival rates in low serum conditions. This problem was further complicated by the need to wash out the dead cells after the first 48 hrs of low serum treatment, prior to experimental treatments, which often resulted in detachment of the surviving cells. To overcome these difficulties we

experimented with various combinations of coating matrices. The cells grow extremely poorly on poly-D-lysine coated coverslips (Figure 3.6A), and very few cell extend processes under these conditions, regardless of the serum content of the media. Type 1 rat-tail collagen coated glass coverslips were better suited to cell growth with cells fairing substantially better in terms of adhesion and cell process extension, however cell detached after 4 to 5 days of sub-culture. A combination of poly-D-lysine and rat-tail collagen produced significantly better differentiation (Figure 3.6 B) irrespective of media type used, but also improved adhesion in long-term cultures.

Since the NSC-34 cells have been reported to adhere to laminin (Hunter *et al.*, 1991), we supplemented our poly-D-lysine or rat-tail collagen matrices with 2-5 $\mu$ g of laminin during the coating procedure. Cells grown on a combination matrix of poly-D-lysine, rat-tail collagen and laminin (PCL matrix) (Figure 3.3 C) sprouted processes more readily and did not detach even after 10 days in culture. Cells grown on PCL matrix with N-2 defined media (Figure 3.3 D), looked healthier and more robust with more cells sprouting projections within a 24-hour period after plating. Generally increasing FBS content of culture media in cultures plated on the PCL matrix from 1% to 3% significantly increased the survival rates as well as adhesion of these cells, making it possible to undertake experimental procedures more readily.

### **3.B.7 Long-term culture in serum free media**

Under normal (10% FBS) or serum reduced (1% FBS) culture conditions the cells usually detached within 5-7 days or when they reached a confluent state. At this stage the cells required subculture, following which they reverted back to a neuroblastoma-like round morphology and subsequently differentiated 1-2 days after re-seeding. In Contrast, defined N-2 media maintained adherent and differentiated NSC-34 cells for periods of up to 21 days with regular media change every 2-3 days (Figure 3.7A-B). Cells maintained in N-2 media also differentiated



**Figure 3.6 Optimization of culture substrate matrix for glass coverslips.** Cells subcultured on 30mm glass coverslips 4 days after initial plating in 3% FBS media coated with **(A)** 0.1mg/ml poly-D-lysine (PDL); **(B)** poly-d-lysine and 0.1mg/ml rat tail collagen matrix (PDL+RTC). **(C)** poly-d-lysine, rat tail collagen and 2µg/ml laminin matrix (PCLM). **(D)** cells grown in culture dish (CD). Neuronal phenotype, including projection on glass coverslips is best achieved on a PCL substrate matrix. **(E)** Effects of different substrates on cell differentiation. Populations grown in plastic culture dishes (CD) versus cells grown on PDL only, PDL+RTC or PCL matrix 96 hrs (n = 4, mean ± SEM). (\*p<0.001, \*\*p<0.05 two-way ANOVA difference to CD growth conditions).


more rapidly following subculture, and provided highly differentiated populations within 3-4 days. In these cultures the signs of differentiation were prominent within 12 hours following subculture. Further, these cells remained attached to the substrate and were resistant to titration with a Pasteur pipette. Withdrawal of the N-2 nutrient mixture and reintroduction of 3% FBS supplemented media maintained these cells for 1-2 days, after which the cells detached and died. Reintroduction of NSC-34 cells to 10% FBS media following N-2 culture increased cell proliferation but decreased cell differentiation as seen in cells only grown in 10% FBS.

### **3.C Discussion**

The choice of the NSC-34 clones over the other available hybrids (NSC-19, MN-1 and VSC-4.1) as an in-vitro model for motor neuron studies was based on many of its inherent morphological and physiological properties resembling primary motor neuron spinal cord cultures in neuronal development. Previously reported characteristics such as poor adhesion and limited ability to culture NSC-34 cells in defined media presented the fundamental obstacles in the ability to use these cells in experiments where adequate substrate adhesion and serum free culture are necessary.

Although existing growth protocols (Hunter *et al.*, 1991; Cashman *et al.*, 1992; Eggett *et al.*, 2000) for this cell line were adequate for studies evaluating neurotoxicity (Liu *et al.*, 2002; Rizzardini *et al.*, 2003; Weishaupt *et al.*, 2006; Wen *et al.*, 2006), the present study increases the future potential of NSC-34 cell line by establishing standardized growth conditions for highly differentiated and adherent cultures in serum supplemented or defined media types.

The effects of different media formulations on NSC-34 cells were analyzed by quantifying cell survival and proliferation, cell type morphology, cell body size and neurite outgrowth. NSC-34 cells maintained in 1% or 2% FBS have reduced survival rates when compared to cell grown in standard 10% FBS. Increasing the



**Figure 3.7 Long term culture of differentiated NSC-34 cells.** Cells subcultured on 30mm glass coverslips coated with PCL matrix in 10% FBS (A), 1% FBS media (B) or 1% N-2 defined media (C) at 10 and 20 days with fresh media change every 48 hours. (D) Quantification of cell attached at given time intervals. Cells proliferate 7-10 days following subculture in 10% FBS or 1% N-2 media, but not 1% FBS media, which causes differentiation of cells that survive serum withdrawal for up to 10 days, after which the remaining cells also die. Both 10% FBS and N-2 media support cells for up to 21 days, however significant differences were observed in cell differentiation (arrows) and substrate adhesion ( $n = 4$ , mean  $\pm$  SEM; Scale bar = 100 $\mu$ m).

FBS concentration in culture media to 3% abolished serum withdrawal associated cell death, and still produced a significant increase in cell differentiation. Switching cultures from standard growth conditions to serum free defined media supplemented with N-1 or N-2 also eliminated cell death as a result of serum withdrawal. Maintenance of NSC-34 cell in all serum reduced or serum free media formulations also produced significant increase in the morphological subtypes from N-type cells to differentiated S-type cells (Figure 3.7).

Reduction of serum in culture media is essential for profound differentiation of NSC-34 cells, and this is clearly supported by the observation that all reduced serum media initiated the growth of significantly longer neurites than observed in control cultures. The use of N-2 defined nutrient mixture produced the most notable improvements in terms of adhesion and the amount of neurite sprouting. Cells maintained in N-2 media also had the highest ratio of differentiating S-type cells, largest soma size and the longest neurites compared to cultures grown in FBS supplemented media.

Although NSC-34 cells differentiate spontaneously to varying degrees dependent on the media they're maintained in, some cell lines of neuroblastic origin such as the SH-SY5Y clone have been cultured in the presence of RA to reduce cell proliferation and induce drastic cell differentiation in 10-15% FBS containing media (Kaplan *et al.*, 1993; Encinas *et al.*, 2000; Edsjo *et al.*, 2003). Additional evidence suggests that RA induced neuronal differentiation of NBs occurs through modulation of TrkB neurotrophin receptor expression (Kaplan *et al.*, 1993; Encinas *et al.*, 2000). To establish whether this method may provide an alternative way of maintaining adherent and differentiated cultures, cells were treated with RA concentrations ranging from 1-10  $\mu\text{M}$ . Long-term culture (7-10 days) of NSC-34 cells in 1 $\mu\text{M}$  retinoic acid resulted in increased cell proliferation. Subsequent addition of BDNF had no effect on proliferation of differentiation of these cells. In contrast, increased concentration of retinoic acid at 10  $\mu\text{M}$  had the opposite effect on NSC-34 cells. Cell proliferation was significantly reduced, and cell differentiation increased compared to cells grown in standard 10% FBS media. However the addition of BDNF to RA cultures did not induce increased

differentiation measured by neurite length, when compared to the RA only groups. The observation that BDNF did not effect cell differentiation may reflect poor RA mediated upregulation of full-length TrkB receptors responsible for BDNF signaling.

Laminins are structural scaffolding glycoproteins of basement membranes that critically contribute to cell survival, differentiation, cell shape and movement, and maintenance of tissue phenotypes (Colognato & Yurchenco, 2000). Laminin is also necessary for the maintenance and differentiation of primary motor neuron cultures (Calof & Reichardt, 1985; Camu & Henderson, 1992). S-laminin, a homologue of laminin has been shown to bind NSC-34 cells through a motor neuron selective attachment site (Hunter *et al.*, 1989; Hunter *et al.*, 1991). Addition of 3µg/ml laminin to coated coverslips in a two-step process with poly-d-lysine and rat-tail collagen (PCL matrix) sufficiently maintained long-term, adherent cultures in both serum-supplemented and defined media. Although the presence of laminin enhanced the differentiation of NSC-34 cells, it was the increased cell adhesion that was most noticeable in all media types. In 10% FBS containing media the use of trypsin was required to disassociate the cells prior to subculture, where as cells cultured without the PCL matrix were easily detached by gentle pipetting. In addition, cultures maintained in media containing FBS never reached differentiation rates observed in serum-free cultures. This observation suggests that FBS may have inhibitory effects on the differentiation of NSC-34 cells. The combination of the PCL matrix and N-2 defined media provided the most suitable conditions for adherent and rapidly differentiating cultures on glass coverslips.

The combination of N-2 defined media and PCL matrix enabled prolonged culture of NSC-34 cell for up to 21 days. This represents an extension of 10 days compared to previously described methods for this cell line (Cashman *et al.*, 1992; Durham *et al.*, 1993). Although N-2 maintained cultures never reached confluence or a homogenous population of differentiated cells, they did not require subculture and always maintained a higher ratio of differentiated cells when compared to all other culture conditions.

In summary, this chapter describes an improved, standardized method for growing stably adherent and highly differentiated NSC-34 motor neuron-like cells for up to three weeks without the need for subculture in defined media. The only requirement for cell survival and differentiation within this time frame is regular media change. This critical step in the characterization of NSC-34 cells provides an opportunity to diversify their usefulness in the field of general motor neuron-specific biology.

**Chapter 4: Characterization Of NSC-34 Cells  
For The Use In Neurotrophin Receptor  
Trafficking Studies**

## 4.A Introduction

Despite the fact that the NSC-34 cell line has been widely used to study various aspects of motor neuron biology, no studies to date have examined its potential for investigating neurotrophin biology. The preferred in-vitro cell lines for the study of neurotrophins have been the PC-12 cells and a handful of neuroblastoma cells (Greene & Tischler, 1976; Kaplan, 1998). The PC-12 cells in particular have been instrumental in the development of the first neurotrophin receptor specific monoclonal antibodies (Chandler *et al.*, 1984; Taniuchi & Johnson, 1985), molecular cloning of p75<sup>NTR</sup> (Chao *et al.*, 1986) and identification of tyrosine kinase receptors (Klein *et al.*, 1991; Kaplan *et al.*, 1991b) amongst others. The continual use and characterization of the PC-12 cell contributed greatly to investigations of neurotrophin specific receptor-ligand interactions (Venkatakrisnan *et al.*, 1990; Squinto *et al.*, 1991; Klein *et al.*, 1992; Wolf *et al.*, 1995), culminating in the development of the signaling endosome hypothesis (Beattie *et al.*, 1996; Grimes *et al.*, 1996; Howe *et al.*, 2001).

The wealth of knowledge gained from using PC-12 cells has greatly advanced our understanding of many critical aspects of neurotrophin interaction with their receptors. However, there is a critical aspect of neurotrophin biology that warrants the study of neurotrophins in different cell types. One of the most challenging aspects of neurotrophin biology is the well-documented observation that different neuronal populations co-express discreet combinations of p75<sup>NTR</sup> and Trk receptors (Bibel *et al.*, 1999; Chao, 2003; Ernfors, 2001; McAllister, 2001). As a consequence of cell type specific receptor expression, neurotrophins are able to elicit varied and contrasting effects such as survival and cell death (Bartlett *et al.*, 1998; Schweigreiter, 2006; Hennigan *et al.*, 2007).

The motor neuron specific expression of neurotrophin receptors (Chiu *et al.*, 1993; Escandon *et al.*, 1994; deLapeyriere & Henderson, 1997; Henderson *et al.*, 1998; Buck *et al.*, 2000) and the effect of neurotrophins on motor neuron populations (Yan *et al.*, 1993; Sendtner *et al.*, 1996; Sendtner *et al.*, 2000) are well documented, providing an information-rich framework for direct comparison

with the NSC-34 cell line. The previous chapter clearly established an improved cell culture protocol for maintaining differentiated and adherent cells within a time frame comparable to PC-12 cells (Greene & Tischler, 1976). The purpose of this chapter is to establish whether NSC-34 cells share enough similarities with motor neurons to make them suitable for neurotrophin receptor trafficking studies.

The neurotrophin receptor profile of the NSC-34 cell line has not been clearly established. The presence of p75<sup>NTR</sup> and full-length TrkB receptors with biological activity has been briefly described (Turner *et al.*, 2004). However, the neurotrophin receptor profile expressed by motor neurons changes in the first postnatal days from p75<sup>NTR</sup> expressing cells, to p75<sup>NTR</sup> deficient cells (Escandon *et al.*, 1994). Since improved culture methods have made growing these cells routine for up to 3 weeks, it may be valuable to establish whether the receptor expression on the NSC-34 cells changes with age. One of the few studies to examine NSC-34 receptor expression demonstrated that changes in glutamate receptor expression occur over a period of 2 weeks (Eggett *et al.*, 2000). Establishing a physiological outcome as a result of exogenous neurotrophins and characterization of antibodies for the use in receptor trafficking will be the remaining focus of this chapter.

## **4.B Analysis of Cell Membrane and Cytosolic Markers**

### **4.B.1 FACS and Immunofluorescence screening**


FACS flow cytometry was used as a preliminary screening tool for all primary fluorescent antibody conjugates produced for the purpose of this study, as well as an initial detection method for receptors of interest outside of the neurotrophin family. A broad range of neuronal antibodies was screened on the NSC-34 cells. Many of the commercial, primarily polyclonal antibodies, lacked mouse antigen specificity and therefore only the positive results are discussed below.

NSC-34 cells express a number of standard markers for developing and


mature motor neurons. Neurotrophin receptors p75<sup>NTR</sup> (MLR-2, 20µg/ml), tyrosine kinase B (Trk-B, 10µl/ws), tyrosine kinase C (Trk-C Ab07-226, 20µg/ml), ciliary neurotrophic factor receptor-α (CNTFR-α) and glial derived neurotrophic factor (GDNF) receptor GFR-α were identified. The most recently included member of the neurotrophin family, the sortilin receptor is also expressed (Ab16640, 20µg/ml). Motor neuron cholinergic marker, vesicular acetylcholine transporter (VACHT V-007, 20µg/ml) and cell membrane lipid raft minor ganglioside subtypes GT1b (AbGT1b, 20µg/ml), which appeared to be expressed at higher levels (median cell counts) and GQ1b (MAb321, 20µg/ml) were also detected (Figure 4.1). The presence of GT1b and GQ1b provides evidence for expression of ganglioside family isoforms previously not examined due to the lack of availability of specific antibodies (Matsumoto *et al.*, 1995). Flow cytometry measurements represent fluorescent signal shift of viable gated populations (green phase) compared to X-63 FITC (red phase) conjugated control IgG as negative control for all experiments. Expression of cell surface proteins detected by FACS was confirmed with immunofluorescence of markers that returned positive results (Figure 4.2).

#### **4.B.2 Western Blot analysis of neurotrophin receptors and endogenously expressed neurotrophins**




The only study to investigate neurotrophin receptor expression of NSC-34 cells reported the presence of p75<sup>NTR</sup> and neurotrophin receptor homologue NRH2, as well as the full-length isoform of TrkB, which appeared to be physiologically active under normal growth conditions (Turner *et al.*, 2004). Western blot analysis of NSC-34 lysates from standard and reduced-serum culture conditions confirmed the presence of neurotrophin receptors detected by flow cytometry including sortilin and TrkC in addition to p75<sup>NTR</sup> and TrkB. However in contrast with the observations by (Turner *et al.*, 2004) the TrkB but also TrkC receptors detected in cell lysates appeared predominantly in the truncated isoforms at ~ 95kDa (Figure 4.3A), with less intense bands representing the full-length (~140kDa) isoforms of these receptors.



**Figure 4.1 FACS screening of NSC-34 cells.** Screening NSC-34 cells using fluorescence activated cell sorting (FACS) indicated the presence of the common neurotrophin receptor p75NTR, tyrosine kinase receptors B and C, and the sortilin receptor. Other growth factor receptors expressed include the CNTF receptor CNTFR- $\alpha$  and the GDNF receptor GFR- $\alpha$ . Cholinergic marker VACHT was detected with an antibody specific to the C-terminus of the transporter exposed on the extracellular membrane during ACh release. Presence of lipid raft components Gt1b and GQ1b (previously not described) was also confirmed. (Red lines represents control IgG X-63-FITC, green lines represent cell surface markers named below the x-axis). Cultures were grown in defined 1% N-2, 1% NEAA and 1% PSG medium for 5 days prior to experimental procedures.



**Figure 4.2 Immunofluorescence of motor-neuronal markers expressed by NSC-34 cells.** NSC-34 cells express two standard markers for motor neurons, namely p75 neurotrophin receptor (p75<sup>NTR</sup>) which is preferentially expressed in the embryonic and neonatal spinal cord and the rate-limiting enzyme for the neurotransmitter acetylcholine, choline acetyltransferase (ChAT). Other motor neuron markers include neurotrophin tyrosine kinase receptors B and C (TrkB, TrkC). Another cholinergic marker, the vesicular acetylcholine transporter (VAcHT), as well as ciliary neurotrophic factor receptor (CNTFR- $\alpha$ ), ganglioside Gt1b and sortilin receptor expression was also detected with antibodies raised against the protein extracellular domains.



**Figure: 4.3 Western blot analysis of neurotrophin receptors and intracellular transport proteins.** (A) NSC-34 (10% FBS media) and NSC-34D (3% and 1% FBS media) cells express a neurotrophin receptor profile consistent with developing motor neurons, including the presence of p75NTR, TrkB, TrkC and sortilin, but no TrkA (data not shown). TrkB and TrkC receptors are present in both full length (140 kDa) and truncated (100 kDa) isoforms. The presence of BDNF (B), but no NGF, NT-3 or NT-4 (data not shown) was detected. BDNF was detected at 26 kDa indicating the homodimer and also at 35 kDa consistent with pre-proBDNF. Both isoforms of BDNF were detected in normal (NSC-34) and differentiated (NSC-34D) cells, but only the homodimer was detected in these cells after 7 days of culture. NSC-34 cells express motor neuron specific markers HB9 and ChAT in cells lysates from normal (10%) and low serum (1-3%) cultures. Other important motor neuron markers such as the cholinergic marker VAcHT, and ganglioside Gt1b are expressed. (C) Critical markers of the endocytic pathway including EEA-1, clathrin heavy chain (clathrin-HC), adaptor protein-1 (AP-1), and the lysosomal markers Lamp-I and Limp-II were also shown to be present.

This is an interesting observation as the western blotting procedure was identical to the one described in (Turner *et al.*, 2004). In addition, preliminary data from mRNA detection in RT-PCR experiments using cDNA specific for truncated isoforms of TrkB (Klein *et al.*, 1990; Middlemas *et al.*, 1991) and TrkC (Tsoulfas *et al.*, 1993; Palko *et al.*, 1999), so far indicate the presence of TrkB.T1, an isoform lacking the kinase domain of the full-length receptor (data not shown). The expression of TrkA was not detected in any cell lysates or membrane preparations, providing additional support for NSC-34 motor neuron-like phenotype.

Spinal motor neurons express combinations of BDNF, NT-3 and NT-4 during development and in adulthood (Funakoshi *et al.*, 1993; Kobayashi *et al.*, 1996; Buck *et al.*, 2000) where these neurotrophins play important roles in synaptic differentiation and plasticity (Thoenen, 2000; McAllister, 2001). Taking into account the spinal cord origin of NSC-34 cells, cell lysates were also screened for the presence of endogenously expressed neurotrophins. The loading of 20 $\mu$ g cell lysate per lane was sufficient to detect the presence of endogenous BDNF in both freshly subcultured and differentiated NSC-34 cells in Western blots (Figure 4.3B). Two bands were detected that correlate with the known molecular weights (MW) for the BDNF homodimer and pre-proBDNF at 26 kDa and 35 kDa respectively. Interestingly, bands corresponding to the MW of pre-proBDNF were only detected in the early stages following subculture, and were absent in cells cultured for 7 days or longer (Figure 4.3B). NGF, NT-3 and NT-4 were not detected in any NSC-34 lysates or cell membrane preparations.

To assess whether NSC-34 cell released BDNF into the media, cells were cultured in both serum and serum-free media until the media in the culture flasks (Figure 4.3), was conditioned and cells started to die. The conditioned media was collected, filtered and subsequently used to culture native or RA primed SH-SY5Y neuroblastoma cells for up to 4 days. Culturing SH-SY5Y cells in RA has been demonstrated to produce cultures that are BDNF dependent for their survival (Kaplan *et al.*, 1993; Encinas *et al.*, 2000). The ability to culture BDNF responsive, but not normal SH-SY5Y cells for up to 96hr provides support for the

release of biologically active BDNF by NSC-34 cells. Although the NSC-34 cells share many characteristics with motor neurons including the above mentioned neurotrophin receptor profile and ChAT expression amongst others (Cashman *et al.*, 1992), to date no study has reported the expression of any motor neuron-specific genetic markers.

One possible criticism of using p75<sup>NTR</sup> expression and cholinergic characteristics as concrete evidence of motor neuron phenotype, is that motor neurons express p75<sup>NTR</sup> only during early development (Yan & Johnson, 1988; Wiese *et al.*, 1999) following injury (Bussmann & Sofroniew, 1999; Johnson *et al.*, 1999; Coulson *et al.*, 2000), or development of motor neuron disease (Chiu *et al.*, 1993; Copray *et al.*, 2003). Motor neurons are also not the only cells in the cortico-spinal tract to express cholinergic properties (Phelps *et al.*, 1984).

Since NSC-34 cells originated from a fusion with spinal-cord cells enriched neuronal population, evidence of motor neuron specific genetic markers should resolve any uncertainty regarding their motor-neuron phenotype. Antibodies against Islet-1 (Pfaff *et al.*, 1996) and Homeobox-9 gene (HB-9) (Arber *et al.*, 1999), as well as antibodies against established cholinergic markers ChAT and VChAT were used to screen NSC-34 lysates prepared from standard and reduced-serum cultures. Although the transcription factor Islet-1 was not detected in any NSC-34 lysate preparations, the presence of motor neuron specific markers HB9, in combination with p75<sup>NTR</sup>, ChAT, VChAT and the lack of TrkA receptors provide further support for a motor-neuronal phenotype of NSC-34 cells (Figure 4.3C).

In addition to screening the cells for neurotrophin receptors, Western blots were also carried out to confirm antibody specific detection of endogenous proteins associated with endosomal compartments. Components of the clathrin mediated endocytosis pathways associated with neurotrophin signaling events such as clathrin heavy-chain (C-HC), adaptor protein AP-1, adaptor protein AP-2, early endosomal autoantigen-1 (EEA-1), Rab GTPase Rab-4, lysosomal markers Lamp-1 and Lamp-2, and lipid raft component GT1b not previously reported in


the NSC-34 cells (Figure 4.3 C).

#### 4.B.3 Effects of Culture Media on Neurotrophin Receptor Expression

Post-mitotic motor neurons undergo changes in neurotrophin receptor expression during their lifespan. In rats, p75<sup>NTR</sup> is expressed in on motor neurons from E15 until the second postnatal week (Yan & Johnson, 1988), and is subsequently re-expressed in 10-15% of motor neurons in aged animals (30 weeks) (Johnson *et al.*, 1999). The full-length TrkB and TrkC receptor expression in embryonic and postnatal motor neurons always precedes the expression of the truncated forms of these receptors (Escandon *et al.*, 1994).

Since changes of receptor expression after 7 days in culture have been reported in the NSC-34 cells for glutamate receptors (Eggett *et al.*, 2000), and in-vivo neurotrophin receptor expression changes during various stages of development we wanted to confirm that the neurotrophin receptors expressed on the NSC-34 cell were present after long-term culture. Due to the need to perform future experiments in serum free media, we also needed to certify that transitions from serum supplemented to defined media did not affect neurotrophin receptor profile of these cells.

Neurotrophin receptor expression profile in NSC-34 cells is maintained at 10 days after plating in both serum reduced (1% and 3% FBS) and serum free N-2 defined media (Figure 4.4). P75<sup>NTR</sup> was consistently detected at slightly lower molecular weight of 70kDa, but expression did not appear affected by change in media growth conditions. TrkB receptor was detected only in the truncated form at ~100kDa, corresponding to one or both known isoforms of this 95kDa receptor. Long term retinoic acid and BDNF treatments, alone and combined, failed to increase the presence of the 140kDa full-length isoform, reported in other neuroblastoma cell lines (Kaplan *et al.*, 1993; Encinas *et al.*, 2000).



**Figure 4.4. Analysis of neurotrophin receptor expression in defined growth media.** NSC-34 express the neurotrophin receptors p75NTR, TrkB, TrkC and sortilin. This receptor expression profile is maintained at 7 days after plating in defined media (see legend below). p75NTR was detected at slightly higher molecular weight of approx. ~ 78kDa. TrkB receptor was detected only in the truncated form at 100kDa. Retinoic acid and BDNF treatments alone and combined did not result in the increased presence of the 140kDa full length isoform as has been reported in other neuroblastoma cell lines. TrkC was present in both the truncated 100kDa and full length 140kDa isoforms. Sortilin expression seemed to decrease substantially in 1% FBS serum media, and media supplemented with retinoic acid. Interestingly the expression of sortilin in 1% FBS media supplemented with 100ng/ml BDNF showed stronger detection of the receptor compared to 1% FBS media alone.

**Legend:** 10%, 3% and 1% indicate percentage of FBS supplement in the growth media; (N-2) serum free media containing 1% N-2 supplement and 1% NEAA; (RA) 1% FBS growth media supplemented with 10 $\mu$ M retinoic acid; (BDNF) 1% FBS media with added 100ng/ml BDNF; (RB) 1% FBS media with added 10 $\mu$ M retinoic acid and 100ng/ml BDNF.

In addition, TrkC appears to be present in both the truncated (95kDa) and full-length (140kDa) isoforms. The sortilin receptor expression appeared to decrease substantially in the low serum (1% FBS) media, and media supplemented with 10 $\mu$ M retinoic acid. Interestingly the expression of sortilin in 1% FBS media supplemented with 100ng/ml BDNF showed a stronger band of detection compared to 1% FBS media alone, however retinoic acid seemed to diminish the expression of sortilin in the presence of BDNF.


## **4.C Physiological responses of NSC-34 cells to neurotrophins**

### **4.C.1 Effect of exogenous neurotrophins on NSC-34 cells**

To determine whether neurotrophins provide any trophic support for NSC-34 cells consistent with the role of these growth factors in development (Klein, 1994; Henderson, 1996; Huang & Reichardt, 2001), cultures were exposed to individual neurotrophins for up to 4 days. Cell proliferation and differentiation rates between treated and untreated cultures were compared. Cell viability assays and neurite length measurements were used to investigate the effects of neurotrophins in undifferentiated (NSC-34) cultures and highly differentiated (NSC-34<sub>D</sub>) cultures. Cells were exposed to NGF, BDNF, NT-3 or NT-4 in concentrations ranging from 10 – 200 ng/ml for 48 hours (Figure 4.5).

Treatment of normal and differentiated NSC-34 cells with individual neurotrophins failed to induce any significant differences in neurite extension. In undifferentiated cultures there was also no significant effect on cell proliferation when treated with NGF, NT-3 and NT-4. The only effect observed was a slight increase in cell viability at 10 ng/ml of BDNF treatment (Figure 4.5A).

In contrast, treatment of differentiated cultures with exogenous 200ng/ml NGF and NT-3 induced significant, dose-dependent cell death of 40-60% after 48 hours (NGF  $^{***}p<0.01$ ; NT-3  $^{*}p<0.05$  difference compared to untreated controls). The rate of cell death did not reach 40% in any individual experiment (Figure 4.5C).



**Figure 4.5 Effects of neurotrophins on NSC-34 and NSC-34D cell survival.**

NSC-34 and NSC-34D cells were treated with 10 – 200ng/ml concentrations NGF or BDNF (**A, C**), NT-3 or NT-4 (**B, D**) in for 48 hr. Treatment of NSC-34 cells with neurotrophins under normal serum conditions (10% FBS) failed to produce any significant effects in these cells within 48 hours, with the exception of slight increase in viability at 10 ng/ml of BDNF treatment (**A**). In NSC-34D cells high doses of NGF and NT-3 induced significant cell death, whereas BDNF and NT-4 stimulates marginal proliferation at small doses (**C, D**). Cell viability under these conditions was assessed by acid phosphatase reduction (n = 5, mean  $\pm$  SEM, \*P < 0.05, \*\*P < 0.01 vs. untreated cells).



There was a small, but significant increase in proliferation with BDNF treatment (Figure 4.5C-D) and NT-4 (Figure 4.5D) treatments at 10ng/ml (\* $p < 0.05$  difference compared to untreated controls), but not at any higher concentrations tested.

#### 4.C.2 Analysis of neurotrophin induced cell death



Since NGF and NT-3 treatment of NSC-34 cells results in cell death, further investigation into the type of cell death would contribute to understanding the possible mechanisms of neurotrophin induced cell death. We used annexin-V-FITC and propidium iodide as markers of early apoptosis and cell death respectively, on cells treated with 100ng/ml of NGF, NT-3 or BDNF. Nuclear DAPI stains were used as markers of total cell numbers in each experiment. Both NGF and NT-3 induced apoptosis in NSC-34 cell as indicated in (Figure 4.6) and (Figure 4.7) respectively. Only treatments at 24 and 48 hours were quantified. After 48 hours cells detached in significant numbers and produced significant irregularities in count analysis.

Apoptosis was evident within 24 hours in both NGF (25–30%) and NT-3 (20-25%) treated cells and the number of apoptotic cells in both treatments was significantly higher than in control groups (~5%) or cells treated with 100ng/ml of BDNF (~10%) (Figure 4.8;  $n=4$ ; \* $p > 0.01$ ; \*\* $p > 0.001$ , two-way ANOVA analysis). However, the rate of apoptosis was not as efficient as staurosporine (55-60%) treated positive controls (Figure 4.8;  $n=4$ ; \*\* $p > 0.001$ ; \* $p > 0.01$ ).



At 24 hours, the ratio of annexin-V positive cells was slightly higher than PI stained cells. This trend was reversed 24 hours later. The rate of apoptosis at 48 hours was significantly higher compared to both control treatments and 24-hour time points in NGF and NT-3 cultures. However the ratio of PI stained cells at 48 hours was marginally higher than annexin-V positive cells, indicating cells in very late stages of apoptosis and cells already dead but not detached.



**Figure 4.6 Analysis of NGF induced cell death with annexin-V apoptotic stain.** Relief contrast and fluorescence micrographs of NSC-34 cells cultured in (A) 1% FBS control growth medium for 48 hours stained with annexin-V-FITC and PI. (B) Cells after 24 hour treatment with 100ng/ml NGF. Presence of both annexin-V-FITC (green) and PI (red) stained indicating early and late apoptosis respectively. (C) An increase in both annexin-V (early apoptosis) and PI (late apoptosis/dead) staining was observed after 48 hours. (D) Quantitative analysis of apoptotic cells expressed as a total of cell population (n=4; \*p>0.01; \*\*p>0.001, two-way ANOVA). Number of apoptotic cells increased in a time dependent manner up to 48 hours. Data analysis after 48 hours was marred by poor substrate adhesion, with majority of apoptotic cells detaching (green arrows in C). Scale bar = 200µm.



**Figure 4.7. Analysis of NT-3 induced cell death with annexin-V apoptotic stain.** Relief contrast and fluorescence micrographs of NSC-34 cells cultured in **(A)** 1% FBS control growth medium for 48 hours stained with annexin-V-FITC and PI. **(B)** Cells after 24 hour treatment with 100ng/ml NT-3. Similar to NGF, both annexin-V-FITC (green) and PI (red) stained cells indicating early and late apoptosis were observed with NT-3 treatment, and both annexin-V (early apoptosis) and PI (late apoptosis/dead) staining increase was observed after 48 hours **(C)**. **(D)** Quantitative analysis of apoptotic cells expressed as a total of cell population (n=4; \*p>0.01; two-way ANOVA). Number of apoptotic cells increased in a time dependent manner up to 48 hours. (Scale bar = 200 $\mu$ m).



**Figure 4.8 Analysis of BDNF and Staurosporine induced cell death with annexin-V apoptotic stain.** Relief contrast and fluorescence micrographs of NSC-34 cells cultured in (A) 1% FBS control growth medium for 48 hours stained with annexin-V-FITC and PI. (B) Cells after 24 hour treatment with 100ng/ml BDNF. Similar to control treatments, both annexin-V-FITC (green) and PI (red) staining is at background levels or marginally higher. Annexin-V staining was dominant in positive control cells treated with 10 $\mu$ M staurosporine for 4 hours, and PI staining observed after 48 hours was slightly but significantly higher (C). (D) Quantitative analysis of apoptotic cells expressed as a total of cell population (n=4; \*\*p>0.001; \*p>0.01, paired t-test). (Scale bar = 200 $\mu$ m).


## **4.D. Neurotrophin receptor interactions with receptor specific antibodies**

### **4.D.1 Effects of neurotrophins on binding of p75<sup>NTR</sup>, TrkB, TrkC and Sortilin**

Competition between antibodies and ligands targeting the same receptor may produce unusual observations when studying receptor internalization dynamics. In the case of p75<sup>NTR</sup>, MC192 antibodies binding to p75<sup>NTR</sup> have been demonstrated to significantly increase binding of NGF to the receptor (Taniuchi & Johnson, 1985; Yan *et al.*, 1988), easily quantified by immunofluorescence (Bronfman *et al.*, 2003). In contrast, another antibody targeting the extracellular domain of p75<sup>NTR</sup> (REX) has been shown to completely inhibit receptor internalization (Weskamp & Reichardt, 1991).

Recently, TrkB antibodies have been generated that mimic the function of BDNF, including activation of downstream signaling molecules by the TrkB receptor (Qian *et al.*, 2006). Interestingly, these antibodies have been confirmed to recognize unique binding sites on TrkB, distinct from sites involved in BDNF docking (Qian *et al.*, 2006), highlighting the possible biological significance of ligand independent receptor-antibody interactions. Since none of the antibodies available against p75<sup>NTR</sup> recognize the mouse form of the receptor, we needed to characterize new p75<sup>NTR</sup> antibodies, which bind the mouse isoform of p75<sup>NTR</sup> (Rogers *et al.*, 2006). Although the primary focus of the next chapter is p75<sup>NTR</sup> trafficking observed via fluorescent antibody conjugates, we tested antibodies against all neurotrophin receptors expressed by the cell line.

To investigate whether neurotrophins interfered with the binding ability of p75<sup>NTR</sup>, TrkB, TrkC or sortilin antibodies on NSC-34 cells, cultures were grown in N-2 defined media for 5 days. Cells were then treated in 1% BSA containing media with either the control antibody X-63 or antibodies to p75<sup>NTR</sup>, (Figure 4.9A),




**Figure 4.9 Binding of p75NTR, TrkB, TrkC and Sortilin antibodies in the presence of neurotrophins.** The binding of antibodies alone (red line), or in the presence of 100ng/ml NGF, BDNF, NT-3 or NT-4 (green line) in NSC-34D cells was analysed by flow cytometry. **(A)**; MLR-2 FITC (10 $\mu$ g/ml), **(B)**; anti-TrkB (20 $\mu$ l/Whole serum + anti-rabbit FITC secondary 1:500), **(C)**; anti-TrkC (20 $\mu$ l/Whole serum + anti-goat FITC secondary 1:500) and **(D)**; anti-Sortilin (20 $\mu$ l/Whole serum + anti-rabbit FITC secondary 1:500) (Median fluorescence measured by flow cytometry; n=4). X-63 is a control IgG. No significant statistical difference was observed with MLR-2 **(A)**, TrkB **(C)** or Gt1b **(D)** however, MLR-3 binding was significantly increased with the addition of 100 ng/ml NGF (n = 4, mean  $\pm$  SEM, \*P < 0.05, vs. NGF and BDNF untreated cells).

TrkB (Figure 4.9B), TrkC (Figure 4.9C) or sortilin (Figure 4.9D) alone, or either pre-incubated or co-incubated with 100ng/ml of NGF, BDNF, NT-3 or NT-4 for 1 hour on ice. Antibody binding was determined using median fluorescence of individual cell counts determined by flow cytometry (n = 4, mean  $\pm$  SEM, \*p < 0.05, NGF, BDNF, NT-3 or NT-4 vs. antibody only treated cells). Pre-incubation or co-incubation of cells with neurotrophins prior to the addition of receptor specific antibodies failed to produce any significant effects on fluorescence intensity, suggesting that neurotrophins do not actively compete for receptor binding sites with MLR-2, TrkB, TrkC or sortilin specific antibodies, at concentrations at or above commonly used for immunofluorescence experiments.

#### 4.D.2 Effects of p75<sup>NTR</sup> antibodies on NGF induced apoptosis

It is well established that NGF (Sedel *et al.*, 1999) and proNGF (Domeniconi *et al.*, 2006) induce programmed cell death or apoptosis in motor neurons. We have demonstrated that exogenous NGF also induces apoptosis in NSC-34 cells in a dose dependent manner. To investigate whether binding of p75<sup>NTR</sup> antibodies MLR-2 and MLR-3 induced NGF-like activation of p75<sup>NTR</sup> in the absence of NGF, or had any effects on NGF mediated cell death, two experiments were carried out. First, antibodies were added to NSC-34 cultures in a dose-dependent manner, and incubated for 48 hours. Second, antibodies (10 $\mu$ g/ml) were co-incubated in the presence of 100 ng/ml NGF for the same time period. Cell survival of treated cultures was compared to controls (no NT) and NGF treated cells.

Incubation of MLR-2 or MLR-3 antibodies with NSC-34 cells ranging from 100 – 0.01 $\mu$ g/ml, failed to induce any changes in cell survival when compared to NGF treated cells (Figure 4.10A-B). Further, no significant difference was observed when compared to control cultures (no NGF). In experiments where MLR-2 and MLR-3 antibodies were co-incubated with NGF over 48 hours, analysis of cell survival revealed a small but significant inhibition of NGF mediated cell death (Figure 4.11C).





**Figure 4.10 Effects of p75NTR antibodies on NGF induced apoptosis.** NSC-34 cells were treated with 100ng/ml NGF, p75NTR antibodies MLR-2 (A), MLR-3 (B) or NGF in the presence of MLR antibodies (C). Treatment of NSC-34 cells with antibodies against p75NTR, MLR-2 & 3 in doses ranging from 0.01 - 100μg/ml does not induce apoptosis when compared to cells exposed to 100ng/ml NGF for 48 hours. Co-incubation with p75NTR antibodies MLR-2 & 3 (10 μg/m) and NGF (100ng/ml) for 48, did however produce a small but significant increase in cell survival when compared to NGF treatment controls. Co-incubation with MC-192 antibody against rat p75NTR and control antibody X-63 did not induce an increase in survival (n=6; \*\*p>0.001; \*p>0.05, two-way Anova - repeated measure with Bonferroni post-test).

Comparison to cells treated with NGF only, co-incubation with control antibody X-63, or co- incubation with rat specific p75<sup>NTR</sup> antibody MC-192, revealed that the presence of 10µg/ml of MLR-2 and MLR-3, increased cell survival of NGF treated cultures by 10-20%. This effect however, was not observed in cultures co-incubated with less than 10µg/ml of MLR-2 or MLR-3 (data not shown).

To gain an insight into the binding domains of p75<sup>NTR</sup> antibodies MLR-2 and MLR-3, mapping of the antibody binding epitopes was kindly determined by Christine Tuffereau at Laboratoire de Genetique des Virus, CNRS, France. Flow cytometry analysis suggests that binding of MLR-2 and MLR-3 appear to require at least cysteine rich domain (CRD) 3 and 4 (Figure AP.1A). In comparison, human anti-p75<sup>NTR</sup> ME20.4 requires only CRD 3. Western blot analysis of MLR-2 in non-reducing conditions shows that this antibody recognizes CRD 234, but not CRD 34 (Appendix Figure AP.1B), suggesting that CRD 2 plays an important role in MLR-2 binding site recognition. Both CRD 2 and CRD 3 contain important recognition sites for NGF binding (Yan & Chao, 1991; Baldwin & Shooter, 1995), and this may explain the partial inhibition of NGF induced apoptosis by MLR antibodies.

#### 4.D.3 Time-lapse internalization of p75<sup>NTR</sup>

To test whether mouse specific antibodies were suitable as an intracellular probe for NGF and BDNF dependent internalization, MLR-3 FITC was incubated on NSC-34 cells in the presence or absence of NGF and BDNF for up to 90 minutes at 37°C. Treatment with MLR-3 was able to induce internalization of p75<sup>NTR</sup> in the absence of neurotrophins (Figure 4.11A and D). However, the time of internalization was faster in the presence of 100ng/ml of NGF (Figure 4.11B, D) or BDNF (Figure 4.11C and D). The treatment with NGF appeared also to increase the total surface and intracellular staining with MLR-3 FITC, compared to BDNF treatment (Figure 4.11D), but this was not quantified.



**Figure 4.11 Time-lapse ligand dependent and independent internalization of p75NTR.** Monoclonal antibody MLR-3 FITC was able to induce ligand independent internalization of p75NTR (A, D), however the time of internalization was faster with the addition of 100ng/ml of NGF (B, D) or BDNF (C, D). The addition of NGF appeared to increase total surface binding and rate of internalization of MLR-3 FITC, compared to BDNF treated cells (D), even though p75NTR has similar affinities for both ligands. The difference of p75NTR internalization rates in NGF compared to BDNF treated cells could possibly indicate a synergistic effect of the MLR-3 antibody with NGF on the p75NTR internalization. (Scale bar = 50  $\mu$ m) Internalization was defined as any sub-cellular surface staining in a subset of randomly selected cells ( $n = 12$ ; \*\* $p > 0.001$ ; \* $p > 0.01$ , two-way ANOVA).



Further, the rate of p75<sup>NTR</sup> internalization in the presence of NGF was slightly faster compared to BDNF. The faster rate of internalization of p75<sup>NTR</sup> in the presence of NGF and MLR-3 compared to BDNF and MLR-3 could indicate a possible synergistic effect of the antibody interacting specifically with NGF but not BDNF to internalize the receptor-ligand complex. Internalization was defined as any sub-cellular surface staining in a subset of randomly selected cells (n = 12).

#### 4.D.4 Time-lapse internalization of TrkB

To test whether rabbit polyclonal antibody to TrkB was suitable as an intracellular probe for NGF and BDNF dependent internalization, anti-TrkB was incubated on NSC-34 cells in the presence or absence of 100ng/ml NGF or BDNF for up to 90 minutes at 37°C. As with the p75<sup>NTR</sup> antibody, anti-TrkB was able to induce internalization of TrkB in the absence of neurotrophins (Figure 4.12A and D), however the time of internalization was increased with the addition of 100ng/ml of NGF (Figure 7B and D), but decreased with the addition of 100ng/ml BDNF (Figure 4.12C and D). The addition of BDNF did not appear to increase the binding and rate of internalization of anti-TrkB, compared to untreated cells (Figure 4.12D). One notable observation was the behavior of anti-TrkB under NGF treatment. Anti-TrkB internalization decreased when treated with NGF compared to untreated cells. Internalization was defined as any sub-cellular surface staining in a subset of randomly selected cells (n = 12).

#### 4.D.5 Effects of k252a on neurotrophin receptor internalization

The binding of neurotrophins in the presence of p75<sup>NTR</sup> and trk receptors may result in the formation of high affinity binding sites, and subsequent internalization of the high affinity receptor complex (Wolf *et al.*, 1995; Bothwell, 1995; Dechant, 2001; Esposito *et al.*, 2001; Teng & Hempstead, 2004; Barker, 2007).



**Figure 4.12 Time-lapse ligand dependent and independent internalization of neurotrophin receptor TrkB.** Anti-TrkB sera was able to induce ligand independent internalization of TrkB in NSC-34 cells (A, D). The presence of 100ng/ml of NGF (B, D), and BDNF (C, D) resulted in altered internalization rates of the TrkB receptor. The presence of BDNF increased the speed of TrkB internalization, but did not appear to increase the cell surface binding, compared to untreated cells (D) (Scale bar = 50 $\mu$ m). One notable observation was the behavior of TrkB in the presence NGF. The speed TrkB internalization decreased when treated with NGF compared to untreated cells. Internalization was defined as any sub-cellular surface staining in a subset of randomly selected cells (n = 12; \*\*p > 0.001; \*p > 0.01, two-way ANOVA).



To investigate whether ligand dependent activation and internalization of Trk receptor could be inhibited without simultaneously affecting p75<sup>NTR</sup> internalization, we used the alkaloid-like compound K-252a. This CaM Kinase II inhibitor is widely used as a selective inhibitor of neurotrophin action on Trk receptors (Berg *et al.*, 1992; Kahle *et al.*, 1994; Auld *et al.*, 2001; Evangelopoulos *et al.*, 2004), and has also been demonstrated to inhibit Trk receptor internalization (Du *et al.*, 2003).

To assess the effects of K-252a on p75<sup>NTR</sup> and Trk receptor internalization, cultures were pre-incubated with 200nM K-252a for 60 minutes prior to the addition of 100ng/ml of NGF, NT-4 or NT-3 in the presence of receptor specific antibodies, and incubated for a further 60 minutes at 4°C (Figure 4.13 A-C).

Cells were then observed at 37°C in a POC chamber under a confocal microscope for up to 60 min. Fluorescence quantification revealed that treatment of NCS-34 cells with K-252a had no significant effect on p75<sup>NTR</sup> internalization when compared to control cultures (Figure 4.13C). In contrast, TrkB internalization in the presence of NT-4, and TrkC internalization with NT-3 was reduced by 60 – 65%. The remaining Trk receptor internalization observed in the presence of K-252a may indicate internalization of truncated forms of Trk receptors lacking tyrosine kinase domains.

#### **4.E Discussion**

Western blot and flow cytometry results confirmed that NSC-34 cells express a neurotrophin receptor profile typical of a developing motoneuron with p75<sup>NTR</sup> and tyrosine kinase receptors TrkB and TrkC present, but lacking the TrkA receptor (Yan *et al.*, 1993). NSC-34 cells also express the sortilin receptor, which was detected in a cell lysate preparation, but showed a relatively weak signal when detected by FACS analysis.



**Figure 4.13 Effects of k252a on neurotrophin receptor internalization.** NSC-34 cells were treated with 200nM k252a for 60 min and then with antibodies against p75NTR (A), TrkB (B) or TrkC (C) for 60 minutes in the presence of 100ng/ml NGF, BDNF and NT-3 respectively. (D) Pre-incubation with k252a had no significant effect on p75NTR internalization in the presence of NGF after 60 minutes. Pre-incubation with k252a significantly reduced both TrkB and TrkC internalization in the presence of receptor specific neurotrophins. (n=3; \*\*\*, \*\*p>0.001; One-way Anova - repeated measure with Bonferroni post-test).

This observation seems to be consistent with reports that sortilin is primarily expressed in the cytoplasm (Petersen *et al.*, 1997), with significantly fewer receptors being expressed on the extracellular membrane (Nielsen *et al.*, 1999). Sortilin immunoreactivity has previously been reported in spinal cord lysates (Petersen *et al.*, 1997), and has recently been reported in cultured embryonic motor neurons, localized in the cell body and the neurites (Domeniconi *et al.*, 2006).

Analysis of molecular-weight bands on Western blots also support the presence of full length and truncated forms of the TrkB and TrkC receptors. Truncated isoforms of TrkB receptors that lack a tyrosine kinase domain (Middlemas *et al.*, 1991) predominate in the adult mammalian CNS (Cabelli *et al.*, 1996), yet their roles remain controversial. Co-expression of the full-length TrkB together with the truncated TrkB.T1 isoform results in decreased levels of full-length TrkB on the cell surface (Haapasalo *et al.*, 2002).

This appears to be the case in the NSC-34 cells as well. Although truncated forms of TrkB.T1 lack a signaling domain, they have been shown to recruit p75<sup>NTR</sup> via intra-membrane and extracellular interactions, and modulate dendritic growth through p75<sup>NTR</sup> signaling (Hartmann *et al.*, 2004).

TrkC is also commonly expressed in neuroblastomas (Brodeur *et al.*, 1997), is expressed in developing motor neurons (Tessarollo *et al.*, 1993; Yan *et al.*, 1993), is rapidly transported in embryonic motor neurons (Tessarollo *et al.*, 1993) and is able to rescue motor neurons after axotomy (Tessarollo *et al.*, 1993). The TrkC locus also encodes a number of kinase deficient isoforms defined as TrkCT1 (Tsoulfas *et al.*, 1993), TrkCNC2 (Menn *et al.*, 1998) and TrkCic158 (Valenzuela *et al.*, 1993). The function of full-length TrkC receptors and their interactions with NT-3 are well defined (Yuen & Mobley, 1999; Dechant, 2001), however the function of truncated TrkC isoforms has largely been attributed to the active inhibition of the kinase-active receptors (Huang & Reichardt, 2001). Despite the lack of initial evidence, to date a number of studies have suggested the potential for other functions mediated by kinase-deficient receptors,

including the activation of signaling pathways (Valenzuela *et al.*, 1993; Baxter *et al.*, 1997; Esteban *et al.*, 2006).

Sortilin has recently emerged as a co-receptor for p75<sup>NTR</sup> in the mechanism of pro-NGF (Nykjaer *et al.*, 2004) and pro-BDNF (Teng *et al.*, 2005) apoptotic signaling, however completely opposing reports are emerging (Fahnestock *et al.*, 2004) regarding the functional mechanisms and biological outcomes of this receptor-ligand complex. The observation that expression of neurotrophin receptors did not change over a 3-week period, with p75<sup>NTR</sup> readily detected at all time points, is consistent with the receptor profile of developing or injured motor neurons (Johnson *et al.*, 1999; Wiese *et al.*, 1999).

Other extracellular and intracellular markers of interest, and possibly connected with neurotrophin receptor trafficking were also identified. These included two members from the ganglioside b-series family; GT1b and GQ1b, which are direct analogues of GD1b. Gangliosides, are broadly distributed in the nervous system, and are sometimes associated with clinical symptoms that imply selective nerve damage (Allende & Proia, 2002; Gong *et al.*, 2002). They have been reported to act as functional nerve cell ligands involved in inhibition of nerve regeneration (Vyas *et al.*, 2002) but have also been implicated in tetanus toxin (Sinha *et al.*, 2000) and cholera toxin (Torgersen *et al.*, 2001) binding and transport. Members of the b-series family of gangliosides have been implicated as essential components of the tetanus toxin receptor complex (Kitamura *et al.*, 1999) and the tetanus toxin fragment TeNT has been reported to associate with p75<sup>NTR</sup> in lipid raft mediated endocytic transport (Lalli & Schiavo, 2002). A partial characterization of NSC-34 gangliosides has been previously described (Matsumoto *et al.*, 1995), however the presence of GT1b and GQ1b was not examined. Physiological markers of interest to intracellular trafficking, in particular markers of the regulated endocytic pathway such as clathrin, AP-1, EEA-1 and acidic organelle/lysosomal markers Lamp-1 and Limp-II, which are pivotal to endosomal compartment identification were detected in NSC-34 cells.

One of the more intriguing findings is the apparent presence of both pro and mature forms of BDNF in NSC-34 cell lysates. BDNF is well recognized as a neurotrophic factor for motor neurons. However, there is also sufficient evidence for BDNF synthesis within developing (Buck *et al.*, 2000) or injured (Kobayashi *et al.*, 1996; Qin *et al.*, 2006) rat motor neurons. Thus, the detection of BDNF protein within the NSC-34 cells is not surprising and consistent with a possible autocrine role for motor neurons (Lindsay, 1996). The observation that conditioned media from NSC-34 cultures was able to keep BDNF SH-SY5Y cells alive for up to 4 days secreted by NSC-34 cells, may be an additional factor contributing to the lack of BDNF responsiveness of the cell line.

None of the neurotrophins elicited visually detectable proliferation or differentiation of NSC-34 cultures, however addition of NGF and NT-3 produced a significant, and dose-dependent cell death in 48 hours of in differentiated NSC-34 cells. It is most likely that the serum in the non-differentiated cell cultures blocked or abolished the effects of NGF and NT-3. Further analysis of these mechanisms confirmed that NGF and NT-3 induced cell death through apoptotic mechanism, providing additional support for p75<sup>NTR</sup> associated cell death. Although NGF mediated cell death via p75<sup>NTR</sup> is consistent with observations in motor neurons (Curtis *et al.*, 1998; Sedel *et al.*, 1999), NT-3 mediated cell death has been seldom studied. However, NT-3 has been reported to induce cell death of adult BDNF-dependent cortico-spinal neurons via TrkC and p75<sup>NTR</sup> signaling (Giehl *et al.*, 2001). Whether production and secretion of BDNF by NSC-34 cells makes them BDNF dependent remains to be determined.

One of the paramount requirements for the study of receptor internalization in the presence of the native ligand is the ability of the antibody and the ligand to bind to the receptor simultaneously, and the ability of that receptor to carry out its function. To investigate the interactions of our antibodies against neurotrophin receptors with their respective ligands, we tested the ability of the antibodies to bind in the presence of neurotrophins. Pre-incubation with NGF, BDNF, NT-3 or NT-4 for 1 hour did not significantly affect the cell surface binding of p75<sup>NTR</sup>, TrkB, TrkC or sortilin antibodies. This result

indicates that there is very little, or no hindrance to the specific antibodies used in binding to their receptors when neurotrophins occupy their respective binding sites.

Part of the characterization process of new antibodies recognizing mouse p75<sup>NTR</sup> included the assessment of detectable physiological effects. Commonly used MC192 antibodies enhance the binding of NGF to the receptor (Taniuchi & Johnson, 1985), and another antibody (REX) completely blocks NGF binding and p75<sup>NTR</sup> internalization (Weskamp & Reichardt, 1991). Mapping of p75<sup>NTR</sup> epitopes required for MLR antibody binding suggests that NGF and MLR antibodies bind to the same cysteine rich domains. Although, the antibodies themselves had no intrinsic biological activity on NSC-34 cells, co-incubation of high amounts of MLR-2 and MLR-3 (10µg/ml) with NGF produced a small but significant reversal of NGF induced cell death.

To test whether MLR-3 and polyclonal TrkB antibodies were suitable as a intracellular probes for the study of neurotrophin receptor internalization, the ability of each antibody to internalize in the presence as well as absence of NGF and BDNF was studied. MLR-3 induced ligand independent internalization of p75<sup>NTR</sup>, however the time of internalization was altered with the addition of NGF or BDNF. The addition of NGF appeared to increase binding and rate of internalization of MLR-3-AF488, compared to BDNF, even though both ligands have similar affinity for p75<sup>NTR</sup>. The slower rate of p75<sup>NTR</sup> internalization in the presence BDNF could indicate possible synergistic effect of MLR-3 antibody with NGF.

As with the p75<sup>NTR</sup> antibodies, polyclonal TrkB antibodies were able to induce ligand independent internalization of TrkB, however the time of internalization was increased with the addition of NGF, and decreased with the addition of BDNF. The addition of BDNF did not seem to increase the binding and rate of internalization of TrkB, compared to untreated cells. One notable observation was the behavior of TrkB under NGF treatment. TrkB internalization decreased when treated with NGF compared to untreated cells. The internalization rates observed in our experiments, for both p75<sup>NTR</sup> and TrkB, were

consistent with the internalization rates for these receptors reported in other cell lines (Grimes *et al.*, 1996; Saxena *et al.*, 2004; Iwasaki *et al.*, 1997). Inhibition of TrkB and TrkC but not p75<sup>NTR</sup> receptors with K-252a may also provide a useful mechanism for the study of p75<sup>NTR</sup> internalization with reduced association with Trk receptors.

The experiments reported in this chapter have expanded the characterization of the NSC-34 cell line to diversify its usefulness in not just the field of neurotrophin research, but also general motor neuron relevant biology. The neurotrophin receptor profile of the NSC-34 cell line offers broad scope to conduct investigations aimed at unraveling the complex receptor interactions that occur as a result of neurotrophin binding, that lead to multiple biological responses including survival, differentiation and programmed cell death. The presence of functional neurotrophin receptors should allow the exploitation of this cell line for studies of receptor trafficking, signaling and downstream responses including those initiated by the pro-neurotrophins through the sortilin and p75<sup>NTR</sup> receptor.

**Chapter 5: Exogenous Neurotrophins  
Regulate The Sub-Cellular Fate Of p75<sup>NTR</sup>**

## 5.A Introduction

Internalization of the neurotrophin-receptor complex is fundamental in many aspects of neurotrophin function. In the last 10 years, a growing body of evidence has emerged in support of spatio-temporal regulation of neurotrophin signaling through vesicular complexes called signaling endosomes (Neet & Campenot, 2001; Barker *et al.*, 2002; Ginty & Segal, 2002; Heerssen & Segal, 2002; Howe & Mobley, 2005; Zweifel *et al.*, 2005). The majority of experimental evidence for the existence of signaling endosomes has been provided by the investigation of TrkA-NGF internalization, trafficking and signaling (Howe *et al.*, 2001; Ye *et al.*, 2003). Following ligand binding, TrkA can be internalized into clathrin-coated vesicles (CCV's) (Grimes *et al.*, 1996; Beattie *et al.*, 2000), caveolae (Bilderback *et al.*, 1999), or pincher-mediated macro-pinosomes (Shao *et al.*, 2002). After internalization receptors are sorted into recycling, retrograde transport or degradation pathways (Dechant, 2001; Yano & Chao, 2004). An established role of NGF signaling events involves a subset of still poorly defined vesicles called signaling endosomes, that associate with specific downstream signaling proteins and adaptors (Grimes *et al.*, 1996; Beattie *et al.*, 2000; Chao, 2003; Zweifel *et al.*, 2005).

In comparison to TrkA, p75<sup>NTR</sup> ligand induced internalization and trafficking remains a poorly understood and controversial topic. Distinct kinetics of neurotrophin binding between TrkA and p75<sup>NTR</sup> indicate that p75<sup>NTR</sup> is more important in surface binding than intracellular accumulation of NGF, BDNF and NT-3 (Saxena *et al.*, 2004). Internalization of p75<sup>NTR</sup> has been shown to be primarily clathrin-dependent in PC12 cells (Bronfman *et al.*, 2003; Saxena *et al.*, 2004), and lipid raft-dependent in sympathetic neurons (Hibbert *et al.*, 2006), and mouse cerebellar neurons (Higuchi *et al.*, 2003). The requirement of p75<sup>NTR</sup> for neurotrophin transport is well established (Johnson *et al.*, 1987; Curtis *et al.*, 1995), however direct evidence for retrogradely transported vesicles containing p75<sup>NTR</sup> and NGF has only recently been observed in motor neurons (Lalli & Schiavo, 2002). Subsequent studies indicate that p75<sup>NTR</sup> is involved in the formation of signaling endosomes (Bronfman *et al.*, 2003), and retrograde carriers

(Hibbert *et al.*, 2006) different to those containing Trks. Ligand stimulation in cell lines results in p75<sup>NTR</sup> being sorted to the recycling pathway (Bronfman *et al.*, 2003), but not in glial cells, where it's sorted to the lysosomal pathway (Kahle *et al.*, 1994). However, in motor neurons NGF bound p75<sup>NTR</sup> does not localize with lysosomal organelles, and is transported with a non-toxic tetanus fragment (Lalli & Schiavo, 2002).

Given the highly cell type specific effects of neurotrophins in the nervous system (Henderson *et al.*, 1998; Bartlett *et al.*, 1998), and the significance of neurotrophin events in motor neuron diseases (Bartlett *et al.*, 1998; Deinhardt & Schiavo, 2005; Bronfman *et al.*, 2007), very little is known about neurotrophin receptor trafficking in motor neurons. Unlike in PC12 cells or sympathetic neurons, NGF does not support survival of motor neurons, but induces apoptosis (Sedel *et al.*, 1999; Sendtner *et al.*, 2000). Motor neurons do not express the TrkA receptor (Escandon *et al.*, 1994), leaving p75<sup>NTR</sup> as the only NGF signaling receptor.

The previous 2 Chapters have established the suitability of the NSC-34 cell line for the study of neurotrophin receptor trafficking (Matusica *et al.*, 2008). This study focuses on the subcellular localization of p75<sup>NTR</sup> to establish neurotrophin dependent differences in p75<sup>NTR</sup> endosomal sorting and lysosomal localization.

## **5.B Internalization of p75<sup>NTR</sup> in the presence of neurotrophins**


### **5.B.1 p75<sup>NTR</sup> internalization rates are altered in the presence of exogenous neurotrophins.**

Ligand-dependent internalization of p75<sup>NTR</sup> has been studied and demonstrated in PC-12 cells (Bronfman *et al.*, 2003; Saxena *et al.*, 2004; Saxena *et al.*, 2005b). In these studies p75<sup>NTR</sup> internalization in the absence of NGF and BDNF was negligible when traced with anti-p75<sup>NTR</sup> (MC192) (Bronfman *et al.*, 2003), but clear differences were observed in p75<sup>NTR</sup> surface binding and internalization, depending on the type of neurotrophin bound (Saxena *et al.*,

2004), using Fab fragments of MC192. However, NSC-34 cells express a discreet combination of neurotrophin receptors in comparison to PC-12 cells, and may therefore possess distinct p75<sup>NTR</sup> internalization kinetics in response to neurotrophin stimulation.

Following a thorough characterization of the MLR clones, it was determined that the MLR-2 antibodies were more suitable for the use in receptor internalization studies. This decision was made based on results indicating that presence MLR-3 produced a significant decrease in NGF induced apoptosis in NSC-34 cells. Since the aim of this study was to investigate p75<sup>NTR</sup> trafficking, the ability of the antibodies to minimize the effect on the receptor function was considered to be important. Although MLR-2 produced a similar effect, the magnitude of apoptosis blocking observed was significantly smaller. The initial semi-quantitative p75<sup>NTR</sup> internalization study in chapter 4 used MLR-3 antibodies, however all experiments performed following the characterization of MLR antibodies were performed with MLR-2. The use of different MLR antibodies may explain the differences observed in p75<sup>NTR</sup> internalization rates in the initial results from chapter 4 and the results reported in this chapter.

Differentiated NSC-34 cells were incubated with MLR-2-AF488 (3µg/ml) in the presence or absence of 100ng/ml of NGF, BDNF, NT-3 or NT-4 for 45 min. at 6°C, and then observed for up to 60 minutes at 37°C (Figure. 5.1A-D) in a POC chamber. MLR-2 antibodies alone induced internalization of p75<sup>NTR</sup> in the absence of neurotrophins (control), with over 50% of total fluorescence observed in intracellular regions of cells within 10-15 minutes. The addition of exogenous neurotrophins resulted in slower internalization rates of p75<sup>NTR</sup>, but significant differences were observed only in presence of NGF, NT-3 and NT-4 (n = 6; \*p>0.05; \*\*p>0.01, two-way ANOVA analysis).





**Figure 5.1 Internalization kinetics of p75NTR following neurotrophin treatment.** Internalization of p75NTR (MLR-2-AF488) following treatment of NSC-34 cells with (A) NGE, (B) NT-3, (C) BDNF or (D) NT-4 over 60 minutes. Internalization kinetics of p75NTR were slower in all neurotrophin treatments when compared to antibody only treatments in the absence of neurotrophins. NGF and NT-3 mediated p75NTR internalization was marginally slower when compared to BDNF and NT-4 internalization rates (n=6; \*p>0.05; \*\*p>0.01, Two-way ANOVA analysis).

In the presence of NGF and NT-3, p75<sup>NTR</sup> internalization reached K<sub>d</sub>50 in just over 30 minutes, where as NT-4 internalized slightly faster with K<sub>d</sub>50 reached within 20 minutes. BDNF induced internalization rates were comparable to the control experiment in the absence of neurotrophins. At 60 minutes in all experiments, fluorescently labeled p75<sup>NTR</sup> was detected in intracellular compartments or bordering the intracellular membrane. Intracellular and extracellular membrane regions were selected according to DIC images of each individual cell.

### **5.B.2 p75<sup>NTR</sup> associates with GT1b on the cell membrane but is internalized via clathrin mediated endocytosis.**

The polysialoganglioside GT1b has been reported to associate with p75<sup>NTR</sup> in two different aspects of neuronal physiology. Firstly, GT1b and p75<sup>NTR</sup> form part of a receptor complex in MAG-mediated inhibition of neurite outgrowth (Yamashita *et al.*, 2002). Secondly, the observation that p75<sup>NTR</sup> and tetanus toxin share the same endocytic transport vesicles in primary motor neurons (Lalli & Schiavo, 2002), combined with the fact that the ganglioside GT1b is essential for tetanus toxin binding and internalization (Staub *et al.*, 1986; Sinha *et al.*, 2000) suggests that p75<sup>NTR</sup> may also be part of GT1b containing receptor complex for tetanus toxin. To investigate whether p75<sup>NTR</sup> and GT1b are associated at the cell membrane, and share the same endocytic vesicle following internalization, the following experiment was carried out. Cells were incubated with MLR-2-AF488 and GT1b-AF568 antibody conjugates in the presence of neurotrophins for 1 hour on ice. Cells were then washed and incubated at 37°C for intervals up to 90 minutes, fixed and processed for microscopy.

Immunostaining of NSC-34 cells in the absence of neurotrophins, shows that approximately 50-55% of p75<sup>NTR</sup> colocalised with GT1b on the cell surface at the early stages of endocytosis (5min.) (Figure 5.2A).




**Figure 5.2 GT1b associates with p75NTR on the plasma membrane but is not internalized with the receptor.** Cell surface colocalization of p75NTR (MLR-2-AF488) and GT1b following treatment of NSC-34 cells with (A) NGF and BDNF at 5 minutes and 90 minutes respectively. (B) Quantitative analysis of p75NTR and GT1b colocalization. Colocalization between p75NTR and GT1b is substantial on the cell surface prior to large scale endocytosis, however following the internalization of p75NTR, GT1b remains located at the cell surface. No differences were observed between controls and NT treated cells. (All neurotrophins were tested NT-3/NT-4 not shown; n=4; \*p>0.001; Two-way ANOVA analysis; scale bars = 25μm).

However the colocalisation of p75<sup>NTR</sup> and GT1b rapidly decreased following internalization of p75<sup>NTR</sup>, and at the 20-minute time-point, very little intracellular colocalisation of the two markers was observed following internalization for up to 90 minutes (Figure 5.2A-B). Colocalisation rates were not affected by the addition of neurotrophins as no differences were observed when compared to controls (no NT).


### 5.B.3 p75<sup>NTR</sup> associates with clathrin HC and transferrin positive endocytic carriers.

The observation that GT1b associates with p75<sup>NTR</sup> at the plasma membrane but is not seen colocalised with the receptor following internalization suggests that GT1b may play a role in sorting of the p75<sup>NTR</sup> on the extracellular membrane prior to internalization. To confirm that p75<sup>NTR</sup> neurotrophin internalization through CME mediated pathway, cells were treated with neurotrophins and counterstained with anti-clathrin HC- AF595. Cells fixed at intervals correlating with timeframes for early endocytosis of p75<sup>NTR</sup> showed high degrees of colocalisation between p75<sup>NTR</sup> and clathrin HC (Figure 5.3a-A). Rates of colocalisation for p75<sup>NTR</sup> and clathrin HC were not influenced significantly by the presence of neurotrophins (figure 5.3a-B).



Transferrin is the best-characterized marker of the clathrin-mediated endocytic pathway involved in recycling to the plasma membrane. The presence of neurotrophin bound p75<sup>NTR</sup> in transferrin positive vesicles has been previously shown (Bronfman *et al.*, 2003). To determine whether the association of p75<sup>NTR</sup> with transferrin-positive endocytic vesicles is affected by the presence of neurotrophins, p75<sup>NTR</sup> internalization was monitored in the presence of NGF, BDNF NT-3 or NT-4 and transferrin-AF-555 for up to 60 min (Figure 5.3b-A). Analysis of colocalisation rates reveals an increased p75<sup>NTR</sup> trafficked via transferrin-associated pathways. NGF and NT-3 associated p75<sup>NTR</sup> shows a 10-20% decrease in transferrin colocalisation compared to control, BDNF or NT-4 experiments (Figure 5.3b-B).



B



**Figure 5.3a p75NTR colocalization with clathrin-HC is not influenced by neurotrophin treatment.** (A) Colocalization of p75NTR (MLR-2-AF488) with clathrin-HC following treatment of NSC-34 cells with NGF, NT-3, BDNF or NT-4 at 30 minutes. (B) Quantification of p75NTR and clathrin-HC colocalization did not show significant differences between each of the neurotrophins and control treatments (n=6; Two-way ANOVA analysis).



**Figure 5.3b** The presence of NGF and NT-3 but not BDNF or NT-4 reduces p75NTR internalization into common endocytic carriers. (A) Analysis of neurotrophin-mediated p75NTR internalization in the presence of transferrin-AF-555 indicates that the kinetics of transferrin internalization are faster than that of p75NTR when NSC-34 cells are treated with 100ng/ml of neurotrophins (NGF and BDNF shown) and observed through time-lapse confocal microscopy. (B) Analysis of p75NTR internalization in the presence of transferrin-AF-555 revealed a consistent decrease across all time points up to 60min of p75NTR/transferrin colocalisation in NGF and NT-3 treated cells and not BDNF or NT-4-mediated colocalisation of p75NTR in transferrin positive endocytic vesicles (n=3; \*p>0.05; two-way ANOVA analysis against no NT control; Scale bar = 25µm).



This decrease in colocalisation appears to be consistent over time and independent of total p75<sup>NTR</sup> internalization.

#### **5.B.4 Inhibition of clathrin-mediated endocytosis prevents p75<sup>NTR</sup> internalization in the presence of BDNF and NT-4, but not NGF and NT-3.**

Internalization of p75<sup>NTR</sup> has been shown to be primarily clathrin-dependent in PC-12 cells (Bronfman *et al.*, 2003; Saxena *et al.*, 2004), but also lipid raft-dependent in sympathetic neurons (Hibbert *et al.*, 2006), and mouse cerebellar neurons (Higuchi *et al.*, 2003).

To investigate whether p75<sup>NTR</sup> is internalized through different endocytic pathways depending on the neurotrophin present, NSC-34 cells were incubated with 100ng/ml of NGF, BDNF, NT-3 or NT-4 for 30 min at 4 °C, and then treated with either regular media, media containing 100mg/ml MDC for 1hr or 10mg/ml PAO for 15 minutes. The internalization of transferrin-AF-555 was used as a control for CME inhibition. P75<sup>NTR</sup> labeled with MLR-2-AF488 was localized inside cytosolic vesicles in the presence or absence of neurotrophins within 60 min (Figure 5.4A). MDC is a competitive inhibitor of transglutaminase, an enzyme essential for the formation of clathrin-coated vesicles. MDC was efficient in blocking 75-80%, of p75<sup>NTR</sup> internalization in control experiments and in cells treated with BDNF and NT-4, and a 10-15% fraction of p75<sup>NTR</sup> internalizing through non-CME pathways.

However cells inhibition of CME with MDC in NGF and NT-3 treated cells was not as effective, blocking only 50-65% of p75<sup>NTR</sup> internalization (Figure 5.4B). Non-specific inhibition of endocytosis with PAO blocked p75<sup>NTR</sup> internalization with an efficiency of 85-95% across all treatments, suggesting that NGF and NT-3 shifts the fraction of p75<sup>NTR</sup> being internalized through a non-CME pathway by more than 2 fold.




**Figure 5.4 Selective inhibition of p75NTR via clathrin-mediated endocytosis completely prevents BDNF and NT-4, but not NGF and NT-3 mediated p75NTR internalization.** Internalization of MLR-2-AF488 and transferrin AF-555 (A), under normal culture conditions (control), and in the presence of clathrin-mediated endocytosis inhibitors monodansylcadaverine (MDC), or phenylarsine oxide (PAO). Quantification of fluorescence reveals that 15min (10 µg/ml) PAO incubation completely abolished endocytosis in all treatments. Some internalization was evident after 1hr of (100 µg/ml) MDC treatment, however the level of internal fluorescence was ~ 10% higher in cells treated with NGF and NT-3 (n=10; \*p>0.05; two-way ANOVA analysis).

## 5.C p75<sup>NTR</sup> endosomal trafficking dynamics

### 5.C.1 NGF and NT-3, but not BDNF and NT-4 decrease lysosomal targeting of p75<sup>NTR</sup>.

Unlike the Trk receptors, which have been reported to undergo lysosomal degradation (Jullien *et al.*, 2002; Saxena *et al.*, 2005b), NGF bound p75<sup>NTR</sup> has been shown to escape lysosomal targeting in PC12 cells (Saxena *et al.*, 2005b), primary motor neuron cultures (Lalli & Schiavo, 2002), and primary hippocampal cultures (Bronfman *et al.*, 2007). To investigate whether p75<sup>NTR</sup> lysosomal targeting, is influenced by the neurotrophin present, NSC-34 cells were treated with 100ng/ml of NGF, BDNF, NT-3 or NT-4. Colocalisation of p75<sup>NTR</sup> and the lysosomal marker LysoTracker DND-99 was quantified in a time dependent manner with all neurotrophins separately. In the absence of neurotrophins, 55% of p75<sup>NTR</sup> colocalised with lysotracker after 15 minutes, with the rate of p75<sup>NTR</sup>/lysotracker colocalisation steadily increasing towards 75-80% at the one-hour mark (Figure 5.5.A-F). In contrast, in cells exposed to NGF and NT-3 p75<sup>NTR</sup> colocalisation with lysotracker was significantly reduced at 15 minutes and remained so after 60 minutes. Interestingly, the level of p75<sup>NTR</sup> and lysotracker colocalisation was marginally higher in NT-3 treated cells (20–30%) across the indicated time points when compared to NGF induced colocalisation rates of 5-20%. In comparison, the overlap observed between p75<sup>NTR</sup> and lysotracker in BDNF or NT-4 treated cells was much higher, with 30% and 50% of p75<sup>NTR</sup> respectively, targeted for degradation at 15 minutes. The levels of p75<sup>NTR</sup>, colocalisation with lysotracker in the presence of BDNF or NT-4 then reached 70% at 60 minutes, marginally lower than control experiments performed in the absence of neurotrophins.



*Figure 5.5a Neurotrophins differentially regulate lysosomal fate of p75NTR.*




Figure 5.5b Neurotrophins differentially regulate lysosomal fate of p75NTR.









Figure 5.5c Neurotrophins differentially regulate lysosomal fate of p75NTR.



**Figure 5.5d Neurotrophins differentially regulate lysosomal fate of p75NTR.** Analysis of p75NTR colocalisation with lysotracker DND-99. (from previous page) Confocal micrographs of NSC-34 cells stained with 3µg/ml MLR-2-AF488 and 35nM Lysotracker DND-99 in the absence of neurotrophins (A, -NT), or in the presence of 100ng/ml exogenous NGF (B), NT-3 (C), BDNF (D) and NT-4 (E) following 60 minute incubation at 4°C and then 37°C. Insert in each merged image provides higher magnification of vesicular structures, arrowheads marked with (\*) indicate single marker and arrowheads with (\*\*) indicate vesicles with both p75NTR and lysotracker. The presence of acidic organelles and p75NTR organelles was also observed in cell projections and mirrored the colocalisation of the two markers in the cell body (figure 5.5d, this page) (F) Quantification of colocalisation rates at 15, 30 and 60-minute time intervals for all treatments. (Measurements represent 6-10 individual cells, n=3; \*p>0.001; two-way ANOVA against treatment control at individual time points; error bars represent SEM; scale bars = 200µm (a,b,c); 20µm, d).

### 5.C.2 p75<sup>NTR</sup> enrichment of EEA-1 positive endosomes is dependent on NGF and NT-3, but not BDNF and NT-4.

EEA-1 is a vesicle-tethering factor (Mu *et al.*, 1995) with multiple binding partners (Mills *et al.*, 2001; Perret *et al.*, 2005) involved in regulating the formation of early/sorting endosomes (Miaczynska & Zerial, 2002) following cargo internalization. EEA-1 positive endosomes represent a crucial sorting step in the targeting of endosomal cargo, and this marker recently has been demonstrated to identify two early endosome populations with distinct maturation kinetics and mobility (Lakadamyali *et al.*, 2006). EEA-1 is also a Rab5 effector protein and is preferentially recruited by Rab5 positive endosomes (Callaghan *et al.*, 1999; Trischler *et al.*, 1999). Further, Rab5 positive endosomes have been implicated as signaling endosomes (Barbieri *et al.*, 2000; Varsano *et al.*, 2006). The role of EEA-1 in p75NTR internalization and endosomal sorting remains unclear, while p75NTR has been detected in EEA-1 positive endosomes in PC-12 cells exposed to exogenous NGF (Bronfman *et al.*, 2003).

Since p75NTR displays altered rates of internalization and transferrin colocalisation in the presence of neurotrophins, we investigated the role of exogenous neurotrophins in the association p75NTR with EEA-1. Markers for p75NTR and EEA-1 show consistent colocalisation in NSC-34 cells at early internalization time point of 15 minutes (confocal micrographs not shown) (Figure 5.6). At 60 minutes, when the majority of p75NTR was internalized, significant differences were observed when compared to early stages of internalization or the vehicle treatments only.

Confocal micrographs at 60 minutes show that p75NTR colocalisation with EEA-1 decreases with time in cells not exposed to neurotrophins, or cells exposed to BDNF and NT-4 (Figure. 5.6A, D and E). In contrast p75NTR trafficking to EEA-1 positive endosomes increased in NGF and NT-3 treated cells (Figure 5.6B-C).




Figure 5.6a NGF and NT-3 increase the association of p75NTR with EEA-1 positive sorting endosomes.





Figure 5.6b NGF and NT-3 increase the association of p75NTR with EEA-1 positive sorting endosomes.

F



**Figure 5.6c Neurotrophins decrease the association of p75NTR with EEA-1 positive recycling endosomes.** Analysis of p75NTR colocalisation with EEA-1 positive early/sorting endosomes. Confocal micrographs of NSC-34 cells stained with MLR-2-AF488 and EEA-1-AF594 in the absence of neurotrophins (A, -NT), or in the presence of 100ng/ml exogenous NGF (B), NT-3 (C), BDNF (D) and NT-4 (E) following 60 minute incubation at 37°C. Insert in each merged image provides higher magnification of vesicular structures, arrowheads marked with (\*) indicate single marker and arrowheads with (\*\*) indicate vesicles with both p75NTR and EEA-1. (F) Quantification of colocalisation rates at 15, 30 and 60-minute time intervals for all treatments. (Measurements represent 6-10 individual cells, n=3; \*p>0.01; paired t-test against treatment control at 15minutes; \*\*p>0.001; paired t-test against treatment control at individual time points; error bars represent SEM; scale bars = 20µm)

Quantitative analysis of different time points indicate that p75<sup>NTR</sup> and EEA-1 colocalise at similar rates of 40-50%, independent of treatment at 15 minutes (Figure 5.6F). At 30 and 60 minutes however, cells exposed to vehicle only, BDNF or NT-4 showing a decrease in p75<sup>NTR</sup>/EEA-1 positive endosomes to 25-30%. In contrast, exposure to NGF and NT-3 leads to increased association of p75<sup>NTR</sup> with EEA-1 and this rate increases to 60% and above, remaining steady or increasing at 60 minutes.

### 5.C.3 NGF and NT-3 reduce p75<sup>NTR</sup> recycling to the plasma membrane.

Rab GTPases are necessary for efficient membrane transport and different members of the Rab superfamily are localized to distinct organelles of the biosynthetic and endosomal pathways (Miaczynska & Zerial, 2002; Jordens *et al.*, 2005). Rab4 regulates “fast recycling” from early endosomes (van der Sluijs *et al.*, 1991; van der Sluijs *et al.*, 1992) and “slow recycling” from the perinuclear-recycling compartment (Daro *et al.*, 1996), but also appears to affect trafficking along degradative pathways (McCaffrey *et al.*, 2001). P75<sup>NTR</sup> transport appears to be regulated by Rab5 and Rab7 in motor neurons (Deinhardt *et al.*, 2006), markers of transport/signaling endosomes (Clague & Urbe, 2001; Barbieri *et al.*, 2004), and late endosomes (Meresse *et al.*, 1995) respectively. However, the involvement of recycling compartments in neurotrophin-mediated p75<sup>NTR</sup> transport has not been clearly established.

To determine whether p75<sup>NTR</sup> recycled back to the plasma membrane following neurotrophin-dependent internalization, antibodies against the endogenous protein GTPase Rab4 were used to identify p75<sup>NTR</sup> containing recycling vesicles. NSC-34 cells were incubated with MLR-2-AF488 in the presence or absence of neurotrophins, fixed at time intervals up to 60 minutes, permeabilized and incubated with Rab4 primary antibodies, followed by Alexa-594 secondary antibodies.

Quantification of p75<sup>NTR</sup> and Rab4 in cells not treated with neurotrophins showed a significant overlap, at 50-60% of total vesicle population across 15, 30, and 60 min incubations (Figure.5.7A-F). In contrast, cells treated with neurotrophins showed reduced rates of colocalisation with Rab4, at all time points, with marginally different rates observed for the individual neurotrophins. P75<sup>NTR</sup> containing vesicles overlapping with Rab4 positive compartments decreased to below 40% in all treatment groups at 15 minutes. The association of Rab4 with p75<sup>NTR</sup> positive carriers continued to decline in cells treated with NGF, NT-3 or BDNF, but not NT-4, when observed at 30 and 60 minutes. Most significant differences in p75<sup>NTR</sup> colocalisation rates with Rab4 were detected at 60 minutes (Figure 5.7A-F), where the overlap between the two markers dropped to below 25% in NGF, NT-3 or BDNF. However p75<sup>NTR</sup> displayed colocalisation with Rab4 in NT-4 treated cells at levels at or above 37%.

These results indicate that p75<sup>NTR</sup> appears to enter more readily into a constitutive recycling pathway regulated by Rab4 in the absence of neurotrophins, but exposure to exogenous neurotrophins appears to reduce the sorting of p75<sup>NTR</sup> to Rab4 positive endosomes. The differences observed between the individual neurotrophins may indicate that each p75<sup>NTR</sup> may be sorted into distinct endocytic carriers depending on the type of neurotrophin bound.




Figure 5.7a Neurotrophins decrease the association of p75NTR with Rab4 positive recycling endosomes.





Figure 5.7b Neurotrophins decrease the association of p75NTR with Rab4 positive recycling endosomes.



**Figure 5.7c Neurotrophins decrease the association of p75NTR with Rab4 positive recycling endosomes.** Analysis of p75NTR colocalisation with Rab4 positive recycling endosomes. Confocal micrographs of NSC-34 cells stained with MLR-2-AF488 and Rab4-AF594 in the absence of neurotrophins (A, -NT), or in the presence of 100ng/ml exogenous NGF (B), NT-3 (C), BDNF (D) and NT-4 (E) following 60 minute incubation at 37°C. Insert in each merged image provides higher magnification of vesicular structures, arrowheads marked with (\*) indicate single marker and arrowheads with (\*\*) indicate vesicles with both p75NTR and Rab4. (F) Quantification of colocalisation rates at 15, 30 and 60-minute time intervals for all treatments. (Measurements represent 6-10 individual cells, n=4; \*p>0.01; \*\*p>0.001; two-way ANOVA analysis; error bars represent SEM; scale bars = 20µm)

## 5.D Discussion

Evidence suggesting that p75<sup>NTR</sup> functions as a signaling receptor in the absence of Trks (Bronfman *et al.*, 2003) and plays a dominant role in the surface binding of neurotrophins in various cell types (Saxena *et al.*, 2004), highlights an important role this receptor plays in the action of neurotrophins. The current study investigated the internalization and subsequent subcellular localization of p75<sup>NTR</sup>. Although numerous aspects of p75<sup>NTR</sup> cellular processing have been recently investigated, the endosomal sorting of this receptor remains poorly understood.

Previous reports have focused on establishing neurotrophin dependent differences in the surface binding and internalization of p75<sup>NTR</sup> (Saxena *et al.*, 2004). In these studies, the internalization of p75<sup>NTR</sup> in the absence of neurotrophins was limited. Notably, these studies used the monoclonal antibody MC192 (Chandler *et al.*, 1984), which significantly *increases* the binding of NGF to p75<sup>NTR</sup> (Taniuchi & Johnson, 1985). Since MC192 does not bind to mouse p75<sup>NTR</sup> (Taniuchi & Johnson, 1985), we used MLR-2 a new p75<sup>NTR</sup> antibody that recognizes mouse form of the receptor (Rogers *et al.*, 2006). MLR antibodies are suitable for p75<sup>NTR</sup> internalization studies as they recognize the extracellular domain of the receptor and their binding is not affected in the presence of neurotrophins or vice versa (Matusica *et al.*, 2008).


Complete internalization of p75<sup>NTR</sup> was observed at 60min in the presence or absence of neurotrophins. Neurotrophins altered the rate of receptor internalization depending on the neurotrophin present. Interestingly, NGF and NT-3 significantly slow down the internalization kinetics of p75<sup>NTR</sup>, but BDNF and NT-4 do not differ significantly from the antibody control. Differential binding of neurotrophins to p75<sup>NTR</sup> has been suggested previously, as BDNF and NT-3 binding to the receptor was different to NGF (Bothwell, 1995; Dechant & Barde, 1997), and may be responsible for attenuating internalization rates for neurotrophin receptors. It is difficult to correlate these observations with previous *in vitro* studies (Bronfman *et al.*, 2003; Saxena *et al.*, 2004), as the

antibodies used to track p75<sup>NTR</sup> may play an important part in influencing receptor behavior. However, these observations clearly differ in that the overall rate of internalization is faster in NSC-34 cells when compared to internalization rates in PC12 cells (Bronfman *et al.*, 2003; Saxena *et al.*, 2004). In addition, the endogenous production of BDNF by the NSC-34 cells throughout the duration of the experiments described in this chapter, may have prevented NGF acting even more efficiently in killing the cell treated cultures. Furthermore, the presence of this endogenous BDNF failed to prevent the effects of NGF.

Internalization of p75<sup>NTR</sup> in PC-12 cells depends primarily on CME (Bronfman *et al.*, 2003; Saxena *et al.*, 2004), where as in sympathetic neurons it is sensitive to both clathrin and lipid raft disruption (Hibbert *et al.*, 2006). However, p75<sup>NTR</sup> is enriched in special lipid rafts linked with signaling called caveolae (Nichols, 2003), following NGF stimulation in PC-12 cells (Huang *et al.*, 1999), and caveolae-like membranes (CLM) may initiate neurotrophin signaling through both Trk and p75<sup>NTR</sup> receptors (Bilderback *et al.*, 1999).

Immunofluorescent localization of p75<sup>NTR</sup> in NSC-34 cells indicates that the receptor localizes with clathrin-HC and lipid raft ganglioside GT1b. The observation that p75<sup>NTR</sup> and GT1b only colocalise on the cell surface is consistent with the recent report indicating that the GT1b analogue ganglioside GD1b, which forms part of the receptor complex for tetanus toxin, doesn't undergo internalization into clathrin-coated or uncoated pits from the plasma membrane following tetanus toxin binding (Deinhardt *et al.*, 2006).

Interestingly, the non-specific blocker of endocytosis PAO effectively blocked p75<sup>NTR</sup> internalization in the presence of all neurotrophins. In contrast, the inhibition of CME with MDC was less effective in the presence of NGF or NT-3, than BDNF or NT-4, suggesting that NGF and NT-3 may trigger p75<sup>NTR</sup> to non-CME routes of internalization. This observation contrasts to similar work published as this manuscript was being finalized. Deinhardt *et al.*, report that in primary motor neurons p75<sup>NTR</sup> is internalized through coated and uncoated structures (Deinhardt *et al.*, 2007), however NGF activation of p75<sup>NTR</sup> results in



**Figure 5.8. Neurotrophin regulation of p75NTR intracellular fate.** All neurotrophins bind to p75NTR with similar affinities. In NSC-34 cells the presence of all neurotrophins results in p75NTR internalisation via clathrin mediated endocytosis. However NGF and NT-3 may also utilize alternate pathways of internalisation, demonstrated by the ability of p75NTR to internalize in the presence of NGF and NT-3 despite pharmacological inhibition of CME. The presence of all neurotrophins results in a decrease of p75NTR recycling back to the plasma membrane, indicated by decreasing colocalization with Rab-4. However, following internalization p75NTR is rapidly sorted into the lysosomal pathway in the presence of BDNF and NT-4. In contrast, sorting of p75NTR in the presence of NGF and NT-3 is driven into an early endosomal pathway and remains associated with EEA-1 positive vesicles.

sorting of the receptor from non-CME to CME pathways coupled to axonal transport (Deinhardt *et al.*, 2007).

These results may represent differing internalization routes for the receptor between primary neurons and NSC-34 cells, or alternatively reflect the way in which neurotrophins interact with the different antibody-receptor complexes used in the two contrasting experimental paradigms.

The lack of targeting of p75<sup>NTR</sup> to the lysosome has been observed in the presence of NGF in cell lines and primary neuronal cultures (Saxena *et al.*, 2005b; Lalli & Schiavo, 2002; Bronfman *et al.*, 2007), however whether this property is dependent on neurotrophins, or represents a recycling observed with receptors such as transferrin (TfR) (Mayor *et al.*, 1993), remains unclear. Certainly, neurotrophin receptors recycling back to the plasma membrane (Grimes *et al.*, 1996; Zapf-Colby & Olefsky, 1998; Bronfman *et al.*, 2003), and prolonged recycling of internalized neurotrophins in the nerve terminal (Weible *et al.*, 2001) has been demonstrated. The present work provides evidence for neurotrophin-dependent differences in regulation of p75<sup>NTR</sup> sorting into endosomal pathways.

Three pools of p75<sup>NTR</sup> were observed in the current experiments in the absence of neurotrophins (Figure 5.9). One pool of vesicles positive for Rab4, suggesting that p75<sup>NTR</sup> is recycled to the plasma membrane, an EEA-1-positive early endosome pool, and a pool targeted for lysosomal degradation. Addition of NGF or NT-3 diverted p75<sup>NTR</sup> from the recycling Rab4-positive pathway, as well as the lysosomal pathway, and into EEA-1-positive sorting endosomes. In contrast, although BDNF and NT-4 treatment resulted in decreased colocalisation of p75<sup>NTR</sup> with Rab4, the receptor was still targeted for lysosomal degradation.

The current findings provide further support for neurotrophin-mediated spatio-temporal regulation of p75<sup>NTR</sup> signaling. NSC-34 cells do not express TrkA, and addition of exogenous NGF results in apoptosis, suggests that p75<sup>NTR</sup> is responsible for apoptotic signaling. Although NT-3 treatment also induces apoptosis, the signaling is complicated by the presence of TrkC. However, the observation that p75<sup>NTR</sup> is diverted away from lysosomal degradation in the presence of NGF or NT-3, which leads to apoptotic signaling, but remains present in EEA-1 positive carriers, suggest that p75<sup>NTR</sup> may signal from early endosomes. Further support for this concept comes from observations that the presence of Rab5 GTPase is necessary for the recruitment of EEA-1.

Taken together the results represented in this study suggest that the fate of the p75<sup>NTR</sup> receptor depends on which neurotrophin is bound. Further the results suggest an intracellular mechanism to explain the many observations indicating p75<sup>NTR</sup> activation by different neurotrophins can lead to contrasting outcomes.

## **Chapter 6: Discussion And Future Prospects**

---

## 6.A Discussion

### 6.A.1 Neurotrophin Biology

Neuronal differentiation, migration, proliferation and survival in the embryonic and adult nervous system are tightly regulated by neurotrophins (Davies, 1994; Bibel & Barde, 2000; Huang & Reichardt, 2001). In addition, neurotrophins have also been implicated in different human pathologies, such as depression, eating disorders, Huntington's, Parkinson's, and Alzheimer's diseases (Eide *et al.*, 1993; Dechant & Barde, 2002; Bronfman *et al.*, 2007). The binding of neurotrophins to their receptors ultimately results in the transmission of neurotrophin signals from the cell surface to the nucleus (Heumann, 1994; Kaplan & Miller, 2000; Chao, 2003). This signal transmission is controlled by many factors including changes in the neurotrophin receptor intracellular domains, recruitment of secondary messenger proteins, intracellular scaffolding proteins, molecular motors and highly organized vesicular membrane domains of the endocytic pathway (Reichardt & Mobley, 2004; Teng & Hempstead, 2004; Yano & Chao, 2004; Arevalo & Wu, 2006).

Since the discovery of NGF some 60 years ago, a major goal of the neurotrophin biology field has been the identification of the molecular components involved in evoking the diverse array of neurotrophin signals. One of the most striking features of the action of neurotrophins is their ability to induce highly varied and often opposing effects (Schweigreiter, 2006). Even thirty years after the discovery of NGF, it remained impossible to describe the precise nature of its mechanism of action and their precise site of synthesis and subsequent transport (Bradshaw, 1978). Fortunately, this initial failure only fueled an increasing number of researchers interested in this problem, and today we understand how the specificity of neurotrophin signaling outcomes depends on precise interactions of neurotrophins with their receptors, and the type and combination of these receptors expressed on different cell types (Dechant, 2001; Segal, 2003). The last two decades of neurotrophin research have also resolved many fundamental issues in neurotrophin signaling (Whitmarsh & Davis, 2001; Arevalo & Wu, 2006). These include the identification of signal transduction

pathways for NGF (Kaplan & Stephens, 1994; Miller & Kaplan, 2001b) and the association of various signaling proteins with retrogradely transported endocytic carriers (Grimes *et al.*, 1997; Howe *et al.*, 2001). In addition, NGF studies have revealed that both Trk and p75<sup>NTR</sup> receptors are found at the cell membrane, clathrin coated endosomes, caveosomes, early endosomes, recycling endosomes, macropinosomes and lysosomes (Yano & Chao, 2004; Bronfman *et al.*, 2007). Despite this wealth of information, the regulation dynamics of neurotrophin receptor transport and endosomal sorting mechanisms appear complex and remain poorly defined.

The majority of studies investigating the trafficking of neurotrophin receptors have focused on TrkA and TrkB receptors (Zapf-Colby & Olefsky, 1998; Beattie *et al.*, 2000; Butowt & von Bartheld, 2001; Jullien *et al.*, 2002; Chen *et al.*, 2005a; Saxena *et al.*, 2005a). Although the retrograde transport of neurotrophin bound p75<sup>NTR</sup> has been studied over the last 15 years (Curtis *et al.*, 1995; Yano & Chao, 2004), the internalization mechanisms and subcellular sorting of p75<sup>NTR</sup> has only recently become the focus of detailed analysis (Lalli & Schiavo, 2002; Bronfman *et al.*, 2003; Saxena *et al.*, 2004; Perrone *et al.*, 2005; Hibbert *et al.*, 2006; Deinhardt *et al.*, 2007). In addition, the role of p75<sup>NTR</sup> in neurotrophin trafficking and signaling remains highly controversial, possibly because it interacts with multiple ligands and co-receptors, and its function is cell-type dependent.

### 6.A.2 The NSC-34 cell line as a motor neuron model

Cell culture models provide a powerful system for the identification of the specific features at the single cell level, and several have been essential in studies of neurotrophin trafficking and signaling (Kaplan, 1998), of which the PC-12 cell has been instrumental in establishing some of the most fundamental concepts, including interaction between neurotrophin receptors (Wolf *et al.*, 1995), internalization of neurotrophin receptors (Beattie *et al.*, 2000; Zhang *et al.*, 2000), and in recognizing p75<sup>NTR</sup> as a Trk-independent signaling receptor (Bronfman *et al.*, 2003). Although many of the molecular discoveries in neurotrophin signaling

have resulted from studies of PC12 cells and cultured sympathetic neurons (Kaplan & Stephens, 1994; Schweigreiter, 2006; Wooten & Geetha, 2006; Bronfman *et al.*, 2007), very little is known about these mechanisms in motor neurons.

The studies described in this thesis have established the NSC-34 cell line as suitable for investigating the trafficking of neurotrophins and their receptors, providing a motor neuron model which should complement ongoing studies in PC-12 cells and cultured sympathetic neurons. The long-term success of the PC-12 cell is a reflection of its detailed characterization over four decades, and its responsiveness to numerous growth factors, and in particular, the effects of NGF, which induces rapid changes in cell shape and gene transcription resulting in differentiation into a sympathetic neuron-like phenotype. This sympathetic neuron phenotype is characterized by the development of electrical excitability and neurotransmitter synthesis and release (Greene *et al.*, 1975).

The motor neuron properties of NSC-34 cells are well described (Cashman *et al.*, 1992). However, due to the relative lack of characterization of the NSC-34 cell line for neurotrophin related studies and documented difficulties in culturing these cells, considerable effort was necessary to establish optimal culture conditions and precisely define its neurotrophin characteristics. The culture and differentiation protocols developed provide a simple and standardized method of growing differentiated NSC-34 cells, with a time-frame and ease similar to the PC-12 cell lines. Further, the NSC-34 cells have a neurotrophin receptor profile resembling developing motor neurons, providing a cell line appropriate for neurotrophin receptor studies without the need to transgenically express the receptors as has been done with the PC-12 cell and TrkB receptors (Iwasaki *et al.*, 1997). An additional advantage results from the identification the sortilin receptor in the studies described in this thesis, which is not expressed by PC-12 cells. As the sortilin receptor has recently been confirmed as an essential co-receptor in p75<sup>NTR</sup> mediated pro-neurotrophin signaling (Nykjaer *et al.*, 2004; Teng *et al.*, 2005; Arnett *et al.*, 2007), its presence in NSC-34 cells provides an opportunity to investigate the mechanism of interaction with

---

p75<sup>NTR</sup> and the subsequent intracellular sorting of the multi-receptor-ligand complex.

### 6.A.3 Neurotrophin receptor trafficking

The shift in our understanding of endocytosis as a mechanism responsible for terminating receptor signaling, to a pivotal system regulating the delivery of specific signals to specific intracellular destinations, is primarily based on insights into the trafficking of growth factor receptors (Ceresa & Schmid, 2000; Cavalli *et al.*, 2001; Miaczynska *et al.*, 2004b). Although the formation of signaling endosomes is well supported by experimental evidence for the TrkA receptor (Grimes *et al.*, 1996; Delcroix *et al.*, 2003; Howe *et al.*, 2001; Howe & Mobley, 2005), the evidence for p75<sup>NTR</sup> signaling endosomes is only slowly emerging (Bronfman *et al.*, 2003; Deinhardt *et al.*, 2007).

Different experimental approaches in studies investigating p75<sup>NTR</sup> internalization and intracellular trafficking present a challenge when attempting to draw direct comparisons, but the obvious differences need to be discussed. In agreement with work performed in PC-12 cells by Saxena *et al.* (Saxena *et al.*, 2004), p75<sup>NTR</sup> internalization in NSC-34 cells appears predominantly associated with clathrin-dependent routes of internalization. In this study, pharmacological blocking of clathrin-mediated endocytosis completely abolished the internalization of p75<sup>NTR</sup>. However, recent work by Deinhardt and colleagues (Deinhardt *et al.*, 2007), performed in primary motor neuron cultures suggest that in the absence of neurotrophins, p75<sup>NTR</sup> enters the cell via both clathrin-dependent and clathrin independent mechanisms. Further, when NGF is present, p75<sup>NTR</sup> is shuttled into a predominantly clathrin-dependent route of internalization followed by an increased amount of the receptor targeted for retrograde transport. In contrast, our observations in the NSC-34 cells indicate the opposite scenario, where p75<sup>NTR</sup> internalization in the presence of NGF is increased through non-clathrin mediated endocytosis. This observation is in agreement with recent reports that p75<sup>NTR</sup> internalization is only partially

sensitive to disruption of the clathrin-mediated endocytosis pathway (Hibbert *et al.*, 2006).

It thus appears that NGF dependent p75<sup>NTR</sup> internalization in NSC-34 cells may exploit alternative routes when compared to primary motor neuron cultures and PC-12 cells. In addition, the internalization rates for p75<sup>NTR</sup> appear to be very different in PC-12 cells (Bronfman *et al.*, 2003; Saxena *et al.*, 2004) compared to our observations in NSC-34 cultures, and of other researchers for primary motor neuron cultures (Deinhardt *et al.*, 2007). However, in agreement with Saxena *et al.* (Saxena *et al.*, 2004), our results also support the observation that different neurotrophins have specific internalization rates via p75<sup>NTR</sup>. Whether the differences are cell-type specific, dependent on Trk receptor co-expression, or signaling-function specific, remains to be determined. However, the experimental protocols for experiments in all these studies were very similar, if not identical.

During the final stages of writing this thesis, Deinhardt and colleagues published a study investigating p75<sup>NTR</sup> internalization and trafficking in primary motor neuron cultures (Deinhardt *et al.*, 2007). Although there are overlapping similarities in experimental design and focus of their study and ours, many of the observations reported by Deinhardt *et al.* (Deinhardt *et al.*, 2007) support our findings in the NSC-34 cell line. However, the studies in this thesis addressed a number of issues not examined by Schiavo and colleagues. One important issue is whether NGF treatment of primary motor neuron cultures results in a physiological outcome. NGF induces a pro-apoptotic effect in intact neural tube explants, but BDNF, NT-3 and NT-4 do not (Sedel *et al.*, 1999). In agreement with these results we detected apoptosis in NSC-34 cells following NGF exposure. In addition, we also observed a similar effect when the cells were treated with NT-3. This observation is interesting because NT-3 has been described as a pro-survival factor in motor neuron populations (Hughes *et al.*, 1993). NT-3 mediated cell death has been reported in medulloblastomas, but this effect was mediated via the TrkC receptor (Kim *et al.*, 1999). However, endogenous NT-3 induces cell death in adult BDNF-dependent cortico-spinal neurons, and this effect appears to

depend on p75<sup>NTR</sup> signaling (Giehl *et al.*, 2001). The molecular mechanisms of this action have not yet been examined.

Despite many similarities in neurotrophin trafficking between NSC-34 cells and primary motor neurons, there are also numerous differences observed between the two culture models. These differences re-emphasize the need to re-examine each finding made in the NSC-34 cell line, in primary motor neurons. However in support of the NSC-34 model, similar differences have been observed in the PC12 cell line when compared to primary sympathetic neuron cultures. Nevertheless the PC12 has been, and continues to be an extremely useful model for the study of sympathetic neuron biology.

#### 6.A.4 Is there a distinct p75<sup>NTR</sup> signaling endosome?

Another unresolved issue is whether physiological outcomes mediated via p75<sup>NTR</sup> signaling require transport of the receptor-ligand complex to specific sites in the cell body. In recent years, p75<sup>NTR</sup> has been recognized as a Trk-independent signal-transducing receptor, and p75<sup>NTR</sup> signaling has been found to promote either survival via activation of the transcription factor NF $\kappa$ B (Carter *et al.*, 1996; Roux & Barker, 2002), or death via the transcription factor c-Jun (Bamji *et al.*, 1998; Coulson *et al.*, 1999). P75<sup>NTR</sup> is present at synapses, yet the effects of transcription factors are necessarily confined to the nucleus. Hence, p75<sup>NTR</sup> mediated signals initiated at the axon terminal, must be retrogradely transported to the cell body to convey survival or death signaling. Signaling might emerge either from receptors located on the cell surface or in endosomal compartments (MacInnis & Campenot, 2002). In addition, receptors internalized from the cell surface may either signal or fulfill other tasks such as subcellular trafficking of their ligands (von Bartheld *et al.*, 2001). Experimental evidence for a p75<sup>NTR</sup> signaling endosome is just beginning to emerge (Bronfman *et al.*, 2003; Deinhardt *et al.*, 2007).

Formation of distinct endosomal vesicles associated with signaling interactors MAGE, NRAGE and necdin has been demonstrated in PC-12 cells (Bronfman *et al.*, 2003). In addition the regulation of intracellular trafficking of

NGF bound p75<sup>NTR</sup> by Rab-5 GTPase has recently been reported (Deinhardt *et al.*, 2007). The significance of Rab-5 regulation is important because this GTPase has been established as a molecular component of signaling endosomes for epidermal growth factor receptors, TrkA receptors, TGF- $\beta$  receptors and G-protein coupled receptors (Barbieri *et al.*, 2000; Clague & Urbe, 2001; McPherson *et al.*, 2001; Barbieri *et al.*, 2004; Miaczynska *et al.*, 2004a; Howe & Mobley, 2005). Rab-5 is also an effector of EEA-1, and the two molecules share a high ratio of co-expression in endosomal vesicles (Simonsen *et al.*, 1998; Callaghan *et al.*, 1999).

The present study focused on determining the sorting dynamics of p75<sup>NTR</sup> as a separate signaling molecule with multiple functions. Although differences in neurotrophin trafficking have been reported for Trks and p75<sup>NTR</sup> (Altar & DiStefano, 1998; Bartlett *et al.*, 1998; Butowt & von Bartheld, 2001; von Bartheld *et al.*, 2001; Adachi *et al.*, 2005), this is the first study to investigate the differences in p75<sup>NTR</sup> intracellular trafficking in the presence of different neurotrophins. The association of p75<sup>NTR</sup> with EEA-1 has been described (Reynolds *et al.*, 2000; Bronfman *et al.*, 2003), however this observation has been interpreted in the context of routine endosomal trafficking, as most receptors internalized through the clathrin-mediated pathway are initially sorted to early endosomes (Bishop, 2003), which then serve as a platform for signaling events (Ceresa & Schmid, 2000; Gonzalez-Gaitan & Stenmark, 2003). Depending on the internalization kinetics of signaling or trafficking receptors, most are found within EEA-1 positive endosomes within 30 minutes of receptor activation (Mellman, 1996; Mousavi *et al.*, 2004; Sorkin, 2004). Association with EEA-1 after 30 minutes decreases, as the receptors and ligands undergo downstream sorting or recycling (Maxfield & McGraw, 2004).

In NSC-34 cells, p75<sup>NTR</sup> exposed to NGF and NT-3 accumulates in EEA-1 positive carriers for up to 60 minutes, whereas p75<sup>NTR</sup> treated with BDNF and NT-4 rapidly accumulates in lysosomes. Considering that NGF and NT-3 produce physiological effects when applied to NSC-34 cells, there appears to be a link between the sorting of p75<sup>NTR</sup> into an alternate pathway, possibly linked with pro-apoptotic signal propagation. The finding that p75<sup>NTR</sup> is targeted for

lysosomal degradation in the presence of a neurotrophin is a unique observation. Traditionally, p75<sup>NTR</sup> has been reported to escape degradation in the presence of NGF (Lalli & Schiavo, 2002; Bronfman *et al.*, 2003; Bronfman *et al.*, 2007) and BDNF (Hibbert *et al.*, 2006), leading to the suggestion that various pathogens and toxins may actively exploit this property of p75<sup>NTR</sup> (Butowt & Von Bartheld, 2003). Our results clearly indicate that the lysosomal fate of p75<sup>NTR</sup> depends on the presence of specific neurotrophins. In addition, the lysosomal fate of p75<sup>NTR</sup> may also depend on the cell type and expression of co-receptors.

The suggestion that p75<sup>NTR</sup> is a recycling receptor has received adequate experimental support (Zapf-Colby & Olefsky, 1998; Saxena *et al.*, 2005b; Deinhardt *et al.*, 2007). In agreement with this conclusion, the p75<sup>NTR</sup> receptor is associated with the recycling endosome marker Rab-4. However, in contrast to the observations made by Deinhardt and colleagues, suggesting that the presence of either NGF or BDNF does not alter the overall number of recycling p75<sup>NTR</sup> receptors, we report a decrease of Rab-4 associated p75<sup>NTR</sup> in the presence of any neurotrophins. This observation is interesting because Deinhardt *et al.* (Deinhardt *et al.*, 2007) reports a redirection of p75<sup>NTR</sup> to a retrograde transport pathway associated with Rab-5, but no detectable changes in the receptor recycling ratio.

Although studies focusing on p75<sup>NTR</sup> trafficking coupled with signaling events are in their infancy, evidence for the existence of a p75<sup>NTR</sup> specific signaling endosome is growing. Reports describing the association of p75<sup>NTR</sup> endosomes with multiple signaling effectors, signaling endosome fusion proteins and the targeting of this receptor for retrograde transport, bear all the characteristics associated with other well characterized signaling endosome models (Clague & Urbe, 2001; Di Fiore & De Camilli, 2001; Howe & Mobley, 2005). The findings in this thesis provide additional support for the existence of a p75<sup>NTR</sup> signaling endosome. The sorting of p75<sup>NTR</sup> to contrasting intracellular fates support active sorting of this receptor based on specific neurotrophin binding. Although the targeting of p75<sup>NTR</sup> to endosomal transport was not examined, the accumulation of p75<sup>NTR</sup> in EEA-1 positive vesicles in the presence of neurotrophins, with associated physiological effects is an important observation. Receptors are

trafficked through the mosaic of intracellular compartments to specific destinations, however the accumulation of p75<sup>NTR</sup> in EEA-1 positive vesicles may represent and a significant sorting step similar to the accumulation of signaling TGF- $\beta$  receptors in EEA-1 positive carriers (Hayes *et al.*, 2002). The novel concept of neurotrophins regulating the fate of the p75 receptor in a dynamic and highly specific manner needs to be investigated further both, in cell lines and primary neuronal cultures, and should bear valuable insights into the mechanisms involved when aided by the impressive range of rapidly improving tools and techniques for the study of real time receptor trafficking.

## 6.B Future Prospects

The NSC-34 cell line is well established as a model for motor neuron neurotoxicity studies (Durham *et al.*, 1993; Liu *et al.*, 2002; Rembach *et al.*, 2004; Babetto *et al.*, 2005; Zhai *et al.*, 2005; Atkin *et al.*, 2006; Raimondi *et al.*, 2006; Rizzardini *et al.*, 2006). The studies described in this thesis have expanded the characterization of this cell line to diversify its usefulness in not just the field of neurotrophin research, but also general motor neuron relevant biology. The neurotrophin receptor profile of the NSC-34 cell line offers broad scope to conduct investigations aimed at unraveling the complex receptor interactions that occur as a result of neurotrophin binding and that lead to multiple biological responses including survival, differentiation or programmed cell death. In particular, the presence of functional neurotrophin receptors should allow the exploitation of this cell line for studies of receptor trafficking, signaling and downstream responses including those initiated by the pro-neurotrophins through the sortilin and p75<sup>NTR</sup> receptor.

A number of recent and exciting discoveries, including the observation that p75<sup>NTR</sup> undergoes sequential cleavage through  $\alpha$ - and  $\gamma$ -secretase (Kanning *et al.*, 2003; Zampieri *et al.*, 2005), the recent identification a tyrosine kinase domain on p75<sup>NTR</sup>, and several new signaling proteins downstream of p75<sup>NTR</sup> (Arevalo *et al.*, 2005; Arevalo & Wu, 2006) have provided many more insights into the intricate functions and mechanisms of neurotrophin actions, and opened an

unpredictable new area of investigation to examine the function of this receptor. P75<sup>NTR</sup> cleavage has been postulated to generate an intracellular domain (ICD) fragment that appears to translocate into the cell nucleus (Frade, 2005), but whether this regulates gene expression in a way similar to other receptors remains to be determined.

Although multiple signaling functions have been attributed to p75<sup>NTR</sup>, the verification of these pathways has been a difficult enterprise due to the weakness of signal transduction and the lack of genetic systems to verify protein-protein interactions. The constant and rapid improvement in research tools, especially highly sensitive microscopy techniques able to detect protein-protein interactions should guide future studies to (1) address the role of these new proteins in the neurotrophin signaling not only in PC-12 and NSC-34 cells, but also in primary neuron populations, (2) use genetically modified animals to verify p75<sup>NTR</sup> function resulting from different neurotrophin activation, (3) identify new signaling molecules, mechanisms, and regulators of p75<sup>NTR</sup> that can explain the puzzling diversity of functions, and (4) understand further the role of neurotrophins in human pathologies. Nevertheless, it is clear these novel findings need to be confirmed in a primary motor neuron. In conclusion, neurotrophins remain mysterious growth factors that will no doubt provide many exciting surprises for years to come.


## **Appendix**

**Appendix 1: Mapping of MLR antibodies binding domains to p75NTR.**

As a integral part of characterizing the MLR antibodies, MLR-2 and MLR-3 variants were sent to Dr. Christine Tuffereau at Laboratoire de Virologie Moléculaire et Structurale, UMR 2472 CNRS-INRA, 91198 Gif-sur-Yvette, France. To map the binding site for MLR2 and MLR3, deletion mutants of the cysteine rich domains (CRDs) in human p75 with the correct folding and processing were constructed. Flow cytometry analysis (A) revealed that MLR2 and MLR3 appear to require at least CRD 3 and 4. In comparison, ME20.4 requires CRD 3. Western blot with MLR2 in non-reducing conditions shows MLR2 recognizes CRD 234, but not CRD 34 (B). The monoclonal antibodies did not recognize any CRDs under reducing conditions (data not shown). The dimer recognized by MLR2 when CRD 1 is absent has been observed previously with ME20.4 (Lange in et al., 2002).

A

| hp75     | MLR1 | MLR2 | MLR3 | Mab 20.4 ( $\alpha$ human) |  |
|----------|------|------|------|----------------------------|--|
| CRD 1234 | +++  | +++  | +++  | +++                        |  |
| CRD 234  | +++  | +++  | +++  | +++                        |  |
| CRD 34   | weak |      | +++  | +++                        |  |
| CRD 1    | -    | -    | -    | -                          |  |
| CRD 12   | -    | -    | -    | -                          |  |
| CRD 123  | -    | -    | -    | +++                        |  |
|          |      |      |      |                            |  |



**Figure A1. Mapping of MLR antibody binding epitopes of p75<sup>NTR</sup>.** To map the binding site for MLR2 and MLR3, deletion mutants of the cysteine rich domains (CRDs) in human p75 with the correct folding and processing were constructed. Flow cytometry analysis (A) revealed that MLR2 and MLR3 appear to require at least CRD 3 and 4. In comparison, ME20.4 requires CRD 3. Western blot with MLR2 in non-reducing conditions shows MLR2 recognizes CRD 234, but not CRD 34 (B). The monoclonals did not recognize any CRDs under reducing conditions (data not shown). The dimmer recognized by MLR2 when CRD 1 is absent has been observed previously with ME20.4 (Lange in et al., 2002).

---

## References:

- Abemayor E. and Sidell N. (1989) Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. *Environ Health Perspect*, **80**:3-15.
- Adachi N., Kohara K. and Tsumoto T. (2005) Difference in trafficking of brain-derived neurotrophic factor between axons and dendrites of cortical neurons, revealed by live-cell imaging. *BMC Neurosci*, **6** (1): 42.
- Alderson R.F., Curtis R., Alterman A.L., Lindsay R.M. and DiStefano P.S. (2000) Truncated TrkB mediates the endocytosis and release of BDNF and neurotrophin-4/5 by rat astrocytes and schwann cells in vitro. *Brain Res*, **871** (2): 210-222.
- Allende M.L. and Proia R.L. (2002) Lubricating cell signaling pathways with gangliosides. *Curr Opin Struct Biol*, **12** (5): 587-592.
- Almenar-Queralt A. and Goldstein L.S. (2001) Linkers, packages and pathways: new concepts in axonal transport. *Curr Opin Neurobiol*, **11** (5): 550-557.
- Aloyz R.S., Bamji S.X., Pozniak C.D., Toma J.G., Atwal J., Kaplan D.R. and Miller F.D. (1998) p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. *Journal of Cell Biology*, **143** (6): 1691-1703.
- Altar C.A. and DiStefano P.S. (1998) Neurotrophin trafficking by anterograde transport. *Trends in Neuroscience*, **21** (10): 433-437.
- Amano T., Hamprecht B. and Kemper W. (1974) High activity of choline acetyltransferase induced in neuroblastoma x glia hybrid cells. *Exp Cell Res*, **85** (2): 399-408.
- Anderson K.N., Potter A.C., Piccenna L.G., Quah A.K., Davies K.E. and Cheema S.S. (2004) Isolation and culture of motor neurons from the newborn mouse spinal cord. *Brain Res Brain Res Protoc*, **12** (3): 132-136.
- Arber S., Han B., Mendelsohn M., Smith M., Jessell T.M. and Sockanathan S. (1999) Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. *Neuron*, **23** (4): 659-674.
- Arevalo J.C., Conde B., Hempstead B.L., Chao M.V., Martin-Zanca D. and Perez P. (2000) TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. *Mol Cell Biol*, **20** (16): 5908-5916.
- Arevalo J.C., Pereira D., Yano H., Teng K.K. and Chao M.V. (2005) Identification of a switch in neurotrophin signaling by selective tyrosine phosphorylation. *J Biol Chem*.
- Arevalo J.C. and Wu S.H. (2006) Neurotrophin signaling: many exciting surprises! *Cell Mol Life Sci*, **63** (13): 1523-1537.
- Arnett M.G., Ryals J.M. and Wright D.E. (2007) pro-NGF, sortilin, and p75(NTR): Potential mediators of injury-induced apoptosis in the mouse dorsal root ganglion. *Brain Res*, **1183**:32-42.
- Atkin J.D. Farg M.A. Turner B.J. et al (2006) Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. *J Biol Chem*, **281** (40): 30152-30165.

- Atwal J.K., Massie B., Miller F.D. and Kaplan D.R. (2000) The TrkB-Shc site signals neuronal survival and local axon growth via MEK and P13-kinase. *Neuron*, **27** (2): 265-277.
- Auld D.S., Mennicken F., Day J.C. and Quirion R. (2001) Neurotrophins differentially enhance acetylcholine release, acetylcholine content and choline acetyltransferase activity in basal forebrain neurons. *J Neurochem*, **77** (1): 253-262.
- Baass P.C., Di Guglielmo G.M., Authier F., Posner B.I. and Bergeron J.J. (1995) Compartmentalized signal transduction by receptor tyrosine kinases. *Trends Cell Biol*, **5** (12): 465-470.
- Babetto E., Mangolini A., Rizzardini M., Lupi M., Conforti L., Rusmini P., Poletti A. and Cantoni L. (2005) Tetracycline-regulated gene expression in the NSC-34-tTA cell line for investigation of motor neuron diseases. *Brain Res Mol Brain Res*, **140** (1-2): 63-72.
- Bai D., Chen H. and Huang B.R. (2003) RanBPM is a novel binding protein for p75NTR. *Biochem Biophys Res Commun*, **309** (3): 552-557.
- Baldwin A.N. and Shooter E.M. (1995) Zone mapping of the binding domain of the rat low affinity nerve growth factor receptor by the introduction of novel N-glycosylation sites. *Journal of Biological Chemistry*, **270** (9): 4594-4602.
- Bamji S.X., Majdan M., Pozniak C.D., Belliveau D.J., Aloyz R., Kohn J., Causing C.G. and Miller F.D. (1998) The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death. *J Cell Biol*, **140** (4): 911-923.
- Barbacid M. (1994) The Trk family of neurotrophin receptors. *J Neurobiol*, **25** (11): 1386-1403.
- Barbieri M.A., Fernandez-Pol S., Hunker C., Horazdovsky B.H. and Stahl P.D. (2004) Role of rab5 in EGF receptor-mediated signal transduction. *Eur J Cell Biol*, **83** (6): 305-314.
- Barbieri M.A., Roberts R.L., Gumusboga A., Highfield H., Alvarez-Dominguez C., Wells A. and Stahl P.D. (2000) Epidermal growth factor and membrane trafficking. EGF receptor activation of endocytosis requires Rab5a. *J Cell Biol*, **151** (3): 539-550.
- Barde Y.A., Edgar D. and Thoenen H. (1982) Purification of a new neurotrophic factor from mammalian brain. *Embo J*, **1** (5): 549-553.
- Barker P.A. (1998) p75NTR: A study in contrasts. *Cell Death Differ*, **5** (5): 346-356.
- Barker P.A. (2004) p75NTR is positively promiscuous: novel partners and new insights. *Neuron*, **42** (4): 529-533.
- Barker P.A. (2007) High Affinity Not in the Vicinity? *Neuron*, **53** (1): 1-4.
- Barker P.A., Hussain N.K. and McPherson P.S. (2002) Retrograde signaling by the neurotrophins follows a well-worn trk. *Trends Neurosci*, **25** (8): 379-381.
- Barrett G.L. and Bartlett P.F. (1994) The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. *Proceedings of the National Academy of Sciences of U S A*, **91** (14): 6501-6505.
- Bartlett S.E., Reynolds A.J. and Hendry I.A. (1998) Retrograde axonal transport of neurotrophins: differences between neuronal populations and implications for motor neuron disease. *Immunology and Cell Biology*, **76** (5): 419-423.

- Bartlett S.E., Reynolds A.J., Weible M., Heydon K. and Hendry I.A. (1997) In sympathetic but not sensory neurones, phosphoinositide-3 kinase is important for NGF-dependent survival and the retrograde transport of 125I-betaNGF. *Brain Res*, **761** (2): 257-262.
- Baxter G.T., Radeke M.J., Kuo R.C. et al (1997) Signal transduction mediated by the truncated trkB receptor isoforms, trkB.T1 and trkB.T2. *J Neurosci*, **17** (8): 2683-2690.
- Beattie E.C., Howe C.L., Wilde A., Brodsky F.M. and Mobley W.C. (2000) NGF signals through TrkA to increase clathrin at the plasma membrane and enhance clathrin-mediated membrane trafficking. *J Neurosci*, **20** (19): 7325-7333.
- Beattie E.C., Zhou J., Grimes M.L., Bunnett N.W., Howe C.L. and Mobley W.C. (1996) A signaling endosome hypothesis to explain NGF actions: potential implications for neurodegeneration. *Cold Spring Harb Symp Quant Biol*, **61**389-406.
- Benedetti M., Levi A. and Chao M.V. (1993) Differential expression of nerve growth factor receptors leads to altered binding affinity and neurotrophin responsiveness. *Proc Natl Acad Sci U S A*, **90** (16): 7859-7863.
- Bentley C.A. and Lee K.F. (2000) p75 is important for axon growth and schwann cell migration during development. *J Neurosci*, **20** (20): 7706-7715.
- Berg D.K. and Fischbach G.D. (1978) Enrichment of spinal cord cell cultures with motoneurons. *J Cell Biol*, **77** (1): 83-98.
- Berg M.M., Sternberg D.W., Parada L.F. and Chao M.V. (1992) K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. *J Biol Chem*, **267** (1): 13-16.
- Berkemeier L.R., Winslow J.W., Kaplan D.R., Nikolics K., Goeddel D.V. and Rosenthal A. (1991) Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. *Neuron*, **7** (5): 857-866.
- Berry M., Barrett L., Seymour L., Baird A. and Logan A. (2001) Gene therapy for central nervous system repair. *Curr Opin Mol Ther*, **3** (4): 338-349.
- Bhattacharyya A., Watson F.L., Bradlee T.A., Pomeroy S.L., Stiles C.D. and Segal R.A. (1997) Trk receptors function as rapid retrograde signal carriers in the adult nervous system. *J Neurosci*, **17** (18): 7007-7016.
- Bibel M. and Barde Y.A. (2000) Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. *Genes Dev*, **14** (23): 2919-2937.
- Bibel M., Hoppe E. and Barde Y.A. (1999) Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. *Embo J*, **18** (3): 616-622.
- Bilderback T.R., Gazula V.R., Lisanti M.P. and Dobrowsky R.T. (1999) Caveolin interacts with Trk A and p75(NTR) and regulates neurotrophin signaling pathways. *J Biol Chem*, **274** (1): 257-263.
- Bishop N.E. (2003) Dynamics of endosomal sorting. *Int Rev Cytol*, **232**1-57.
- Bloch A. and Blochl R. (2007) A cell-biological model of p75(NTR) signaling. *J Neurochem*.
- Bloch A., Blumenstein L. and Ahmadian M.R. (2004) Inactivation and activation of Ras by the neurotrophin receptor p75. *Eur J Neurosci*, **20** (9): 2321-2335.
- Boland B. and Nixon R.A. (2006) Neuronal macroautophagy: from development to degeneration. *Mol Aspects Med*, **27** (5-6): 503-519.

- Bothwell M. (1995) Functional interactions of neurotrophins and neurotrophin receptors. *Annu Rev Neurosci*, **18**:223-253.
- Bradshaw R.A. (1978) Nerve growth factor. *Annu Rev Biochem*, **47**:191-216.
- Brann A.B., Scott R., Neuberger Y., Abulafia D., Boldin S., Fainzilber M. and Futerman A.H. (1999) Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. *J Neurosci*, **19** (19): 8199-8206.
- Brann A.B., Tcherpakov M., Williams I.M., Futerman A.H. and Fainzilber M. (2002) Nerve growth factor-induced p75-mediated death of cultured hippocampal neurons is age-dependent and transduced through ceramide generated by neutral sphingomyelinase. *J Biol Chem*, **277** (12): 9812-9818.
- Brodeur G.M., Nakagawara A., Yamashiro D.J., Ikegaki N., Liu X.G., Azar C.G., Lee C.P. and Evans A.E. (1997) Expression of TrkA, TrkB and TrkC in human neuroblastomas. *J Neurooncol*, **31** (1-2): 49-55.
- Bronfman F.C., Escudero C.A., Weis J. and Kruttgen A. (2007) Endosomal transport of neurotrophins: Roles in signaling and neurodegenerative diseases. *Dev Neurobiol*.
- Bronfman F.C. and Fainzilber M. (2004) Multi-tasking by the p75 neurotrophin receptor: sortilin things out? *EMBO Rep*, **5** (9): 867-871.
- Bronfman F.C., Tcherpakov M., Jovin T.M. and Fainzilber M. (2003) Ligand-induced internalization of the p75 neurotrophin receptor: a slow route to the signaling endosome. In: *J Neurosci*, Vol. 23, pp. 3209-3220.
- Bucci C., Thomsen P., Nicoziani P., McCarthy J. and van Deurs B. (2000) Rab7: a key to lysosome biogenesis. *Mol Biol Cell*, **11** (2): 467-480.
- Buck C.R., Seburn K.L. and Cope T.C. (2000) Neurotrophin expression by spinal motoneurons in adult and developing rats. *J Comp Neurol*, **416** (3): 309-318.
- Bussmann K.A. and Sofroniew M.V. (1999) Re-expression of p75NTR by adult motor neurons after axotomy is triggered by retrograde transport of a positive signal from axons regrowing through damaged or denervated peripheral nerve tissue. *Neuroscience*, **91** (1): 273-281.
- Butowt R. and von Bartheld C.S. (2001) Sorting of internalized neurotrophins into an endocytic transcytosis pathway via the Golgi system: Ultrastructural analysis in retinal ganglion cells. *J Neurosci*, **21** (22): 8915-8930.
- Butowt R. and Von Bartheld C.S. (2003) Connecting the dots: trafficking of neurotrophins, lectins and diverse pathogens by binding to the neurotrophin receptor p75NTR. *Eur J Neurosci*, **17** (4): 673-680.
- Buttigieg H., Kawaja M.D. and Fahnstock M. (2007) Neurotrophic activity of proNGF in vivo. *Exp Neurol*, **204** (2): 832-835.
- Cabelli R.J., Allendoerfer K.L., Radeke M.J., Welcher A.A., Feinstein S.C. and Shatz C.J. (1996) Changing patterns of expression and subcellular localization of TrkB in the developing visual system. *J Neurosci*, **16** (24): 7965-7980.
- Cai D., Shen Y., De Bellard M., Tang S. and Filbin M.T. (1999) Prior exposure to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin via a cAMP-dependent mechanism. *Neuron*, **22** (1): 89-101.
- Callaghan J., Nixon S., Bucci C., Toh B.H. and Stenmark H. (1999) Direct interaction of EEA1 with Rab5b. *Eur J Biochem*, **265** (1): 361-366.

- Calof A.L. and Reichardt L.F. (1984) Motoneurons purified by cell sorting respond to two distinct activities in myotube-conditioned medium. *Dev Biol*, **106** (1): 194-210.
- Calof A.L. and Reichardt L.F. (1985) Response of purified chick motoneurons to myotube conditioned medium: laminin is essential for the substratum-binding, neurite outgrowth-promoting activity. *Neurosci Lett*, **59** (2): 183-189.
- Campenot R.B. and MacInnis B.L. (2004) Retrograde transport of neurotrophins: Fact and function. *J Neurobiol*, **58** (2): 217-229.
- Camu W. and Henderson C.E. (1992) Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor. *J Neurosci Methods*, **44** (1): 59-70.
- Carter B.D., Kaltschmidt C., Kaltschmidt B., Offenhauser N., Bohm-Matthaei R., Baeuerle P.A. and Barde Y.A. (1996) Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. *Science*, **272** (5261): 542-545.
- Casaccia-Bonnel P., Carter B.D., Dobrowsky R.T. and Chao M.V. (1996) Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. *Nature*, **383** (6602): 716-719.
- Casademunt E., Carter B.D., Benzel I., Frade J.M., Dechant G. and Barde Y.A. (1999) The zinc finger protein NRIF interacts with the neurotrophin receptor p75(NTR) and participates in programmed cell death. *Embo J*, **18** (21): 6050-6061.
- Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S. and Antel J.P. (1992) Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. *Dev Dyn*, **194** (3): 209-221.
- Cavalli V., Corti M. and Gruenberg J. (2001) Endocytosis and signaling cascades: a close encounter. *FEBS Lett*, **498** (2-3): 190-196.
- Ceresa B.P. and Schmid S.L. (2000) Regulation of signal transduction by endocytosis. *Curr Opin Cell Biol*, **12** (2): 204-210.
- Chandler C.E., Parsons L.M., Hosang M. and Shooter E.M. (1984) A monoclonal antibody modulates the interaction of nerve growth factor with PC12 cells. *J Biol Chem*, **259** (11): 6882-6889.
- Chao M.V. (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat Rev Neurosci*, **4** (4): 299-309.
- Chao M.V., Bothwell M.A., Ross A.H., Koprowski H., Lanahan A.A., Buck C.R. and Sehgal A. (1986) Gene transfer and molecular cloning of the human NGF receptor. *Science*, **232** (4749): 518-521.
- Chao M.V. and Hempstead B.L. (1995) p75 and Trk: a two-receptor system. *Trends Neurosci*, **18** (7): 321-326.
- Chapman L.A. and Chan H.M. (1999) Inorganic mercury pre-exposures protect against methyl mercury toxicity in NSC-34 (neuron x spinal cord hybrid) cells. *Toxicology*, **132** (2-3): 167-178.
- Chen Z.Y., Ieraci A., Tanowitz M. and Lee F.S. (2005a) A Novel Endocytic Recycling Signal Distinguishes Biological Responses of Trk Neurotrophin Receptors. *Mol Biol Cell*.
- Chen Z.Y., Ieraci A., Teng H., Dall H., Meng C.X., Herrera D.G., Nykjaer A., Hempstead B.L. and Lee F.S. (2005b) Sortilin controls intracellular sorting

- of brain-derived neurotrophic factor to the regulated secretory pathway. *J Neurosci*, **25** (26): 6156-6166.
- Chittka A., Arevalo J.C., Rodriguez-Guzman M., Perez P., Chao M.V. and Sendtner M. (2004) The p75NTR-interacting protein SC1 inhibits cell cycle progression by transcriptional repression of cyclin E. *J Cell Biol*, **164** (7): 985-996.
- Chiu A.Y., Chen E.W. and Loera S. (1993) A motor neuron-specific epitope and the low-affinity nerve growth factor receptor display reciprocal patterns of expression during development, axotomy, and regeneration. *J Comp Neurol*, **328** (3): 351-363.
- Citron B.A., Zhang S.X., Smirnova I.V. and Festoff B.W. (1997) Apoptotic, injury-induced cell death in cultured mouse murine motor neurons. *Neurosci Lett*, **230** (1): 25-28.
- Clague M.J. and Urbe S. (2001) The interface of receptor trafficking and signalling. *J Cell Sci*, **114** (Pt 17): 3075-3081.
- Clary D.O. and Reichardt L.F. (1994) An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. *Proc Natl Acad Sci U S A*, **91** (23): 11133-11137.
- Claude P., Hawrot E., Dunis D.A. and Campenot R.B. (1982) Binding, internalization, and retrograde transport of <sup>125</sup>I-nerve growth factor in cultured rat sympathetic neurons. *J Neurosci*, **2** (4): 431-442.
- Cohen A.W., Hnasko R., Schubert W. and Lisanti M.P. (2004) Role of caveolae and caveolins in health and disease. *Physiol Rev*, **84** (4): 1341-1379.
- Cohen S. (1960) Purification of a Nerve-Growth Promoting Protein from the Mouse Salivary Gland and Its Neuro-Cytotoxic Antiserum. *Proc Natl Acad Sci U S A*, **46** (3): 302-311.
- Cognato H. and Yurchenco P.D. (2000) Form and function: the laminin family of heterotrimers. *Dev Dyn*, **218** (2): 213-234.
- Colom L.V., Alexianu M.E., Mosier D.R., Smith R.G. and Appel S.H. (1997) Amyotrophic lateral sclerosis immunoglobulins increase intracellular calcium in a motoneuron cell line. *Exp Neurol*, **146** (2): 354-360.
- Conner S.D. and Schmid S.L. (2003) Regulated portals of entry into the cell. *Nature*, **422** (6927): 37-44.
- Copray J.C., Jaarsma D., Kust B.M., Bruggeman R.W., Mantingh I., Brouwer N. and Boddeke H.W. (2003) Expression of the low affinity neurotrophin receptor p75 in spinal motoneurons in a transgenic mouse model for amyotrophic lateral sclerosis. *Neuroscience*, **116** (3): 685-694.
- Corbit K.C., Foster D.A. and Rosner M.R. (1999) Protein kinase Cdelta mediates neurogenic but not mitogenic activation of mitogen-activated protein kinase in neuronal cells. *Mol Cell Biol*, **19** (6): 4209-4218.
- Coulson E.J., Reid K. and Bartlett P.F. (1999) Signaling of neuronal cell death by the p75NTR neurotrophin receptor. *Mol Neurobiol*, **20** (1): 29-44.
- Coulson E.J., Reid K., Murray S.S., Cheema S.S. and Bartlett P.F. (2000) Role of neurotrophin receptor p75NTR in mediating neuronal cell death following injury. *Clin Exp Pharmacol Physiol*, **27** (7): 537-541.
- Crawford G.D., Jr., Le W.D., Smith R.G., Xie W.J., Stefani E. and Appel S.H. (1992) A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. *J Neurosci*, **12** (9): 3392-3398.

- Curtis R., Adryan K.M., Stark J.L. et al (1995) Differential role of the low affinity neurotrophin receptor (p75) in retrograde axonal transport of the neurotrophins. *Neuron*, **14** (6): 1201-1211.
- Curtis R., Tonra J.R., Stark J.L., Adryan K.M., Park J.S., Cliffer K.D., Lindsay R.M. and DiStefano P.S. (1998) Neuronal injury increases retrograde axonal transport of the neurotrophins to spinal sensory neurons and motor neurons via multiple receptor mechanisms. *Mol Cell Neurosci*, **12** (3): 105-118.
- D'Hondt K., Heese-Peck A. and Riezman H. (2000) Protein and lipid requirements for endocytosis. *Annu Rev Genet*, **34**:255-295.
- Daro E., van der Sluijs P., Galli T. and Mellman I. (1996) Rab4 and cellubrevin define different early endosome populations on the pathway of transferrin receptor recycling. *Proc Natl Acad Sci U S A*, **93** (18): 9559-9564.
- Das A., Sribnick E.A., Wingrave J.M., Del Re A.M., Woodward J.J., Appel S.H., Banik N.L. and Ray S.K. (2005) Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. *J Neurosci Res*, **81** (4): 551-562.
- Davey F. and Davies A.M. (1998) TrkB signalling inhibits p75-mediated apoptosis induced by nerve growth factor in embryonic proprioceptive neurons. *Curr Biol*, **8** (16): 915-918.
- Davies A.M. (1994) The role of neurotrophins in the developing nervous system. *J Neurobiol*, **25** (11): 1334-1348.
- Dechant G. (2001) Molecular interactions between neurotrophin receptors. *Cell Tissue Res*, **305** (2): 229-238.
- Dechant G. and Barde Y.A. (1997) Signalling through the neurotrophin receptor p75NTR. *Curr Opin Neurobiol*, **7** (3): 413-418.
- Dechant G. and Barde Y.A. (2002) The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. *Nat Neurosci*, **5** (11): 1131-1136.
- DeFreitas M.F., McQuillen P.S. and Shatz C.J. (2001) A novel p75NTR signaling pathway promotes survival, not death, of immunopurified neocortical subplate neurons. *J Neurosci*, **21** (14): 5121-5129.
- Deinhardt K., Berninghausen O., Willison H.J., Hopkins C.R. and Schiavo G. (2006) Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. *J Cell Biol*, **174** (3): 459-471.
- Deinhardt K., Reversi A., Berninghausen O., Hopkins C.R. and Schiavo G. (2007) Neurotrophins Redirect p75(NTR) from a Clathrin-Independent to a Clathrin-Dependent Endocytic Pathway Coupled to Axonal Transport. *Traffic*.
- Deinhardt K., Salinas S., Verastegui C., Watson R., Worth D., Hanrahan S., Bucci C. and Schiavo G. (2006) Rab5 and Rab7 Control Endocytic Sorting along the Axonal Retrograde Transport Pathway. *Neuron*, **52** (2): 293-305.
- Deinhardt K. and Schiavo G. (2005) Endocytosis and retrograde axonal traffic in motor neurons. *Biochem Soc Symp*, (72): 139-150.
- deLapeyriere O. and Henderson C.E. (1997) Motoneuron differentiation, survival and synaptogenesis. *Curr Opin Genet Dev*, **7** (5): 642-650.

- Delcroix J.D., Valletta J.S., Wu C., Hunt S.J., Kowal A.S. and Mobley W.C. (2003) NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. *Neuron*, **39** (1): 69-84.
- Della-Bianca V., Rossi F., Armato U., Dal-Pra I., Costantini C., Perini G., Politi V. and Della Valle G. (2001) Neurotrophin p75 receptor is involved in neuronal damage by prion peptide-(106-126). *J Biol Chem*, **276** (42): 38929-38933.
- Demaurex N. (2002) pH Homeostasis of cellular organelles. *News Physiol Sci*, **171**-5.
- Di Fiore P.P. and De Camilli P. (2001) Endocytosis and signaling. an inseparable partnership. *Cell*, **106** (1): 1-4.
- Di Guglielmo G.M., Baass P.C., Ou W.J., Posner B.I. and Bergeron J.J. (1994) Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. *Embo J*, **13** (18): 4269-4277.
- Digby J., Harrison R., Jehanli A., Lunt G.G. and Clifford-Rose F. (1985) Cultured rat spinal cord neurons: interaction with motor neuron disease immunoglobulins. *Muscle Nerve*, **8** (7): 595-605.
- Dikic I. (2003) Mechanisms controlling EGF receptor endocytosis and degradation. *Biochem Soc Trans*, **31** (Pt 6): 1178-1181.
- DiStefano P.S. (1993) Neurotrophic factors in the treatment of motor neuron disease and trauma. *Exp Neurol*, **124** (1): 56-59.
- Domeniconi M., Hempstead B.L. and Chao M.V. (2006) Pro-NGF secreted by astrocytes promotes motor neuron cell death. *Mol Cell Neurosci*.
- Du J., Feng L., Zaitsev E., Je H.S., Liu X.W. and Lu B. (2003) Regulation of TrkB receptor tyrosine kinase and its internalization by neuronal activity and Ca<sup>2+</sup> influx. *J Cell Biol*, **163** (2): 385-395.
- Durham H.D., Dahrouge S. and Cashman N.R. (1993) Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. *Neurotoxicology*, **14** (4): 387-395.
- Eagleson K.L. and Bennett M.R. (1983) Survival of purified motor neurones in vitro: effects of skeletal muscle-conditioned medium. *Neurosci Lett*, **38** (2): 187-192.
- Edsjo A., Lavenius E., Nilsson H., Hoehner J.C., Simonsson P., Culp L.A., Martinsson T., Larsson C. and Pahlman S. (2003) Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment. *Lab Invest*, **83** (6): 813-823.
- Eggett C.J., Crosier S., Manning P., Cookson M.R., Menzies F.M., McNeil C.J. and Shaw P.J. (2000) Development and characterisation of a glutamate-sensitive motor neurone cell line. *J Neurochem*, **74** (5): 1895-1902.
- Ehlers M.D., Kaplan D.R., Price D.L. and Koliatsos V.E. (1995) NGF-stimulated retrograde transport of trkA in the mammalian nervous system. *J Cell Biol*, **130** (1): 149-156.
- Eide F.F., Lowenstein D.H. and Reichardt L.F. (1993) Neurotrophins and their receptors--current concepts and implications for neurologic disease. *Exp Neurol*, **121** (2): 200-214.
- Eide F.F., Vining E.R., Eide B.L., Zang K., Wang X.Y. and Reichardt L.F. (1996) Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. *J Neurosci*, **16** (10): 3123-3129.

- Encinas M., Iglesias M., Liu Y., Wang H., Muhaisen A., Cena V., Gallego C. and Comella J.X. (2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. *J Neurochem*, **75** (3): 991-1003.
- Encinas M., Iglesias M., Llecha N. and Comella J.X. (1999) Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. *J Neurochem*, **73** (4): 1409-1421.
- Ernfors P. (2001) Local and target-derived actions of neurotrophins during peripheral nervous system development. *Cell Mol Life Sci*, **58** (8): 1036-1044.
- Ernfors P., Ibanez C.F., Ebendal T., Olson L. and Persson H. (1990) Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. *Proc Natl Acad Sci U S A*, **87** (14): 5454-5458.
- Escandon E., Soppet D., Rosenthal A., Mendoza-Ramirez J.L., Szonyi E., Burton L.E., Henderson C.E., Parada L.F. and Nikolics K. (1994) Regulation of neurotrophin receptor expression during embryonic and postnatal development. *J Neurosci*, **14** (4): 2054-2068.
- Esposito D., Patel P., Stephens R.M., Perez P., Chao M.V., Kaplan D.R. and Hempstead B.L. (2001) The cytoplasmic and transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor. *J Biol Chem*, **276** (35): 32687-32695.
- Esteban P.F., Yoon H.Y., Becker J. et al (2006) A kinase-deficient TrkC receptor isoform activates Arf6-Rac1 signaling through the scaffold protein tamalin. *J Cell Biol*, **173** (2): 291-299.
- Evangelopoulos M.E., Weis J. and Kruttgen A. (2004) Neurotrophin effects on neuroblastoma cells: correlation with trk and p75NTR expression and influence of Trk receptor bodies. *J Neurooncol*, **66** (1-2): 101-110.
- Fahnestock M., Yu G., Michalski B., Mathew S., Colquhoun A., Ross G.M. and Coughlin M.D. (2004) The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. *J Neurochem*, **89** (3): 581-592.
- Figlewicz D.A., Dong L., Mlodzienski M. and Turcotte J.C. (2000) Culture models of neurodegenerative disease. *Ann N Y Acad Sci*, **919**:106-118.
- Fischbach G.D. and Dichter M.A. (1974) Electrophysiologic and morphologic properties of neurons in dissociated chick spinal cord cell cultures. *Dev Biol*, **37** (1): 100-116.
- Foehr E.D., Lin X., O'Mahony A., Gelezianus R., Bradshaw R.A. and Greene W.C. (2000) NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells. *J Neurosci*, **20** (20): 7556-7563.
- Frade J.M. (2005) Nuclear translocation of the p75 neurotrophin receptor cytoplasmic domain in response to neurotrophin binding. *J Neurosci*, **25** (6): 1407-1411.
- Francke U., de Martinville B., Coussens L. and Ullrich A. (1983) The human gene for the beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. *Science*, **222** (4629): 1248-1251.

- Frankowski H., Castro-Obregon S., del Rio G., Rao R.V. and Bredesen D.E. (2002) PLAIDD, a type II death domain protein that interacts with p75 neurotrophin receptor. *Neuromolecular Med*, **1** (3): 153-170.
- Funakoshi H., Frisen J., Barbany G., Timmusk T., Zachrisson O., Verge V.M. and Persson H. (1993) Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. *J Cell Biol*, **123** (2): 455-465.
- Giehl K.M. Rohrig S. Bonatz H. et al (2001) Endogenous brain-derived neurotrophic factor and neurotrophin-3 antagonistically regulate survival of axotomized corticospinal neurons in vivo. *J Neurosci*, **21** (10): 3492-3502.
- Gil C., Cubi R. and Aguilera J. (2007) Shedding of the p75NTR neurotrophin receptor is modulated by lipid rafts. *FEBS Lett*, **581** (9): 1851-1858.
- Ginty D.D. and Segal R.A. (2002) Retrograde neurotrophin signaling: Trk-ing along the axon. *Curr Opin Neurobiol*, **12** (3): 268-274.
- Gong Y., Tagawa Y., Lunn M.P., Laroy W., Heffer-Laue M., Li C.Y., Griffin J.W., Schnaar R.L. and Sheikh K.A. (2002) Localization of major gangliosides in the PNS: implications for immune neuropathies. *Brain*, **125** (Pt 11): 2491-2506.
- Gonzalez-Gaitan M. and Stenmark H. (2003) Endocytosis and signaling: a relationship under development. *Cell*, **115** (5): 513-521.
- Grabe M. and Oster G. (2001) Regulation of organelle acidity. *J Gen Physiol*, **117** (4): 329-344.
- Greene L.A., Shain W., Chalazonitis A., Breakfield X., Minna J., Coon H.G. and Nirenberg M. (1975) Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells. *Proc Natl Acad Sci U S A*, **72** (12): 4923-4927.
- Greene L.A. and Tischler A.S. (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. *Proc Natl Acad Sci U S A*, **73** (7): 2424-2428.
- Grimes M.L., Beattie E. and Mobley W.C. (1997) A signaling organelle containing the nerve growth factor-activated receptor tyrosine kinase, TrkA. *Proc Natl Acad Sci U S A*, **94** (18): 9909-9914.
- Grimes M.L. Zhou J. Beattie E.C. et al (1996) Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. *J Neurosci*, **16** (24): 7950-7964.
- Haapasalo A., Sipola I., Larsson K., Akerman K.E., Stoilov P., Stamm S., Wong G. and Castren E. (2002) Regulation of TRKB surface expression by brain-derived neurotrophic factor and truncated TRKB isoforms. *J Biol Chem*, **277** (45): 43160-43167.
- Hallbook F. (1999) Evolution of the vertebrate neurotrophin and Trk receptor gene families. *Curr Opin Neurobiol*, **9** (5): 616-621.
- Hamburger V. (1958) Regression versus peripheral control of differentiation in motor hypoplasia. *Am J Anat*, **102** (3): 365-409.
- Hammond D.N., Wainer B.H., Tonsgard J.H. and Heller A. (1986) Neuronal properties of clonal hybrid cell lines derived from central cholinergic neurons. *Science*, **234** (4781): 1237-1240.
- Hapner S.J., Boeshore K.L., Large T.H. and Lefcort F. (1998) Neural differentiation promoted by truncated trkC receptors in collaboration with p75(NTR). *Dev Biol*, **201** (1): 90-100.

- Harrington A.W., Leiner B., Blechschmitt C. et al (2004) Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. *Proc Natl Acad Sci U S A*, **101** (16): 6226-6230.
- Hartmann M., Brigadski T., Erdmann K.S., Holtmann B., Sendtner M., Narz F. and Lessmann V. (2004) Truncated TrkB receptor-induced outgrowth of dendritic filopodia involves the p75 neurotrophin receptor. *J Cell Sci*, **117** (Pt 24): 5803-5814.
- Haucke V. (2006) Cargo takes control of endocytosis. *Cell*, **127** (1): 35-37.
- Hayes S., Chawla A. and Corvera S. (2002) TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. *J Cell Biol*, **158** (7): 1239-1249.
- He B.P., Wen W. and Strong M.J. (2002) Activated microglia (BV-2) facilitation of TNF-alpha-mediated motor neuron death in vitro. *J Neuroimmunol*, **128** (1-2): 31-38.
- Heerssen H.M., Pazyra M.F. and Segal R.A. (2004) Dynein motors transport activated Trks to promote survival of target-dependent neurons. *Nat Neurosci*, **7** (6): 596-604.
- Heerssen H.M. and Segal R.A. (2002) Location, location, location: a spatial view of neurotrophin signal transduction. *Trends Neurosci*, **25** (3): 160-165.
- Hempstead B.L. (2002) The many faces of p75(NTR). *Curr Opin Neurobiol*, **12** (3): 260-267.
- Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F. and Chao M.V. (1991) High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. *Nature*, **350** (6320): 678-683.
- Hempstead B.L., Rabin S.J., Kaplan L., Reid S., Parada L.F. and Kaplan D.R. (1992) Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth factor-induced differentiation. *Neuron*, **9** (5): 883-896.
- Henderson C.E. (1996) Role of neurotrophic factors in neuronal development. *Curr Opin Neurobiol*, **6** (1): 64-70.
- Henderson C.E., Yamamoto Y., Livet J., Arce V., Garces A. and deLapeyriere O. (1998) Role of neurotrophic factors in motoneuron development. *J Physiol Paris*, **92** (3-4): 279-281.
- Hendry I.A. (1992) Retrograde factors in peripheral nerves. *Pharmacol Ther*, **56** (3): 265-285.
- Hendry I.A., Stockel K., Thoenen H. and Iversen L.L. (1974) The retrograde axonal transport of nerve growth factor. *Brain Res*, **68** (1): 103-121.
- Hennigan A., O'Callaghan R.M. and Kelly A.M. (2007) Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. *Biochem Soc Trans*, **35** (Pt 2): 424-427.
- Heumann R. (1994) Neurotrophin signalling. *Curr Opin Neurobiol*, **4** (5): 668-679.
- Heumann R., Ocalan M., Kachel V. and Hamprecht B. (1979) Clonal hybrid cell lines expressing cholinergic and adrenergic properties. *Proc Natl Acad Sci U S A*, **76** (9): 4674-4677.
- Hibbert A.P., Kramer B.M., Miller F.D. and Kaplan D.R. (2006) The localization, trafficking and retrograde transport of BDNF bound to p75NTR in sympathetic neurons. *Mol Cell Neurosci*, **32** (4): 387-402.
- Higuchi H., Yamashita T., Yoshikawa H. and Tohyama M. (2003) PKA phosphorylates the p75 receptor and regulates its localization to lipid rafts. *Embo J*, **22** (8): 1790-1800.

- Hirokawa N. and Takemura R. (2003) Biochemical and molecular characterization of diseases linked to motor proteins. *Trends Biochem Sci*, **28** (10): 558-565.
- Hirst J. and Robinson M.S. (1998) Clathrin and adaptors. *Biochim Biophys Acta*, **1404** (1-2): 173-193.
- Holgado-Madruga M., Moscatello D.K., Emlet D.R., Dieterich R. and Wong A.J. (1997) Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. *Proc Natl Acad Sci U S A*, **94** (23): 12419-12424.
- Howe C.L. and Mobley W.C. (2004) Signaling endosome hypothesis: A cellular mechanism for long distance communication. *J Neurobiol*, **58** (2): 207-216.
- Howe C.L. and Mobley W.C. (2005) Long-distance retrograde neurotrophic signaling. *Curr Opin Neurobiol*, **15** (1): 40-48.
- Howe C.L., Valletta J.S., Rusnak A.S. and Mobley W.C. (2001) NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. *Neuron*, **32** (5): 801-814.
- Huang C.S., Zhou J., Feng A.K., Lynch C.C., Klumperman J., DeArmond S.J. and Mobley W.C. (1999) Nerve growth factor signaling in caveolae-like domains at the plasma membrane. *J Biol Chem*, **274** (51): 36707-36714.
- Huang E.J. and Reichardt L.F. (2001) Neurotrophins: roles in neuronal development and function. *Annu Rev Neurosci*, **24**: 677-736.
- Huang E.J. and Reichardt L.F. (2003) Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem*, **72**: 609-642.
- Hughes R.A., Sendtner M. and Thoenen H. (1993) Members of several gene families influence survival of rat motoneurons in vitro and in vivo. *J Neurosci Res*, **36** (6): 663-671.
- Hunter D.D., Cashman N., Morris-Valero R., Bullock J.W., Adams S.P. and Sanes J.R. (1991) An LRE (leucine-arginine-glutamate)-dependent mechanism for adhesion of neurons to S-laminin. *J Neurosci*, **11** (12): 3960-3971.
- Hunter D.D., Porter B.E., Bullock J.W., Adams S.P., Merlie J.P. and Sanes J.R. (1989) Primary sequence of a motor neuron-selective adhesive site in the synaptic basal lamina protein S-laminin. *Cell*, **59** (5): 905-913.
- Hutson L.D. and Bothwell M. (2001) Expression and function of *Xenopus laevis* p75(NTR) suggest evolution of developmental regulatory mechanisms. *J Neurobiol*, **49** (2): 79-98.
- Ibanez C.F., Hallbook F., Godeau F. and Persson H. (1992) Expression of neurotrophin-4 mRNA during oogenesis in *Xenopus laevis*. *Int J Dev Biol*, **36** (2): 239-245.
- Ichinose T. and Snider W.D. (2000) Differential effects of TrkC isoforms on sensory axon outgrowth. *J Neurosci Res*, **59** (3): 365-371.
- Ikonen E. (2001) Roles of lipid rafts in membrane transport. *Curr Opin Cell Biol*, **13** (4): 470-477.
- Inagaki N., Thoenen H. and Lindholm D. (1995) TrkA tyrosine residues involved in NGF-induced neurite outgrowth of PC12 cells. *Eur J Neurosci*, **7** (6): 1125-1133.
- Iwasaki Y., Ishikawa M., Okada N. and Koizumi S. (1997) Induction of a distinct morphology and signal transduction in TrkB/PC12 cells by nerve growth factor and brain-derived neurotrophic factor. *J Neurochem*, **68** (3): 927-934.

- Jackson A.C. and Park H. (1999) Experimental rabies virus infection of p75 neurotrophin receptor-deficient mice. *Acta Neuropathol (Berl)*, **98** (6): 641-644.
- Johnson D., Lanahan A., Buck C.R., Sehgal A., Morgan C., Mercer E., Bothwell M. and Chao M. (1986) Expression and structure of the human NGF receptor. *Cell*, **47** (4): 545-554.
- Johnson E.M., Jr., Taniuchi M., Clark H.B., Springer J.E., Koh S., Tayrien M.W. and Loy R. (1987) Demonstration of the retrograde transport of nerve growth factor receptor in the peripheral and central nervous system. *J Neurosci*, **7** (3): 923-929.
- Johnson H., Hokfelt T. and Ulfhake B. (1999) Expression of p75(NTR), trkB and trkC in nonmanipulated and axotomized motoneurons of aged rats. *Brain Res Mol Brain Res*, **69** (1): 21-34.
- Jordens I., Marsman M., Kuijl C. and Neefjes J. (2005) Rab proteins, connecting transport and vesicle fusion. *Traffic*, **6** (12): 1070-1077.
- Jullien J., Guili V., Reichardt L.F. and Rudkin B.B. (2002) Molecular kinetics of nerve growth factor receptor trafficking and activation. *J Biol Chem*, **277** (41): 38700-38708.
- Kahle P., Barker P.A., Shooter E.M. and Hertel C. (1994) p75 nerve growth factor receptor modulates p140trkA kinase activity, but not ligand internalization, in PC12 cells. *J Neurosci Res*, **38** (5): 599-606.
- Kandel E.R., Schwartz J.H. and Jessell T.M. (2000) ***Principles of Neural Science***, 4th Edition. McGraw-Hill Medical.
- Kang H.J. and Schuman E.M. (1995) Neurotrophin-induced modulation of synaptic transmission in the adult hippocampus. *J Physiol Paris*, **89** (1): 11-22.
- Kanning K.C., Hudson M., Amieux P.S., Wiley J.C., Bothwell M. and Schecterson L.C. (2003) Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. *J Neurosci*, **23** (13): 5425-5436.
- Kao S., Jaiswal R.K., Kolch W. and Landreth G.E. (2001) Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. *J Biol Chem*, **276** (21): 18169-18177.
- Kaplan D.R. (1998) Studying signal transduction in neuronal cells: the Trk/NGF system. *Prog Brain Res*, **117**:35-46.
- Kaplan D.R., Hempstead B.L., Martin-Zanca D., Chao M.V. and Parada L.F. (1991a) The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. *Science*, **252** (5005): 554-558.
- Kaplan D.R., Martin-Zanca D. and Parada L.F. (1991b) Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. *Nature*, **350** (6314): 158-160.
- Kaplan D.R., Matsumoto K., Lucarelli E. and Thiele C.J. (1993) Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. *Neuron*, **11** (2): 321-331.
- Kaplan D.R. and Miller F.D. (1997) Signal transduction by the neurotrophin receptors. *Curr Opin Cell Biol*, **9** (2): 213-221.
- Kaplan D.R. and Miller F.D. (2000) Neurotrophin signal transduction in the nervous system. *Curr Opin Neurobiol*, **10** (3): 381-391.

- Kaplan D.R. and Stephens R.M. (1994) Neurotrophin signal transduction by the Trk receptor. *J Neurobiol*, **25** (11): 1404-1417.
- Kato A.C., Touzeau G., Bertrand D. and Bader C.R. (1985) Human spinal cord neurons in dissociated monolayer cultures: morphological, biochemical, and electrophysiological properties. *J Neurosci*, **5** (10): 2750-2761.
- Keir S.D., Xiao X., Li J. and Kennedy P.G. (2001) Adeno-associated virus-mediated delivery of glial cell line-derived neurotrophic factor protects motor neuron-like cells from apoptosis. *J Neurovirol*, **7** (5): 437-446.
- Khursigara G., Orlicki J.R. and Chao M.V. (1999) Association of the p75 neurotrophin receptor with TRAF6. *J Biol Chem*, **274** (5): 2597-2600.
- Kim J.Y. Sutton M.E. Lu D.J. et al (1999) Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. *Cancer Res*, **59** (3): 711-719.
- Kitamura M., Takamiya K., Aizawa S., Furukawa K. and Furukawa K. (1999) Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. *Biochim Biophys Acta*, **1441** (1): 1-3.
- Klein R. (1994) Role of neurotrophins in mouse neuronal development. *Faseb J*, **8** (10): 738-744.
- Klein R., Conway D., Parada L.F. and Barbacid M. (1990) The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. *Cell*, **61** (4): 647-656.
- Klein R., Jing S.Q., Nanduri V., O'Rourke E. and Barbacid M. (1991) The trk proto-oncogene encodes a receptor for nerve growth factor. *Cell*, **65** (1): 189-197.
- Klein R., Lamballe F., Bryant S. and Barbacid M. (1992) The trkB tyrosine protein kinase is a receptor for neurotrophin-4. *Neuron*, **8** (5): 947-956.
- Klein R., Parada L.F., Coulier F. and Barbacid M. (1989) trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. *Embo J*, **8** (12): 3701-3709.
- Kobayashi N.R., Bedard A.M., Hincke M.T. and Tetzlaff W. (1996) Increased expression of BDNF and trkB mRNA in rat facial motoneurons after axotomy. *Eur J Neurosci*, **8** (5): 1018-1029.
- Koh S.H., Lee Y.B., Kim K.S., Kim H.J., Kim M., Lee Y.J., Kim J., Lee K.W. and Kim S.H. (2005) Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. *Eur J Neurosci*, **22** (2): 301-309.
- Kong H., Boulter J., Weber J.L., Lai C. and Chao M.V. (2001) An evolutionarily conserved transmembrane protein that is a novel downstream target of neurotrophin and ephrin receptors. *J Neurosci*, **21** (1): 176-185.
- Krieger C. and Kim S.U. (1991) Neonatal mammalian spinal cord neurons and motoneurons in monolayer culture. *Muscle Nerve*, **14** (1): 14-21.
- Kruttgen A., Saxena S., Evangelopoulos M.E. and Weis J. (2003) Neurotrophins and neurodegenerative diseases: receptors stuck in traffic? *J Neuropathol Exp Neurol*, **62** (4): 340-350.
- Kuhn T.B. (2003) Growing and working with spinal motor neurons. *Methods Cell Biol*, **71**: 67-87.
- Kuner P., Schubel R. and Hertel C. (1998) Beta-amyloid binds to p75NTR and activates NFkappaB in human neuroblastoma cells. *J Neurosci Res*, **54** (6): 798-804.

- Lakadamyali M., Rust M.J. and Zhuang X. (2006) Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. *Cell*, **124** (5): 997-1009.
- Lalli G., Bohnert S., Deinhardt K., Verastegui C. and Schiavo G. (2003) The journey of tetanus and botulinum neurotoxins in neurons. *Trends Microbiol*, **11** (9): 431-437.
- Lalli G. and Schiavo G. (2002) Analysis of retrograde transport in motor neurons reveals common endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. *J Cell Biol*, **156** (2): 233-239.
- Lamballe F., Klein R. and Barbacid M. (1991) trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. *Cell*, **66** (5): 967-979.
- Langevin C., Jaaro H., Bressanelli S., Fainzilber M. and Tuffereau C. (2002) Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor. *J Biol Chem*, **277** (40): 37655-37662.
- Lee F.S., Kim A.H., Khursigara G. and Chao M.V. (2001a) The uniqueness of being a neurotrophin receptor. *Curr Opin Neurobiol*, **11** (3): 281-286.
- Lee H.J., Hammond D.N., Large T.H. and Wainer B.H. (1990) Immortalized young adult neurons from the septal region: generation and characterization. *Brain Res Dev Brain Res*, **52** (1-2): 219-228.
- Lee K.F., Li E., Huber L.J., Landis S.C., Sharpe A.H., Chao M.V. and Jaenisch R. (1992) Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. *Cell*, **69** (5): 737-749.
- Lee R., Kermani P., Teng K.K. and Hempstead B.L. (2001b) Regulation of cell survival by secreted proneurotrophins. *Science*, **294** (5548): 1945-1948.
- Levi-Montalcini R. and Hamburger V. (1951) Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. *J Exp Zool*, **116** (2): 321-361.
- Levi-Montalcini R., Skaper S.D., Dal Toso R., Petrelli L. and Leon A. (1996) Nerve growth factor: from neurotrophin to neurokine. *Trends Neurosci*, **19** (11): 514-520.
- Li R., Thode S., Zhou J., Richard N., Pardinias J., Rao M.S. and Sah D.W. (2000) Motoneuron differentiation of immortalized human spinal cord cell lines. *J Neurosci Res*, **59** (3): 342-352.
- Liepinsh E., Ilag L.L., Otting G. and Ibanez C.F. (1997) NMR structure of the death domain of the p75 neurotrophin receptor. *Embo J*, **16** (16): 4999-5005.
- Lievremont J.P., Sciorati C., Morandi E., Paolucci C., Bunone G., Della Valle G., Meldolesi J. and Clementi E. (1999) The p75(NTR)-induced apoptotic program develops through a ceramide-caspase pathway negatively regulated by nitric oxide. *J Biol Chem*, **274** (22): 15466-15472.
- Lindsay R.M. (1996) Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview. *Philos Trans R Soc Lond B Biol Sci*, **351** (1338): 365-373.
- Liu R., Li B., Flanagan S.W., Oberley L.W., Gozal D. and Qiu M. (2002) Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1-mediated motor neuron cell death and

- increase amyotrophic lateral sclerosis-like transgenic mouse survival. *J Neurochem*, **80** (3): 488-500.
- Lombard-Golly D., Wong V. and Kessler J.A. (1990) Regulation of cholinergic expression in cultured spinal cord neurons. *Dev Biol*, **139** (2): 396-406.
- Lu B. (2003) Pro-region of neurotrophins: role in synaptic modulation. *Neuron*, **39** (5): 735-738.
- Lu B., Pang P.T. and Woo N.H. (2005) The yin and yang of neurotrophin action. *Nat Rev Neurosci*, **6** (8): 603-614.
- MacDonald J.I. and Meakin S.O. (1996) Deletions in the extracellular domain of rat trkA lead to an altered differentiative phenotype in neurotrophin responsive cells. *Mol Cell Neurosci*, **7** (5): 371-390.
- MacInnis B.L. and Campenot R.B. (2002) Retrograde support of neuronal survival without retrograde transport of nerve growth factor. *Science*, **295** (5559): 1536-1539.
- Marshall C.J. (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. *Cell*, **80** (2): 179-185.
- Martin-Zanca D., Hughes S.H. and Barbacid M. (1986) A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. *Nature*, **319** (6056): 743-748.
- Martin-Zanca D., Oskam R., Mitra G., Copeland T. and Barbacid M. (1989) Molecular and biochemical characterization of the human trk proto-oncogene. *Mol Cell Biol*, **9** (1): 24-33.
- Martinou J.C., Falls D.L., Fischbach G.D. and Merlie J.P. (1991) Acetylcholine receptor-inducing activity stimulates expression of the epsilon-subunit gene of the muscle acetylcholine receptor. *Proc Natl Acad Sci U S A*, **88** (17): 7669-7673.
- Matsumoto A., Yoshino H., Yuki N., Hara Y., Cashman N.R., Handa S. and Miyatake T. (1995) Ganglioside characterization of a cell line displaying motor neuron-like phenotype: GM2 as a possible major ganglioside in motor neurons. *J Neurol Sci*, **131** (2): 111-118.
- Matusica D., Fenech M.P., Rogers M.L. and Rush R.A. (2008) Characterization and use of the NSC-34 cell line for study of neurotrophin receptor trafficking. *J Neurosci Res*, **86** (3): 553-565.
- Maxfield F.R. and McGraw T.E. (2004) Endocytic recycling. *Nat Rev Mol Cell Biol*, **5** (2): 121-132.
- Mayor S., Presley J.F. and Maxfield F.R. (1993) Sorting of membrane components from endosomes and subsequent recycling to the cell surface occurs by a bulk flow process. *J Cell Biol*, **121** (6): 1257-1269.
- Mazella J., Zsurger N., Navarro V. et al (1998) The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. *J Biol Chem*, **273** (41): 26273-26276.
- McAllister A.K. (2001) Neurotrophins and neuronal differentiation in the central nervous system. *Cell Mol Life Sci*, **58** (8): 1054-1060.
- McCaffrey M.W., Bielli A., Cantalupo G., Mora S., Roberti V., Santillo M., Drummond F. and Bucci C. (2001) Rab4 affects both recycling and degradative endosomal trafficking. *FEBS Lett*, **495** (1-2): 21-30.
- McGee A.W. and Strittmatter S.M. (2003) The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. *Trends Neurosci*, **26** (4): 193-198.

- McPherson P.S., Kay B.K. and Hussain N.K. (2001) Signaling on the endocytic pathway. *Traffic*, **2** (6): 375-384.
- Mellman I. (1996) Endocytosis and molecular sorting. *Annu Rev Cell Dev Biol*, **12**:575-625.
- Menn B., Timsit S., Calothy G. and Lamballe F. (1998) Differential expression of TrkC catalytic and noncatalytic isoforms suggests that they act independently or in association. *J Comp Neurol*, **401** (1): 47-64.
- Mercer E.A., Korhonen L., Skoglosa Y., Olsson P.A., Kukkonen J.P. and Lindholm D. (2000) NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. *Embo J*, **19** (14): 3597-3607.
- Meresse S., Gorvel J.P. and Chavrier P. (1995) The rab7 GTPase resides on a vesicular compartment connected to lysosomes. *J Cell Sci*, **108** ( Pt **11**):3349-3358.
- Miaczynska M., Christoforidis S., Giner A., Shevchenko A., Uttenweiler-Joseph S., Habermann B., Wilm M., Parton R.G. and Zerial M. (2004a) APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. *Cell*, **116** (3): 445-456.
- Miaczynska M., Pelkmans L. and Zerial M. (2004b) Not just a sink: endosomes in control of signal transduction. *Curr Opin Cell Biol*, **16** (4): 400-406.
- Miaczynska M. and Zerial M. (2002) Mosaic organization of the endocytic pathway. *Exp Cell Res*, **272** (1): 8-14.
- Middlemas D.S., Lindberg R.A. and Hunter T. (1991) trkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. *Mol Cell Biol*, **11** (1): 143-153.
- Miller F.D. and Kaplan D.R. (1998) Life and death decisions: a biological role for the p75 neurotrophin receptor. *Cell Death Differ*, **5** (5): 343-345.
- Miller F.D. and Kaplan D.R. (2001a) Neurotrophin signalling pathways regulating neuronal apoptosis. *Cell Mol Life Sci*, **58** (8): 1045-1053.
- Miller F.D. and Kaplan D.R. (2001b) On Trk for retrograde signaling. *Neuron*, **32** (5): 767-770.
- Miller F.D. and Kaplan D.R. (2002) Neurobiology. TRK makes the retrograde. *Science*, **295** (5559): 1471-1473.
- Mills I.G., Urbe S. and Clague M.J. (2001) Relationships between EEA1 binding partners and their role in endosome fusion. *J Cell Sci*, **114** (Pt 10): 1959-1965.
- Mischel P.S., Smith S.G., Vining E.R., Valletta J.S., Mobley W.C. and Reichardt L.F. (2001) The extracellular domain of p75NTR is necessary to inhibit neurotrophin-3 signaling through TrkA. *J Biol Chem*, **276** (14): 11294-11301.
- Mitsumoto H. and Tsuzaka K. (1999a) Neurotrophic factors and neuro-muscular disease: II. GDNF, other neurotrophic factors, and future directions. *Muscle Nerve*, **22** (8): 1000-1021.
- Mitsumoto H. and Tsuzaka K. (1999b) Neurotrophic factors and neuromuscular disease: I. General comments, the neurotrophin family, and neuropoietic cytokines. *Muscle Nerve*, **22** (8): 983-999.
- Moscato L.M. and Sanes J.R. (1995) Expression of four immunoglobulin superfamily adhesion molecules (L1, Nr-CAM/Bravo, neurofascin/ABGP, and N-CAM) in the developing mouse spinal cord. *J Comp Neurol*, **352** (3): 321-334.

- Mosier D.R., Baldelli P., Delbono O., Smith R.G., Alexianu M.E., Appel S.H. and Stefani E. (1995) Amyotrophic lateral sclerosis immunoglobulins increase Ca<sup>2+</sup> currents in a motoneuron cell line. *Ann Neurol*, **37** (1): 102-109.
- Mousavi S.A., Malerod L., Berg T. and Kjekken R. (2004) Clathrin-dependent endocytosis. *Biochem J*, **377** (Pt 1): 1-16.
- Mu F.T. Callaghan J.M. Steele-Mortimer O. et al (1995) EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. *J Biol Chem*, **270** (22): 13503-13511.
- Mukai J. Hachiya T. Shoji-Hoshino S. et al (2000) NADE, a p75NTR-associated cell death executor, is involved in signal transduction mediated by the common neurotrophin receptor p75NTR. *J Biol Chem*, **275** (23): 17566-17570.
- Mukhopadhyay G., Doherty P., Walsh F.S., Crocker P.R. and Filbin M.T. (1994) A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. *Neuron*, **13** (3): 757-767.
- Munck Petersen C., Nielsen M.S., Jacobsen C., Tauris J., Jacobsen L., Gliemann J., Moestrup S.K. and Madsen P. (1999) Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. *Embo J*, **18** (3): 595-604.
- Nagappan G. and Lu B. (2005) Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications. *Trends Neurosci*, **28** (9): 464-471.
- Nakamura T., Komiya M., Sone K., Hirose E., Gotoh N., Morii H., Ohta Y. and Mori N. (2002) Grit, a GTPase-activating protein for the Rho family, regulates neurite extension through association with the TrkA receptor and N-Shc and CrkL/Crk adapter molecules. *Mol Cell Biol*, **22** (24): 8721-8734.
- Neet K.E. and Campenot R.B. (2001) Receptor binding, internalization, and retrograde transport of neurotrophic factors. *Cell Mol Life Sci*, **58** (8): 1021-1035.
- Nichols B. (2003) Caveosomes and endocytosis of lipid rafts. *J Cell Sci*, **116** (Pt 23): 4707-4714.
- Nichols B.J. and Lippincott-Schwartz J. (2001) Endocytosis without clathrin coats. *Trends Cell Biol*, **11** (10): 406-412.
- Nielsen M.S., Jacobsen C., Olivecrona G., Gliemann J. and Petersen C.M. (1999) Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. *J Biol Chem*, **274** (13): 8832-8836.
- Nielsen M.S., Madsen P., Christensen E.I., Nykjaer A., Gliemann J., Kasper D., Pohlmann R. and Petersen C.M. (2001) The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. *Embo J*, **20** (9): 2180-2190.
- Ninkina N., Adu J., Fischer A., Pinon L.G., Buchman V.L. and Davies A.M. (1996) Expression and function of TrkB variants in developing sensory neurons. *Embo J*, **15** (23): 6385-6393.
- Ninkina N., Grashchuck M., Buchman V.L. and Davies A.M. (1997) TrkB variants with deletions in the leucine-rich motifs of the extracellular domain. *J Biol Chem*, **272** (20): 13019-13025.
- Nykjaer A. Lee R. Teng K.K. et al (2004) Sortilin is essential for proNGF-induced neuronal cell death. *Nature*, **427** (6977): 843-848.

- O'Brien R.J. and Fischbach G.D. (1986) Isolation of embryonic chick motoneurons and their survival in vitro. *J Neurosci*, **6** (11): 3265-3274.
- Oppenheim R.W. (1991) Cell death during development of the nervous system. *Annu Rev Neurosci*, **14**:453-501.
- Oppenheim R.W. (1996) Neurotrophic survival molecules for motoneurons: an embarrassment of riches. *Neuron*, **17** (2): 195-197.
- Palko M.E., Coppola V. and Tessarollo L. (1999) Evidence for a role of truncated trkC receptor isoforms in mouse development. *J Neurosci*, **19** (2): 775-782.
- Paratcha G. and Ibanez C.F. (2002) Lipid rafts and the control of neurotrophic factor signaling in the nervous system: variations on a theme. *Curr Opin Neurobiol*, **12** (5): 542-549.
- Park K.S., Kim H.J., Choi W.J., Kim M. and Lee K.W. (2004) Detection method of the adjacent motor neuronal death in an in vitro co-culture model of familial ALS-associated Cu/Zn superoxide dismutase. *Biotechnol Lett*, **26** (15): 1201-1205.
- Patapoutian A. and Reichardt L.F. (2001) Trk receptors: mediators of neurotrophin action. *Curr Opin Neurobiol*, **11** (3): 272-280.
- Peacock J.H., Nelson P.G. and Goldstone M.W. (1973) Electrophysiologic study of cultured neurons dissociated from spinal cords and dorsal root ganglia of fetal mice. *Dev Biol*, **30** (1): 137-152.
- Perez P., Coll P.M., Hempstead B.L., Martin-Zanca D. and Chao M.V. (1995) NGF binding to the trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains. *Mol Cell Neurosci*, **6** (2): 97-105.
- Perini G., Della-Bianca V., Politi V., Della Valle G., Dal-Pra I., Rossi F. and Armato U. (2002) Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. *J Exp Med*, **195** (7): 907-918.
- Perret E., Lakkaraju A., Deborde S., Schreiner R. and Rodriguez-Boulan E. (2005) Evolving endosomes: how many varieties and why? *Curr Opin Cell Biol*, **17** (4): 423-434.
- Perrone L., Paladino S., Mazzone M., Nitsch L., Gulisano M. and Zurzolo C. (2005) Functional interaction between p75NTR and TrkA: the endocytic trafficking of p75NTR is driven by TrkA and regulates TrkA-mediated signalling. *Biochem J*, **385** (Pt 1): 233-241.
- Petersen C.M., Nielsen M.S., Nykjaer A. et al (1997) Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. *J Biol Chem*, **272** (6): 3599-3605.
- Pfaff S.L., Mendelsohn M., Stewart C.L., Edlund T. and Jessell T.M. (1996) Requirement for LIM homeobox gene *Isl1* in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. *Cell*, **84** (2): 309-320.
- Phelps P.E., Barber R.P., Houser C.R., Crawford G.D., Salvaterra P.M. and Vaughn J.E. (1984) Postnatal development of neurons containing choline acetyltransferase in rat spinal cord: an immunocytochemical study. *J Comp Neurol*, **229** (3): 347-361.
- Piper R.C. and Luzio J.P. (2001) Late endosomes: sorting and partitioning in multivesicular bodies. *Traffic*, **2** (9): 612-621.
- Prusiner S.B. (1987) Prions and neurodegenerative diseases. *N Engl J Med*, **317** (25): 1571-1581.

- Puthenveedu M.A. and von Zastrow M. (2006) Cargo regulates clathrin-coated pit dynamics. *Cell*, **127** (1): 113-124.
- Qian M.D., Zhang J., Tan X.Y., Wood A., Gill D. and Cho S. (2006) Novel agonist monoclonal antibodies activate TrkB receptors and demonstrate potent neurotrophic activities. *J Neurosci*, **26** (37): 9394-9403.
- Qin D.X., Zou X.L., Luo W., Zhang W., Zhang H.T., Li X.L., Zhang H., Wang X.Y. and Wang T.H. (2006) Expression of some neurotrophins in the spinal motoneurons after cord hemisection in adult rats. *Neurosci Lett*.
- Rabizadeh S., Bitler C.M., Butcher L.L. and Bredesen D.E. (1994) Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity. *Proc Natl Acad Sci U S A*, **91** (22): 10703-10706.
- Radeke M.J., Misko T.P., Hsu C., Herzenberg L.A. and Shooter E.M. (1987) Gene transfer and molecular cloning of the rat nerve growth factor receptor. *Nature*, **325** (6105): 593-597.
- Raimondi A. Mangolini A. Rizzardini M. et al (2006) Cell culture models to investigate the selective vulnerability of motoneuronal mitochondria to familial ALS-linked G93ASOD1. *Eur J Neurosci*, **24** (2): 387-399.
- Rappoport J., Simon S. and Benmerah A. (2004) Understanding living clathrin-coated pits. *Traffic*, **5** (5): 327-337.
- Read M.L., Logan A. and Seymour L.W. (2005) Barriers to gene delivery using synthetic vectors. *Adv Genet*, **53**: 19-46.
- Reichardt L.F. and Mobley W.C. (2004) Going the distance, or not, with neurotrophin signals. *Cell*, **118** (2): 141-143.
- Rembach A. Turner B.J. Bruce S. et al (2004) Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. *J Neurosci Res*, **77** (4): 573-582.
- Reynolds A.J., Bartlett S.E. and Hendry I.A. (1998) Signalling events regulating the retrograde axonal transport of 125I-beta nerve growth factor in vivo. *Brain Res*, **798** (1-2): 67-74.
- Reynolds A.J., Bartlett S.E. and Hendry I.A. (2000) Molecular mechanisms regulating the retrograde axonal transport of neurotrophins. *Brain Res Brain Res Rev*, **33** (2-3): 169-178.
- Riccio A., Pierchala B.A., Ciarallo C.L. and Ginty D.D. (1997) An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons. *Science*, **277** (5329): 1097-1100.
- Rizzardini M., Lupi M., Bernasconi S., Mangolini A. and Cantoni L. (2003) Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. *J Neurol Sci*, **207** (1-2): 51-58.
- Rizzardini M., Lupi M., Mangolini A., Babetto E., Ubezio P. and Cantoni L. (2006) Neurodegeneration induced by complex I inhibition in a cellular model of familial amyotrophic lateral sclerosis. *Brain Res Bull*, **69** (4): 465-474.
- Rodman J.S., Mercer R.W. and Stahl P.D. (1990) Endocytosis and transcytosis. *Curr Opin Cell Biol*, **2** (4): 664-672.
- Rogers M.L., Atmosukarto I., Berhanu D.A., Matusica D., Macardle P. and Rush R.A. (2006) Functional monoclonal antibodies to p75 neurotrophin receptor raised in knockout mice. *J Neurosci Methods*, **158** (1): 109-120.
- Rosch H., Schweigreiter R., Bonhoeffer T., Barde Y.A. and Korte M. (2005) The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus. *Proc Natl Acad Sci U S A*, **102** (20): 7362-7367.

- Ross G.M., Shamovsky I.L., Lawrance G., Solc M., Dostaler S.M., Weaver D.F. and Riopelle R.J. (1998) Reciprocal modulation of TrkA and p75NTR affinity states is mediated by direct receptor interactions. *Eur J Neurosci*, **10** (3): 890-898.
- Roux P.P. and Barker P.A. (2002) Neurotrophin signaling through the p75 neurotrophin receptor. *Prog Neurobiol*, **67** (3): 203-233.
- Salama-Cohen P., Arevalo M.A., Meier J., Grantyn R. and Rodriguez-Tebar A. (2005) NGF controls dendrite development in hippocampal neurons by binding to p75NTR and modulating the cellular targets of Notch. *Mol Biol Cell*, **16** (1): 339-347.
- Salazar-Gruesso E.F., Kim S. and Kim H. (1991) Embryonic mouse spinal cord motor neuron hybrid cells. *Neuroreport*, **2** (9): 505-508.
- Salehi A.H., Roux P.P., Kubu C.J., Zeindler C., Bhakar A., Tannis L.L., Verdi J.M. and Barker P.A. (2000) NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. *Neuron*, **27** (2): 279-288.
- Sandow S.L., Heydon K., Weible M.W., 2nd, Reynolds A.J., Bartlett S.E. and Hendry I.A. (2000) Signalling organelle for retrograde axonal transport of internalized neurotrophins from the nerve terminal. *Immunol Cell Biol*, **78** (4): 430-435.
- Saragovi H.U. Zheng W. Maliartchouk S. et al (1998) A TrkA-selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals. *J Biol Chem*, **273** (52): 34933-34940.
- Saxena S., Bucci C., Weis J. and Kruttgen A. (2005a) The small GTPase Rab7 controls the endosomal trafficking and neuritogenic signaling of the nerve growth factor receptor TrkA. *J Neurosci*, **25** (47): 10930-10940.
- Saxena S., Howe C.L., Cosgaya J.M., Hu M., Weis J. and Kruttgen A. (2004) Differences in the surface binding and endocytosis of neurotrophins by p75NTR. *Mol Cell Neurosci*, **26** (2): 292-307.
- Saxena S., Howe C.L., Cosgaya J.M., Steiner P., Hirling H., Chan J.R., Weis J. and Kruttgen A. (2005b) Differential endocytic sorting of p75NTR and TrkA in response to NGF: a role for late endosomes in TrkA trafficking. *Mol Cell Neurosci*, **28** (3): 571-587.
- Schiavo G., Matteoli M. and Montecucco C. (2000) Neurotoxins affecting neuroexocytosis. *Physiol Rev*, **80** (2): 717-766.
- Schimmoller F., Simon I. and Pfeffer S.R. (1998) Rab GTPases, directors of vesicle docking. *J Biol Chem*, **273** (35): 22161-22164.
- Schmidt M.R. and Haucke V. (2007) Recycling endosomes in neuronal membrane traffic. *Biol Cell*, **99** (6): 333-342.
- Schor N.F. (2005) The p75 neurotrophin receptor in human development and disease. *Prog Neurobiol*, **77** (3): 201-214.
- Schweigreiter R. (2006) The dual nature of neurotrophins. *Bioessays*, **28** (6): 583-594.
- Sedel F., Bechade C. and Triller A. (1999) Nerve growth factor (NGF) induces motoneuron apoptosis in rat embryonic spinal cord in vitro. *Eur J Neurosci*, **11** (11): 3904-3912.
- Segal R.A. (2003) Selectivity in neurotrophin signaling: theme and variations. *Annu Rev Neurosci*, **26**:299-330.
- Sendtner M., Holtmann B. and Hughes R.A. (1996) The response of motoneurons to neurotrophins. *Neurochem Res*, **21** (7): 831-841.

- Sendtner M., Pei G., Beck M., Schweizer U. and Wiese S. (2000) Developmental motoneuron cell death and neurotrophic factors. *Cell Tissue Res*, **301** (1): 71-84.
- Sendtner M., Schmalbruch H., Stockli K.A., Carroll P., Kreutzberg G.W. and Thoenen H. (1992) Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. *Nature*, **358** (6386): 502-504.
- Senger D.L. and Campenot R.B. (1997) Rapid retrograde tyrosine phosphorylation of trkA and other proteins in rat sympathetic neurons in compartmented cultures. *J Cell Biol*, **138** (2): 411-421.
- Shao Y., Akmentin W., Toledo-Aral J.J., Rosenbaum J., Valdez G., Cabot J.B., Hilbush B.S. and Halegoua S. (2002) Pincher, a pinocytic chaperone for nerve growth factor/TrkA signaling endosomes. *J Cell Biol*, **157** (4): 679-691.
- Sheff D.R., Daro E.A., Hull M. and Mellman I. (1999) The receptor recycling pathway contains two distinct populations of early endosomes with different sorting functions. *J Cell Biol*, **145** (1): 123-139.
- Simonsen A., Lippe R., Christoforidis S. et al (1998) EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. *Nature*, **394** (6692): 494-498.
- Sinha K., Box M., Lalli G., Schiavo G., Schneider H., Groves M., Siligardi G. and Fairweather N. (2000) Analysis of mutants of tetanus toxin Hc fragment: ganglioside binding, cell binding and retrograde axonal transport properties. *Mol Microbiol*, **37** (5): 1041-1051.
- Smith R.G., Alexianu M.E., Crawford G., Nyormoi O., Stefani E. and Appel S.H. (1994) Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. *Proc Natl Acad Sci U S A*, **91** (8): 3393-3397.
- Sobkowitz H.M., Guillery R.W. and Bornstein M.B. (1968) Neuronal organization in long term cultures of the spinal cord of the fetal mouse. *J Comp Neurol*, **132** (3): 365-395.
- Sofroniew M.V., Howe C.L. and Mobley W.C. (2001) Nerve growth factor signaling, neuroprotection, and neural repair. *Annu Rev Neurosci*, **24**: 1217-1281.
- Sonnichsen B., De Renzis S., Nielsen E., Rietdorf J. and Zerial M. (2000) Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. *J Cell Biol*, **149** (4): 901-914.
- Sorkin A. (2004) Cargo recognition during clathrin-mediated endocytosis: a team effort. *Curr Opin Cell Biol*, **16** (4): 392-399.
- Squinto S.P., Stitt T.N., Aldrich T.H. et al (1991) trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. *Cell*, **65** (5): 885-893.
- Staub G.C., Walton K.M., Schnaar R.L., Nichols T., Baichwal R., Sandberg K. and Rogers T.B. (1986) Characterization of the binding and internalization of tetanus toxin in a neuroblastoma hybrid cell line. *J Neurosci*, **6** (5): 1443-1451.
- Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A. and Kaplan D.R. (1994) Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. *Neuron*, **12** (3): 691-705.

- Stoeckel K., Schwab M. and Thoenen H. (1975) Specificity of retrograde transport of nerve growth factor (NGF) in sensory neurons: a biochemical and morphological study. *Brain Res*, **89** (1): 1-14.
- Strohmaier C., Carter B.D., Urfer R., Barde Y.A. and Dechant G. (1996) A splice variant of the neurotrophin receptor trkB with increased specificity for brain-derived neurotrophic factor. *Embo J*, **15** (13): 3332-3337.
- Suzuki S., Numakawa T., Shimazu K., Koshimizu H., Hara T., Hatanaka H., Mei L., Lu B. and Kojima M. (2004) BDNF-induced recruitment of TrkB receptor into neuronal lipid rafts: roles in synaptic modulation. *J Cell Biol*, **167** (6): 1205-1215.
- Taniuchi M. and Johnson E.M., Jr. (1985) Characterization of the binding properties and retrograde axonal transport of a monoclonal antibody directed against the rat nerve growth factor receptor. *J Cell Biol*, **101** (3): 1100-1106.
- Tcherpakov M., Bronfman F.C., Conticello S.G., Vaskovsky A., Levy Z., Niinobe M., Yoshikawa K., Arenas E. and Fainzilber M. (2002) The p75 neurotrophin receptor interacts with multiple MAGE proteins. *J Biol Chem*, **277** (51): 49101-49104.
- Teng H.K. Teng K.K. Lee R. et al (2005) ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. *J Neurosci*, **25** (22): 5455-5463.
- Teng K.K. and Hempstead B.L. (2004) Neurotrophins and their receptors: signaling trios in complex biological systems. *Cell Mol Life Sci*, **61** (1): 35-48.
- Tessarollo L., Tsoulfas P., Martin-Zanca D., Gilbert D.J., Jenkins N.A., Copeland N.G. and Parada L.F. (1993) trkC, a receptor for neurotrophin-3, is widely expressed in the developing nervous system and in non-neuronal tissues. *Development*, **118** (2): 463-475.
- Thiele C.J., Reynolds C.P. and Israel M.A. (1985) Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. *Nature*, **313** (6001): 404-406.
- Thoenen H. (2000) Neurotrophins and activity-dependent plasticity. *Prog Brain Res*, **128**:183-191.
- Thoenen H., Hughes R.A. and Sendtner M. (1993) Trophic support of motoneurons: physiological, pathophysiological, and therapeutic implications. *Exp Neurol*, **124** (1): 47-55.
- Thoenen H. and Sendtner M. (2002) Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. *Nat Neurosci*, **5 Suppl**:1046-1050.
- Torgersen M.L., Skretting G., van Deurs B. and Sandvig K. (2001) Internalization of cholera toxin by different endocytic mechanisms. *J Cell Sci*, **114** (Pt 20): 3737-3747.
- Trischler M., Stoorvogel W. and Ullrich O. (1999) Biochemical analysis of distinct Rab5- and Rab11-positive endosomes along the transferrin pathway. *J Cell Sci*, **112** (Pt 24):4773-4783.
- Trupp M., Scott R., Whittemore S.R. and Ibanez C.F. (1999) Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. *J Biol Chem*, **274** (30): 20885-20894.
- Tsoulfas P., Soppet D., Escandon E., Tessarollo L., Mendoza-Ramirez J.L., Rosenthal A., Nikolics K. and Parada L.F. (1993) The rat trkC locus

- encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC12 cells. *Neuron*, **10** (5): 975-990.
- Tuffereau C., Benejean J., Blondel D., Kieffer B. and Flamand A. (1998) Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. *Embo J*, **17** (24): 7250-7259.
- Turner B.J., Murray S.S., Piccenna L.G., Lopes E.C., Kilpatrick T.J. and Cheema S.S. (2004) Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. *J Neurosci Res*, **78** (2): 193-199.
- Turner B.J., Rembach A., Spark R., Lopes E.C. and Cheema S.S. (2003) Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. *J Neurosci Res*, **74** (4): 605-613.
- Urfer R., Tsoulfas P., O'Connell L., Hongo J.A., Zhao W. and Presta L.G. (1998) High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the Trk receptors. *J Biol Chem*, **273** (10): 5829-5840.
- Usuki S., Ren J., Utsunomiya I., Cashman N.R., Inokuchi J. and Miyatake T. (2001) GM2 ganglioside regulates the function of ciliary neurotrophic factor receptor in murine immortalized motor neuron-like cells (NSC-34). *Neurochem Res*, **26** (4): 375-382.
- Valdez G., Akmentin W., Philippidou P., Kuruvilla R., Ginty D.D. and Halegoua S. (2005) Pincher-mediated macroendocytosis underlies retrograde signaling by neurotrophin receptors. *J Neurosci*, **25** (21): 5236-5247.
- Valenzuela D.M. Maisonpierre P.C. Glass D.J. et al (1993) Alternative forms of rat TrkC with different functional capabilities. *Neuron*, **10** (5): 963-974.
- van der Sluijs P., Hull M., Webster P., Male P., Goud B. and Mellman I. (1992) The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. *Cell*, **70** (5): 729-740.
- van der Sluijs P., Hull M., Zahraoui A., Tavitian A., Goud B. and Mellman I. (1991) The small GTP-binding protein rab4 is associated with early endosomes. *Proc Natl Acad Sci U S A*, **88** (14): 6313-6317.
- van Meer G. and Sprong H. (2004) Membrane lipids and vesicular traffic. *Curr Opin Cell Biol*, **16** (4): 373-378.
- Varsano T., Dong M.Q., Niesman I., Gacula H., Lou X., Ma T., Testa J.R., Yates J.R., 3rd and Farquhar M.G. (2006) GIPC is recruited by APPL to peripheral TrkA endosomes and regulates TrkA trafficking and signaling. *Mol Cell Biol*, **26** (23): 8942-8952.
- Vega J.A., Garcia-Suarez O., Hannestad J., Perez-Perez M. and Germana A. (2003) Neurotrophins and the immune system. *J Anat*, **203** (1): 1-19.
- Venkatakrishnan G., McKinnon C.A., Ross A.H. and Wolf D.E. (1990) Lateral diffusion of nerve growth factor receptor: modulation by ligand-binding and cell-associated factors. *Cell Regul*, **1** (8): 605-614.
- Verveer P.J., Wouters F.S., Reynolds A.R. and Bastiaens P.I. (2000) Quantitative imaging of lateral ErbB1 receptor signal propagation in the plasma membrane. *Science*, **290** (5496): 1567-1570.
- Vetter M.L., Martin-Zanca D., Parada L.F., Bishop J.M. and Kaplan D.R. (1991) Nerve growth factor rapidly stimulates tyrosine phosphorylation of phospholipase C-gamma 1 by a kinase activity associated with the product of the trk protooncogene. *Proc Natl Acad Sci U S A*, **88** (13): 5650-5654.

- Von Bartheld C.S. (2004) Axonal transport and neuronal transcytosis of trophic factors, tracers, and pathogens. *J Neurobiol*, **58** (2): 295-314.
- von Bartheld C.S., Wang X. and Butowt R. (2001) Anterograde axonal transport, transcytosis, and recycling of neurotrophic factors: the concept of trophic currencies in neural networks. *Mol Neurobiol*, **24** (1-3): 1-28.
- von Schack D., Casademunt E., Schweigreiter R., Meyer M., Bibel M. and Dechant G. (2001) Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. *Nat Neurosci*, **4** (10): 977-978.
- Vyas A.A., Patel H.V., Fromholt S.E., Heffer-Laue M., Vyas K.A., Dang J., Schachner M. and Schnaar R.L. (2002) Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. *Proc Natl Acad Sci U S A*, **99** (12): 8412-8417.
- Wang K.C., Kim J.A., Sivasankaran R., Segal R. and He Z. (2002) P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. *Nature*, **420** (6911): 74-78.
- Wang X., Shao Z., Zetoune F.S., Zeidler M.G., Gowrishankar K. and Vincenz C. (2003) NRADD, a novel membrane protein with a death domain involved in mediating apoptosis in response to ER stress. *Cell Death Differ*, **10** (5): 580-591.
- Watson F.L., Heerssen H.M., Bhattacharyya A., Klesse L., Lin M.Z. and Segal R.A. (2001) Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. *Nat Neurosci*, **4** (10): 981-988.
- Watson P., Jones A.T. and Stephens D.J. (2005) Intracellular trafficking pathways and drug delivery: fluorescence imaging of living and fixed cells. *Adv Drug Deliv Rev*, **57** (1): 43-61.
- Weible M.W., 2nd, Bartlett S.E., Reynolds A.J. and Hendry I.A. (2001) Prolonged recycling of internalized neurotrophins in the nerve terminal. *Cytometry*, **43** (3): 182-188.
- Weishaupt J.H., Bartels C., Polking E. et al (2006) Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. *J Pineal Res*, **41** (4): 313-323.
- Wen W., Sanelli T., Ge W., Strong W. and Strong M.J. (2006) Activated microglial supernatant induced motor neuron cytotoxicity is associated with upregulation of the TNFR1 receptor. *Neurosci Res*, **55** (1): 87-95.
- Weskamp G. and Reichardt L.F. (1991) Evidence that biological activity of NGF is mediated through a novel subclass of high affinity receptors. *Neuron*, **6** (4): 649-663.
- Whitmarsh A.J. and Davis R.J. (2001) Signal transduction by target-derived neurotrophins. *Nat Neurosci*, **4** (10): 963-964.
- Wiese S., Metzger F., Holtmann B. and Sendtner M. (1999) The role of p75NTR in modulating neurotrophin survival effects in developing motoneurons. *Eur J Neurosci*, **11** (5): 1668-1676.
- Wolf D.E., McKinnon C.A., Daou M.C., Stephens R.M., Kaplan D.R. and Ross A.H. (1995) Interaction with TrkA immobilizes gp75 in the high affinity nerve growth factor receptor complex. *J Biol Chem*, **270** (5): 2133-2138.
- Wooten M.W. and Geetha T. (2006) The role of ubiquitin in neurotrophin receptor signalling and sorting. *Biochem Soc Trans*, **34** (Pt 5): 757-760.
- Wu C., Lai C.F. and Mobley W.C. (2001a) Nerve growth factor activates persistent Rap1 signaling in endosomes. *J Neurosci*, **21** (15): 5406-5416.

- Wu M.M., Grabe M., Adams S., Tsien R.Y., Moore H.P. and Machen T.E. (2001b) Mechanisms of pH regulation in the regulated secretory pathway. *J Biol Chem*, **276** (35): 33027-33035.
- Yaar M., Zhai S., Fine R.E., Eisenhauer P.B., Arble B.L., Stewart K.B. and Gilchrest B.A. (2002) Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. *J Biol Chem*, **277** (10): 7720-7725.
- Yaar M., Zhai S., Pilch P.F., Doyle S.M., Eisenhauer P.B., Fine R.E. and Gilchrest B.A. (1997) Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. *J Clin Invest*, **100** (9): 2333-2340.
- Yacoubian T.A. and Lo D.C. (2000) Truncated and full-length TrkB receptors regulate distinct modes of dendritic growth. *Nat Neurosci*, **3** (4): 342-349.
- Yamashita T., Higuchi H. and Tohyama M. (2002) The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. *J Cell Biol*, **157** (4): 565-570.
- Yan H. and Chao M.V. (1991) Disruption of cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding. *J Biol Chem*, **266** (18): 12099-12104.
- Yan Q., Elliott J.L., Matheson C., Sun J., Zhang L., Mu X., Rex K.L. and Snider W.D. (1993) Influences of neurotrophins on mammalian motoneurons in vivo. *J Neurobiol*, **24** (12): 1555-1577.
- Yan Q. and Johnson E.M., Jr. (1988) An immunohistochemical study of the nerve growth factor receptor in developing rats. *J Neurosci*, **8** (9): 3481-3498.
- Yan Q. and Miller J.A. (1993) The use of trophic factors in degenerative motoneuron diseases. *Exp Neurol*, **124** (1): 60-63.
- Yan Q., Snider W.D., Pinzone J.J. and Johnson E.M., Jr. (1988) Retrograde transport of nerve growth factor (NGF) in motoneurons of developing rats: assessment of potential neurotrophic effects. *Neuron*, **1** (4): 335-343.
- Yang K., Clifton G.L. and Hayes R.L. (1997) Gene therapy for central nervous system injury: the use of cationic liposomes: an invited review. *J Neurotrauma*, **14** (5): 281-297.
- Yano H. and Chao M.V. (2004) Mechanisms of neurotrophin receptor vesicular transport. *J Neurobiol*, **58** (2): 244-257.
- Yano H., Lee F.S., Kong H., Chuang J., Arevalo J., Perez P., Sung C. and Chao M.V. (2001) Association of Trk neurotrophin receptors with components of the cytoplasmic dynein motor. *J Neurosci*, **21** (3): RC125.
- Ye H., Kuruvilla R., Zweifel L.S. and Ginty D.D. (2003) Evidence in support of signaling endosome-based retrograde survival of sympathetic neurons. *Neuron*, **39** (1): 57-68.
- York R.D., Molliver D.C., Grewal S.S., Stenberg P.E., McCleskey E.W. and Stork P.J. (2000) Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced extracellular signal-regulated kinase activation via Ras and Rap1. *Mol Cell Biol*, **20** (21): 8069-8083.
- York R.D., Yao H., Dillon T., Ellig C.L., Eckert S.P., McCleskey E.W. and Stork P.J. (1998) Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. *Nature*, **392** (6676): 622-626.
- Yuen E.C. and Mobley W.C. (1999) Early BDNF, NT-3, and NT-4 signaling events. *Exp Neurol*, **159** (1): 297-308.

- Zaccaro M.C., Ivanisevic L., Perez P., Meakin S.O. and Saragovi H.U. (2001) p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. *J Biol Chem*, **276** (33): 31023-31029.
- Zagrebelsky M., Holz A., Dechant G., Barde Y.A., Bonhoeffer T. and Korte M. (2005) The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. *J Neurosci*, **25** (43): 9989-9999.
- Zampieri N., Xu C., Neubert T.A. and Chao M.V. (2005) Cleavage of p75 neurotrophin receptor by alpha -secretase and gamma -secretase requires specific receptor domains. *J Biol Chem*.
- Zapf-Colby A. and Olefsky J.M. (1998) Nerve growth factor processing and trafficking events following TrkA-mediated endocytosis. *Endocrinology*, **139** (7): 3232-3240.
- Zhai J., Lin H., Canete-Soler R. and Schlaepfer W.W. (2005) HoxB2 binds mutant SOD1 and is altered in transgenic model of ALS. *Hum Mol Genet*, **14** (18): 2629-2640.
- Zhang Y., Moheban D.B., Conway B.R., Bhattacharyya A. and Segal R.A. (2000) Cell surface Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced differentiation. *J Neurosci*, **20** (15): 5671-5678.
- Zhou F.Q., Zhou J., Dedhar S., Wu Y.H. and Snider W.D. (2004) NGF-induced axon growth is mediated by localized inactivation of GSK-3beta and functions of the microtubule plus end binding protein APC. *Neuron*, **42** (6): 897-912.
- Zirrgiebel U., Ohga Y., Carter B., Berninger B., Inagaki N., Thoenen H. and Lindholm D. (1995) Characterization of TrkB receptor-mediated signaling pathways in rat cerebellar granule neurons: involvement of protein kinase C in neuronal survival. *J Neurochem*, **65** (5): 2241-2250.
- Zweifel L.S., Kuruvilla R. and Ginty D.D. (2005) Functions and mechanisms of retrograde neurotrophin signalling. *Nat Rev Neurosci*, **6** (8): 615-625.

*Verum  
est quoque*



*decorus futurus  
vitualamen*